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Bordetella pertussis, a strict human pathogen, is the causative agent of whooping 
cough. As a pathogen naturally infecting the respiratory tract, B. pertussis is particularly 
well adapted for the nasal delivery of heterologous vaccines candidates and has already 
been reported as a promising mucosal vaccine delivery system. Recently, a highly 
attenuated B. pertussis strain, BPZE1, has been engineered. In addition, BPZE1 has 
entered phase I clinical trial in humans as live pertussis vaccine. Although highly 
attenuated as evidenced by a markedly reduced lung inflammation in the infected animals, 
BPZE1 bacteria still maintain the ability to colonize the mice lungs efficiently and induce 
protective immunity against pertussis infection. These features make BPZE1 strain not 
only an attractive live pertussis vaccine candidate but also a potential vehicle for vaccine 
delivery via the nasal route. 
In this study, H5N1 specific antigen candidate NA, and several other antigens that 
are highly conserved among influenza A viruses, namely the ectodomain of M2 protein 
(M2e), 3 conserved neutralizing epitopes in H5 and the nucleocapsid protein (NP) were 
selected and expressed in attenuated B. pertussis BPZE1. These antigens were either 
expressed in the cytoplasm of B. pertussis or secreted into the external milieu using the 
filamentous hemagglutinin (FHA) as carrier. 
Unexpectedly, we observed in this study that prior nasal administration of an 
attenuated strain of BPZE1 provided effective and sustained protection against lethal 
challenge with mouse-adapted H3N2 influenza A virus. No significant protection was 
observed in the mice pre-treated once with BPZE1 and challenged 3 weeks later whereas 
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70% protection was observed in those challenged 6 weeks later, indicating that the 
protection mechanism needs more than 3 weeks to be effective. Protection rates against 
H3N2 virus of 70% and 100% were achieved in adult mice pre-treated once and twice 
with live BPZE1 bacteria, respectively.  Furthermore, administration of live but not killed 
BPZE1 bacteria conferred cross-protection, suggesting that lung colonization is necessary 
to trigger the protective mechanism(s).  
Surprisingly, no significant difference in the viral load was observed between 
BPZE1-immunized and non-immunized mice, indicating that the processes involved in 
the cross-protection do not directly target the viral particles and/or infected cells. This 
hypothesis is further supported by the observation that no cross-reactive antibodies and 
T-cells were found in mice pre-treated with BPZE1 and then stimulated with heat-killed 
H3N2 influenza virus.  
Instead, mice pre-treated with BPZE1 were protected from influenza-induced-
lymphocyte depletion in the lungs and displayed markedly reduced lung inflammation 
and tissue damage as well as decreased neutrophilic infiltration as shown by histological 
examination, and a significantly lower production of the major pro-inflammatory 
cytokines and chemokines in their broncho-alveolar lavage fluid samples. In addition, we 
showed that nasal pre-treatment with BPZE1 also protected against H1N1 virus challenge, 
although with a lesser efficacy. These observations thus pointed to nonspecific anti-
inflammatory properties of BPZE1 and suggested a potential prophylactic application to 
protect against highly pathogenic influenza A viruses. 
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We also investigated the potential of recombinant B. pertussis strains expressing 
antigen candidates from influenza virus as live recombinant vaccines against influenza 
virus, thus combining the nonspecific anti-inflammatory properties of BPZE1 and the 
specific anti-influenza immune responses. In particular, the universal influenza vaccine 
candidate M2e was expressed in BPZE1 as a FHA-(M2e)3 chimera and the nasal 
administration of the recombinant BPLR3 bacteria triggered significant production of 
anti-M2e IgA antibodies in the respiratory tract. Although BPLR3 immunization did not 
provide further protection compared with BPZE1 in the challenge experiments, BPLR3 
still represents a promising universal vaccine against influenza A viruses and deserves 
future improvement.  In addition, we showed for the first time that the cytoplasmic 
expression of heterologous antigens such as NP and truncated NA in BPZE1 may not be 
an effective approach to prime the host immune system. 
In conclusion, our data indicates that BPZE1 represents a promising vehicle for 
the nasal delivery of subunit vaccine candidates against influenza virus by combining the 
non-specific anti-inflammatory properties of the vehicle BPZE1 with the specific 
adaptive immunity induced by the production of the foreign antigens.  
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      Continuing outbreaks of highly pathogenic avian influenza (HPAI) in several 
Asian countries, due to influenza type A virus of H5N1 subtype, has been causing serious 
concerns worldwide (Viseshakul et al., 2004). In recent years, avian influenza viruses, in 
particular virulent H5N1 subtype, have crossed the species barrier to cause fatal disease 
in humans and pose a possible pandemic threat (Li et al., 2004). Moreover, an influenza 
epidemic was detected in April 2009 at the border between the United States and Mexico. 
Through rapid and frequent international travel, it has spread to over 209 countries 
around the world and over 14142 deaths have been reported up to January 17, 2010 
(WHO, 2010 update 84. Available at: 
http://www.who.int/csr/don/2010_01_22/en/index.html Date accessed: January 24, 2010). 
On June 11
th
, 2009, the World Health Organization declared an influenza pandemic, 
caused by novel S-OIV A (H1N1). 
 
            The use of antiviral drugs represents one of the most promising means of 
combating influenza. However, these drugs only reduce symptoms and duration of the 
disease partially (Nicholson et al., 2000). In addition, the H5N1 subtype has been shown 
to be resistant to M2 inhibitors amantadine and rimantadine (Brooks et al., 2004). 
Therefore, vaccination is considered the most effective preventive means of controlling 
influenza. However, conventional immunization strategies have major limitations. The 
current flu vaccines are composed of inactivated whole virus, purified subunit proteins or 
live attenuated influenza viruses (Cold Adapted Viruses-Flumist
®
). One of the common 
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features shared by all current flu vaccines is that these vaccines rely primarily on the 
production of neutralizing antibodies mainly against two virus surface proteins, namely 
hemagglutinin (HA) and neuraminidase (NA). However, HA and NA can undergo 
mutations through antigenic drift and shift, the vaccine formulations need to be changed 
on a yearly basis in order to match the circulating strains, and/or based on the scientists 
prediction of the subtype that will be responsible for the next, outbreak (Nicholson et al., 
2003; Smith et al., 2004). Moreover, a rapidly developing pandemic would shorten the 
timeframe to identify the viral strain and mass-produce the antigenically matched vaccine. 
Therefore, a vaccine using conserved components of influenza A virus that can provide 
broad protection against different viral variants or strains, and does not require frequent 
updates, is highly desirable. A variety of conserved vaccine candidates have been 
reviewed and discussed in detail in the following chapter. Moreover, immunity induced 
by influenza virus infection and influenza vaccines have been covered in the first part of 
that chapter in order to provide a basis for discussing influenza vaccine design and 
development. 
 
            On the other hand, as influenza virus is a respiratory pathogen and influenza 
infections are initiated at mucosal surfaces, it is expected that mucosal vaccines that are 
able to elicit both local and systemic immune responses would provide a more effective 
protection by stopping the initial steps of influenza infection. A number of mucosal 
routes have been considered for vaccination purposes, including the oral, nasal, rectal and 
vaginal routes. By far oral and intranasal vaccinations have been the most commonly and 
extensively studied. Immune induction via the nasal route offers several advantages over 
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the oral route. Intranasal vaccination generally elicits stronger immune responses than 
oral administration of the same vaccine. In addition to local immunity, systemic immune 
responses are also achieved more easily by intranasal delivery. However, although 
generally more effective than oral vaccination, intranasal vaccination usually still 
requires repeated delivery of large amounts of antigen, or the addition of mucosal 
adjuvants (Wu & Russell, 1997). Therefore, live respiratory bacteria represent an 
attractive vaccine delivery system. They may mimic natural infection and interact with 
the mucosal, humoral and cellular compartments of the host‟s immune system. In 
addition, since bacterial vectors replicate within the host, they may provide sustained 
exposure of the antigen vaccine candidate to the host‟s immune system, thereby inducing 
a strong specific immune response.  
 
           As a pathogen naturally infecting the respiratory tract, B. pertussis, the causative 
agent of whooping cough, is particularly well adapted for the nasal delivery of 
heterologous vaccines which target respiratory pathogens such as influenza viruses.  
Several heterologous antigens from various bacterial pathogens have been successfully 
expressed in B. pertussis and the nasal administration of the recombinant strains have 
been shown to induce local and systemic immune responses against the foreign proteins 
(Alonso et al., 2005; Coppens et al., 2001; Mielcarek et al., 2001a; Mielcarek et al., 1997; 
Renauld-Mongenie et al., 1996b; Reveneau et al., 2001). Recently, a highly attenuated 
strain of Bordetella pertussis, namely BPZE1, has been engineered (Locht, 2008; 
Mielcarek et al., 2006a; Mielcarek et al., 2006b) and was shown to be a promising and 
attractive candidate for the delivery of heterologous vaccine antigens via the nasal route 
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(Ho et al., 2008). In order to have a comprehensive understanding of the potential of 
attenuated B. pertussis as a live nasal delivery vehicle, detailed B. pertussis immunology 
has been reviewed in Chapter 2. In addition, the different B. pertussis antigen carriers that 
have been so far employed to present heterologous vaccine candidates have been 
discussed. 
 
            In this study, this project aims to develop a universal vaccine against HPAI 
viruses, using a highly attenuated Bordetella pertussis strain as live vector for vaccine 
delivery through the nasal route. We have selected one H5N1 specific antigen candidate 
NA, and several other antigens that are highly conserved among influenza A viruses, 
namely 3 conserved neutralizing epitopes in H5subtype, the nucleocapsid protein (NP) 
and the ectodomain of M2 protein (M2e). These antigens were either expressed in the 
cytoplasm of B. pertussis or secreted into the external milieu using the filamentous 
hemagglutinin (FHA) as carrier. Specific immune responses have been studied and 
challenge experiments have also been done for the recombinant B. pertussis strains that 
show promising immune responses. Interestingly, we have investigated an unexpected 
cross-protection between the attenuated B. pertussis BPZE1 and mouse-adapted H3N2 
influenza virus. 
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(I) INFLUENZA VIRUSES 
 
2.1 INFLUENZA MORBIDITY, MORTALITY AND HISTORY OF INFLUENZA 
PANDEMICS 
            Influenza has long been recognized as a significant public health problem that 
presents a considerable economic burden on society due to both epidemics, local or 
regional outbreaks, and pandemics. Influenza epidemics have been considered as a major 
cause of morbidity and increased mortality, especially in young children (<5 years of age) 
and the elderly (≥65 years of age) (Carrat & Flahault, 2007). Each year, seasonal 
influenza epidemics result in 3-5 million cases of severe illness and kills between 0.25 
and 0.5 million people worldwide (Nicholson et al., 2003). Three major influenza 
pandemics struck the world in the 20th century. By far the most devastating pandemic 
was the 1918 Spanish flu outbreak (H1N1) which killed at least 50 million people, 
justifying its description as “the last great plague of mankind”. The subsequent 
pandemics in 1957 Asian flu (H2N2) and 1968 Hong Kong flu (H3N2) were milder, but 
nonetheless also caused a total of approximately 2 million deaths. The recent spread of 
HPAI H5N1 virus across Asia and parts of Europe and the Middle East, as well as the 
occasional infections of humans with an overall fatality rate of over 60%, have caused 
worldwide concern about a potential new global epidemic of influenza. Currently, there 
have been 421 confirmed human cases and 257 deaths of avian H5N1 virus infection as 
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of April 23, 2009 (WHO, 2009). Presently, a novel influenza A virus of the H1N1 
subtype has spread all around the world at an unprecedented speed, resulting in an global 
pandemic. Through rapid and frequent international travel, it has spread to over 209 
countries around the world and over 14142 deaths have been reported up to January 17, 
2010 (WHO, 2010). On June 11, 2009, the World Health Organization declared an 
influenza pandemic, caused by novel S-OIV A (H1N1). 
 
2.2   INFLUENZA VIRUSES CLASSIFICATION 
            Influenza viruses are segmented, enveloped negative sense single-stranded RNA 
viruses, belonging to the Orthomyxoviridae family. There are three influenza virus genera 
within this family, namely influenza A, B and C, distinguishable on the basis of antigenic 
differences between their matrix proteins (M1 and M2) and nucleoproteins (NP). 
Influenza A, B and C viruses also differ with respect to host range, surface glycoproteins, 
genome organization and morphology (Lamb, 2001b). Among the three genera, influenza 
A viruses are the best characterized and responsible for pandemic outbreaks of influenza 
and for most of the well-known annual flu epidemics.  Influenza A viruses are classified 
into serologically different subtypes based on antigenic differences between their two 
surface glycoproteins, haemagglutinin and neuraminidase. 16 haemagglutinin subtypes 
(H1-H16) and 9 neuraminidase subtypes (N1-N9) have been identified for influenza A 
viruses. Viruses of all haemagglutinin and neuraminidase subtypes have been recovered 
from aquatic birds, but only three haemagglutinin subtypes (H1, H2, and H3) and two 
neuraminidase subtypes (N1 and N2) have established stable lineages in the human 
population since 1918.  
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2.3   INFLUENZA A VIRUS: STRUCTURE AND REPLICATION 
2.3.1   Influenza A Virus Genome and Its Major Protein Products 
            The influenza A genome consists of eight single-stranded negative-sense RNA 
molecules (Figure 2.1). The genes encode 10 proteins; envelope glycoproteins 
hemagglutinin (HA) and neuraminidase (NA), matrix protein 1 (M1), nucleoprotein (NP), 
a polymerase complex formed by three polymerases (PB1, PB2 and PA), ion channel 
protein (M2), and nonstructural protein 1 (NS1). Each of the looped RNA gene segments 
is encapsidated by NP and the polymerase complex is associated at one end of each gene 
segment (Lamb, 2001b). 
 
            HA and NA are the two major glycoproteins presented as spike-like projections 
on the virus surface.  The HA spike is a rod-like shaped trimer, consisting of three 
individual HA monomers, while the NA spike is a mushroom-shaped tetramer. HA is 
synthesized as an HA0 precursor that forms non-covalently bound homotrimers on the 
viral surface (Steinhauer, 1999). The HA0 precursor is cleaved by host proteases at a 
conserved arginine (R) residue to generate two subunits, HA1 and HA2, which are 
associated by a single disulfide bond. Cleavage of HA0 is essential for the molecule to be 
able to mediate membrane fusion between the viral envelope and the host cell membrane. 
HA1 is responsible for binding of the virus to its cellular sialic acid receptor. It also 
contains the major antigenic epitopes of the molecule. HA2 forms the fibrous stem of the 
viral spike. The N-terminus of HA2 contains a conserved stretch of 20, mostly 
hydrophobic, amino acid residues. This sequence is generally referred to as the “fusion 
peptide”; it triggers the membrane fusion process between the viral envelope and the host 
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cell membrane (Skehel & Wiley, 2000). Through its enzymatic activity, NA cleaves the 
terminal sialic acid residues of influenza A virus cellular receptors and is involved in the 
release and spread of mature virions from the surface of infected cells; it may also 
contribute to initial viral entry (Matrosovich et al., 2004). NA is the target of antiviral 
drugs such as oseltamivir (Tamiflu
®
) and zanamivir (Relenza
®
). These drugs are sialic 
acid analogues (von Itzstein et al., 1993), which inhibit the enzymatic activity of NA, 
thus slowing down the release of progeny virus from infected cells. However, antibodies 
against NA, as well as neuraminidase inhibitors, do not neutralize virus infection, but 
rather aid in ameliorating the infection process. 
 
            M2 protein is the third integral membrane protein of the influenza A virus. It is 
present in a small number of copies in the viral particle and forms a tetramer with ion 
channel activity. Sharing eight amino-terminal residues with M1 protein, M2 protein 
exists as a homotetramer formed by two disulfide linked dimers, each of which consists 
of 97 amino acids (Lamb et al., 1985; Sugrue & Hay, 1991). M2 tetramers exhibit pH-
inducible proton transport activity and regulate the pH of the viral core after virus uptake 
into the host cell‟s endosomal compartment during initiation of infection. M2 is the target 
of the antiviral drugs amantidine and rimantidine. M1 is another matrix protein of 
influenza A viruses, which is encoded by the same single RNA segment as M2 and 
generated by RNA splicing. M1 is entirely internal and located immediately below the 
lipid bilayer of the virus, while M2 has a small extracellular surface domain (M2e) 
(Hilleman, 2002). 
 
CHAPTER 2 SURVEY OF LITERATURE 
9 
 
            Another RNA segment consists of the nonstructural (NS) gene, which encodes 
NS1 and NS2, also known as the nuclear export protein (NEP), the transcripts for which 
are also generated by RNA splicing. NS1 is not present in the virion but this protein is 
abundantly found in infected cells (Wilschut, et. al., 2006). It antagonizes the type I 
interferon (IFN) antiviral activity of the host cells by sequestering viral genomic RNA 
from intracellular receptors; NEP is involved in the nuclear export of RNA and viral 
assembly (Hilleman, 2002). The remaining four RNA segments encode RNA polymerase 
complex which is involved in viral gene transcription and the nucleoprotein (NP) that 
























Figure 2.1 Structure and immunogenicity of the influenza A virus.  
The genome consists of eight single-stranded RNA molecules that are associated with 
nucleoprotein (NP) and a RNA polymerase complex consisting of the PB1, PB2, and PA 
proteins. Hemagglutinin (HA) and neuraminidase (NA), which are embedded in a lipid 
bilayer, are the major surface proteins of the virus. The M2 protein is an ion channel that 
has a small external domain that is also a potential antibody target. The NS1 protein, 
which limits the host response to the virus, is not a component of the mature virion.  
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 2.3.2   Antigenic Shift and Drift 
Influenza viruses continuously undergo antigenic evolution which allows them to 
evade any pre-existing immunity of the host. In other words, the immune responses 
mounted against earlier variants of influenza virus are barely effective against newer 
variants. The occurrence of annual influenza epidemics and occasional pandemics are the 
result of the antigenic evolution of influenza viruses. There are two main mechanisms by 
which influenza A viruses change their antigenic properties, namely antigenic shift and 
antigenic drift. Antigenic shift may be the result of direct transmission of an avian 
influenza virus to humans. It may also be due to a genetic reassortment between an avian 
and a human influenza virus, with pigs or humans serving as a “mixing vessel”. In the 
process of genetic “reassortment”, a human influenza virus acquires a number of gene 
segments from an avian influenza virus. It is well established that antigenic shift has been 
the basis of the 1957 H2N2 (Asian flu) and 1968 H3N2 (Hong Kong flu) outbreaks (Ito et 
al., 1998), as well as the current H1N1 influenza pandemic. In contrast, antigenic drift 
occurs through continuous mutation of the RNA genome of the virus, mainly amino acid 
substitutions in the HA and NA proteins. Antigenic drift accounts for annual flu 
epidemics and necessitates update of the composition of the influenza vaccines every 
year.  
 
2.3.3   Determinants of Tissue Tropism and virulence 
            Influenza virus infection occurs after the virus attaches to sialic acid (SA)-
terminated glycans on the surface of host cells via the receptor binding domain of the HA 
surface glycoprotein. The binding specificity of influenza A HA for particular SA 
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moieties appears to be a key determinant of whether a particular influenza A subtype can 
infect humans (Figure 2.2a). Human adapted influenza viruses preferentially bind to a 
terminal SA linked to galactose by α 2-6 linkage (α 2-6 SA), a major glycan of human 
respiratory epithelia, whereas avian influenza viruses, such as the H5N1 subtype, 
preferentially bind SA in an α 2-3 linkage with galactose (α 2-3 SA), which are abundant 
in the respiratory and intestinal tracts of aquatic birds (Connor et al., 1994; Ito et al., 
1998; Matrosovich et al., 2000; Shinya & Kawaoka, 2006). The tracheal epithelia of 
birds and humans mainly express influenza A receptors with α 2-3 linkage and 2-6 
linkage of sialic acid, respectively (Ito et al., 1998). However, pig tracheal respiratory 
epithelium expresses receptors with both 2-3 and 2-6 linkages (Figure 2.2b) (Ito et al., 
1998), leading to the hypothesis of the pig as a “mixing bowl” for both avian and human 
influenza viruses, and is proposed to facilitate reassortment and the generation of new 
human pandemic strains with efficient human-to-human transmission. 
 
            As mentioned above, cleavage of HA0 precursor by host proteases is an essential 
step during infection. The nature of the amino acids around the HA cleavage site 
determines the susceptibility of HA to host proteases and has been identified as a 
determinant of tissue tropism for influenza viruses. Low pathogenic avian influenza 
(LPAI) viruses and human influenza viruses possess a cleavage site that is cleaved by 
host trypsin-like proteases that limit the virus to tissues of the respiratory tract. However, 
HPAI viruses display additional basic amino acids within the HA cleavage site that make 
HA susceptible to a wide range of host proteases and allow the virus to replicate outside 
the respiratory tract (Lewis, 2006). 
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The outcome of influenza virus infection is influenced by both host and virus. If 
the host has had prior exposure to a related strain, the effects of a highly pathogenic strain 
may be weakened. However, in an immunologically naïve host, virulence is mostly 
determined by the virus. Many viral genes can contribute to pathogenicity. Multiple 
molecular determinants affecting virus virulence have been identified using animal 
models of influenza. As mentioned above, HA glycoprotein is involved in host-cell 
recognition and is therefore an important determinant of the pathogenesis and virulence 
of HPAI strains. However, studies in mammalian animal models showed that the 
virulence of H5N1 viruses is not always dictated by HA, indicating that additional 
virulence determinants are involved (Govorkova et al., 2005; Maines et al., 2005). NS1 
protein can directly influence the host immune response to influenza infection. The NS 
gene of the 1918 influenza virus was shown to block the expression of IFN-related genes 
more efficiently than the NS gene of a less virulent H1N1 virus (Geiss et al., 2002). The 
NS proteins of 1997 H5N1 viruses were found to upregulate the expression of 
proinflammatory cytokines in mice and pigs, directly contributing to the virulent 
phenotype observed (Lipatov et al., 2005; Seo et al., 2002). Furthermore, the resistance 
of highly pathogenic H5N1 viruses to the antiviral effects of IFN and TNF-α is directly 
attributable to expression of an NS1 protein containing a glutamic acid at position 92 
(Seo et al., 2002). The polymerase complex (including the PB1, PB2 and PA proteins) is 
also implicated in HPAI virus virulence and virus adaptation to mammalian hosts, and 
efficient polymerase activity has been identified as a virulence marker (Gabriel et al., 
2005; Salomon et al., 2006). The recently identified PB1-F2 protein encoded by an 
alternate reading frame in the PB1 gene segment of influenza A virus has been shown to 
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enhance viral virulence in a mouse model (Zamarin et al., 2006).  The PB1-F2 protein 
contributes to virulence by inducing apoptosis in macrophages resulting in down-
regulation of the host immune response to infection (Chen et al., 2001; Coleman, 2007). 
The PB1-F2 is also found to be associated with secondary bacterial infections and 














Figure 2.2 Determinants of tissue tropism and virulence of influenza virus. 
a) Sialic acid residues can be covalently attached to galactose residues of integral 
glycoproteins and glycolipids via either 2–3 or 2–6 α linkages.  
(b) Species-specific expression of sialic acid linkages with galactose by respiratory 
epithelial glycoproteins and glycolipids. The avian, human, and swine upper respiratory 
tract epitheliae preferentially express 2–3 linkages, 2–6 linkages, and both 2–3 and 2–6 
linkages, respectively. A subset of human respiratory epithelial cells of the lower tract 
that are ciliated mainly express 2–3 linkages (Not shown in the figure). These expression 
patterns account for the ability of avian influenza A strains, which preferentially bind via 
HA to 2–3 sialic acid residues, to infect both birds and pigs but not humans, at least in 
cases of upper respiratory tract infection. However, since 1997 there have been multiple 
cases of avian H5N1 virus directly infecting humans, indicating that this restriction is not 
absolute. Adapted from Lewis, 2006 (Lewis, 2006). 
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2.4   IMMNUE RESPONSE TO INFLUENZA A VIRUS INFECTION 
            When influenza A viruses infect the cells of the respiratory tract, both innate and 
adaptive immune responses are stimulated.  
 
2.4.1   Innate Immunity 
            The innate immune response develops very quickly after influenza A virus 
infection and controls virus replication during the early stages of infection. It is activated 
within a few hours of infection and lasts for as long as 7 days during a primary influenza 
infection, while the adaptive immune response takes longer to be activated.  
 
            The early detection of infection in the epithelium by Toll-like receptors (TLRs), 
the production of proinflammatory cytokines, such as type I interferons (IFN-α/β), tumor 
necrosis factor-α (TNF-α), interleukin-12 (IL-12), and chemoattractant chemokines, and 
the activation of antigen-presenting cells (macrophages and dendritic cells) as well as 
natural killer (NK) cells, are likely to be important parts of the innate response to 
influenza infection. Recognition of double-stranded RNA by TLR3 and single-stranded 
RNA by TLR7 and TLR8 has also been proposed (Diebold et al., 2004; Lund et al., 
2004). TLR3 is expressed by human lung epithelial cells, and activation may occur 
mainly at intracellular sites (Guillot et al., 2005). TLR7 and TLR8 activation also appears 
to be mainly intracellular, occurring in an acidic endosomal compartment into which 
influenza A normally enters following cellular internalization (Diebold et al., 2004).  
            The proinflammatory cytokines and chemokines produced upon influenza A virus 
infection attract immune cells to the site of infection, including macrophages, neutrophils 
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and NK cells. These in turn produce additional cytokines, chemokines and other antiviral 
proteins. This process activates a number of immune cells, including those of the 
adaptive immune response. Type I IFNs are among the most important cytokines 
produced by the host innate immune system and have a chief protective function in the 
early stages of influenza virus infection.  Interferons induce the expression of „Mx’ genes 
which inhibit primary transcription of at least the viral PB2 polymerase. Mx1–/– mice are 
indeed more susceptible to influenza (Engelhardt et al., 2004; Turan et al., 2004). In 
contrast, the viral „NS‟ gene encodes a type 1 interferon antagonist that promotes virus 
growth (Garcia-Sastre et al., 1998; Geiss et al., 2002; Lipatov et al., 2005; Seo et al., 
2002). Type I IFNs can also recruit monocytes/macrophages, T cells and NK cells 
(Wilschut et al., 2006). They also influence the outcome of adaptive immune responses 
by favoring the differentiation of naive CD4
+
 T cells into Th1 effector cells that produce 
high levels of interferon-γ (IFN-γ) (Lewis, 2006). IFN-γ, in turn, not only synergizes with 
other cytokines in promoting a direct antiviral effect but may also upregulate expression 
of TLRs by antigen-presenting cells (APCs) and lung epithelial cells (Miettinen et al., 
2001). In addition to cytokines, NK cells play an important role in the innate immune 
response against viral infections. NK cells are large granular lymphocytes that detect 
virus-infected cells in a non-specific manner (Empson et al., 2010). 
 
2.4.2   Effector Mechanisms of the Adaptive Immunity  
            Once intracellular infection is established, immune control largely depends on the 
detection and elimination of infected host cells by adaptive immunity. An important 
element of the transition from the innate to adaptive immune response is the stimulation 
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of TLRs in endosomes of antigen-presenting cells (primarily dendritic cells) (Diebold et 
al., 2004).  
 
            Influenza strain-specific antibodies, produced during the adaptive immune 
response, represent the principal mechanism for immediate, sterilizing immunity to 
influenza virus infection. The main virus-neutralizing antibodies are directed against the 
viral surface glycoprotein HA. Mice with severe combined immunodeficiency do not 
survive influenza infection, but such mice receiving intraperitoneal injection of a 
substantial dose (200 μg) of an HA-specific neutralizing monoclonal antibody as late as 
24 h after virus challenge survive infection (Gerhard, 2001).  Both locally produced 
immunoglobulin A (IgA) and systemic IgG function to neutralize virus growth and, even 
if there is only partial cross-reactivity, can exert a good measure of early control (Riberdy 
et al., 1999). Most influenza A–specific antibody production following vaccination or 
infection is dependent on CD4
+
 T cells providing help in the form of CD40-ligand 
(Crowe et al., 2003). There is also evidence that murine CD4
+
 T cells aid the production 
of neutralizing IgA by a CD40-ligand-independent mechanism (Sangster et al., 2003). 
Furthermore, NK cells bind to antibody-virus complexes on the surface of infected cells 
and kill the infected cells by antibody-dependent cell-mediated cytotoxicity (ADCC) as 
part of the adaptive immune response. Monoclonal antibodies specific for NA and matrix 
protein 2 (M2) proteins can also reduce virus titers (Mozdzanowska et al., 2003) (see 
section 2.4.3.1). 
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            However, due to antigenic drift of influenza A viruses, mutant viruses produced 
may escape antibody binding due to changes in their antigenic B cell epitopes. Thus 
antibodies resulting from pre-exposure or vaccination to a different strain of influenza 
may not provide adequate protection against the circulating strains. In this case, 
activation of the T cell-mediated adaptive immunity is required to clear the infected 
respiratory epithelial cells and allow recovery from illness. 
 
            In cases of established intracellular influenza A infection, the elimination of 
infected cells is mainly carried out by effector CD8
+
 T cells, also known as cytolytic T 
lymphocytes (CTLs) (Turner et al., 2004). Human studies showed that CTL activity is 
important for recovery from influenza infection even in the presence of protective 
antibodies to the infecting virus strain (McMichael et al., 1983). CTLs that reach sites of 
infection recognize infected target cells that express major histocompatibility complex 
(MHC) class I associated with foreign peptides of the influenza A virus derived from 
cytoplasmic proteins. Evidence suggests that CD8
+
 effector T cells eliminate influenza 
virus–infected lung cells mainly by CD69 (Fas)–mediated or perforin-and-granzyme-
mediated cytotoxicity (Topham et al., 1997). 
 
            CD4
+ 
T cells also play an important role in influenza-specific immunity. As 
mentioned above, influenza-specific CD4
+
 T cells promote high quality antibody 
responses by B cells in the form of cell-surface proteins, such as CD40-ligand (CD154) 
and secreted cytokines. In addition, CD4
+ 
T cells can secrete cytokines, such as IFN-γ 
and TNF-α (Seo & Webster, 2002; Swain et al., 2004), which have direct antiviral 
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activity on infected cells. IFN-γ enhances the accumulation of APCs, such as myeloid 
dendritic cells in the lung, following influenza A infection (Dahl et al., 2004). 
Furthermore, CD4
+ 
T cells also assist the generation and maintenance of functional 
antiviral CD8
+
 T cells.  CD4
+ 
T cells can be further classified into two different subsets. T 
helper type 1 cells (Th1) preferentially produce IFN-γ and IL-2 whereas Th2 cells 
preferentially produce IL-4 and IL-5. These cytokine responses contribute to the 
regulation of both antibody and the cytotoxic T lymphocyte responses to vaccination. 
While both Th1 and Th2 provide T cell help for antibody production, an increased Th1 
relative to the Th2 response to vaccination is needed for optimal stimulation of CTL 
responses (Palladino et al., 1991). 
 
2.4.3   Immune Correlates of Protection 
2.4.3.1 Role of HA, NA and M2 specific antibodies in the protection of                 
influenza virus infection 
            It is generally accepted that antibodies directed against the influenza virus 
hemagglutinin (HA) constitute a major correlate of protection. Since HA is involved in 
virus-host cell binding, antibodies that are directed to epitopes located in or in close 
proximity to the receptor-binding site of HA block the receptor-binding site on the HA. 
This prevents attachment and cell entry of the virus particles, thus effectively neutralizing 
the virus. Induction of sufficiently high serum titers of virus strain-specific antibodies by 
vaccination or infection will protect subjects from subsequent infection. For this reason, 
the induction of HA-specific antibodies is used as a correlate of vaccine efficacy and the 
European Medicines Agency (EMEA) has formally standardized the EU requirements for 
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annual evaluation of influenza vaccine efficacy according to the serological outcome of 
vaccination (Table 2.1) and potency of the vaccine (>15µg HA per vaccine strain). 
Typically, the serological outcome of vaccination is measured with the hemagglutination 
inhibition (HI) assay. 
 
 NA, which is another major surface glycoprotein of influenza virus, cleaves 
cellular neuraminic acid and facilitates release of newly produced virus. Various in vitro 
as well as in vivo systems have shown that antibodies directed against the enzymatic site 
of NA block its function and can contribute to the protective immunity (Beutner et al., 
1979; Johansson et al., 1989; Johansson et al., 1993; Johansson & Kilbourne, 1993; 
Johansson et al., 1998; Kilbourne et al., 2004). In contrast to the HA-specific antibodies, 
NA-specific antibodies cannot prevent infection, but limit the release and further spread 
of virus from infected cells, and thus have a favorable effect on the clinical outcome of 
the infection. Therefore vaccine-induced NA specific antibodies do not provide 
sterilizing immunity, but can prevent serious disease or fatal outcome of the infection. 
 
            M2 protein is another influenza virus surface protein that protective antibodies 
may be generated against. As mentioned in section 2.3.1, M2 is a 97 amino acid 
homotetramer. Residues 1–24 compose the extracellular domain (M2e), residues 25–43 
constitute the transmembrane segment, and the remaining 54 residues form the 
cytoplasmic tail (Figure 2.3). Whereas only a few copies of M2 protein become 
incorporated into the envelope of mature infectious virus particles, M2 is expressed at 
high density in the plasma membrane of infected cells  (Frace et al., 1999; Zebedee & 
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Lamb, 1988). Thus, in contrast to the HA protein, antibodies to the extracellular portion 
of M2 (M2e) are not virus-neutralizing. Anti-M2e antibodies bind to M2e expressed on 
infected host cells and reduce virus cell-cell dissemination by interfering with virus 
budding (Zebedee & Lamb, 1989). This probably causes the killing of infected lung 
epithelial cells by complement or by cells of the innate immune system (ADCC) 
(Mozdzanowska et al., 1999).  
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Table 2.1 Criteria of the European Medicines Agency (EMEA) of the EU for the 
evaluation of influenza vaccine efficacy.  
 
Criterion 18-60 years > 60 years 
Seroconversions or 












Patients achieving HI titer ≥ 









For each virus strain, at least one of the above criteria should be met 
Issued by the Committee on Proprietary Medical Products (CPMP). Note for guidance on 










Figure 2.3 Structure of Matrix protein 2 
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2.4.3.2 Role of influenza specific cell mediated immunity in the protection of 
influenza virus infection 
            As mentioned in section 2.4.2, influenza-specific CD4
+
 T cells function mainly to 
promote high quality antibody responses. Important as it is, CD4
+
 T cells have not been 
shown to operate directly as chief effectors of virus control (Topham & Doherty, 1998). 
IFN-γ enzyme-linked immunospot and intracellular cytokine staining assays have 
suggested that influenza-specific CD4
+
 T cell clonal proliferation is both smaller in 
magnitude and more diverse than concomitant CD8
+
 T cell responses (Crowe et al., 2006; 
Doherty & Christensen, 2000). 
 
            Compared to CD4
+
 T cells, however, cytotoxic CD8
+
 T lymphocytes (CTL) were 
found to be more protective than helper T cells.  It has been demonstrated that CTL 
contribute to protective immunity and are largely directed to epitopes within conserved 
viral proteins (e.g., nucleoprotein and matrix protein), and that are shared by the various 
subtypes of influenza A, including H5N1 (Jameson et al., 1999; Kreijtz et al., 2008; 
Zweerink et al., 1977). In the presence of virus specific serum antibodies induced by 
vaccination or previous infections, memory CTL immunity may not provide further 
protection. However, under circumstances in which pre-existing humoral immunity in the 
population is not or poorly protective against the circulating outbreak strain, for example, 
in the case with antigenic drift variants or the introduction of a pandemic influenza A 
virus of a novel subtype, the induction of cross-protective CTL may be relevant and 
protective (Rimmelzwaan et al., 2007). H1N1-primed mice with relatively modest 
numbers of influenza virus–specific memory CD8+ T cells (less than 1% of total CD8+ 
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cells) were shown to clear intranasal H3N2 infection 1–2 days earlier than do naive mice 
(Doherty et al., 2006). Furthermore, mice primed with H1N1 and boosted with H3N2 
have large numbers of cross-reactive CD8
+
 memory T cells, demonstrate only transient 
weight loss and survive respiratory exposure to extremely virulent H5N1 and H7N7 
viruses (Christensen et al., 2000; O'Neill et al., 2000; Thomas et al., 2006). However, in 
contrast to findings in mice, evidence for a protective role of CTL in humans is sparse. 
The classical study by McMichael et al. demonstrated that in experimentally infected 
individuals, virus specific cytotoxicity inversely correlated with the extent of virus 
shedding in the absence of serum antibodies specific for the strain used for infection 
(McMichael et al., 1983). Furthermore, the fact that mutations in genes encoding NP 
peptides recognized by human CD8
+
 T cells allow viral “escape” (Berkhoff et al., 2004; 
Gog et al., 2003) emphasizes the idea that CD8
+
 T cells can potentially be involved in 
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2.5   INFLUENZA PATHOGENESIS 
 
2.5.1   Clinical Presentations of Influenza and Links with Immune Dysregulation 
            Influenza virus infection elicits a complex network of host immune responses that, 
in uncomplicated influenza, results in effective control of the virus and the development 
of long-term memory responses. The typical uncomplicated influenza A syndrome is 
characterized in its full form by the sudden onset of high fever, coryza, cough, headache, 
prostration, malaise, and inflammation of the upper respiratory tree and trachea. 
Complications of influenza virus infection arise primarily in the very young or elderly 
and can involve the exacerbation of underlying health conditions such as chronic 
pulmonary and cardiopulmonary diseases and can progress to viral or, more commonly, 
secondary bacterial pneumonia (Nicholson, 1992; Thompson et al., 2003). In primary 
influenza virus pneumonia, infection occurs in the alveolar epithelial lining which 
undergoes necrosis and desquamation. Alveolar macrophages are present in large 
numbers and in early stages, neutrophils predominate the infiltrating leukocytes, while in 
later stages, lymphocytes and plasma cells predominate (Taubenberger & Morens, 2008). 
 
            However, severe complications arising from pandemic influenza such as the 1918 
influenza virus or the HPAI H5N1 viruses are often associated with rapid, massive 
inflammatory cell infiltration, acute respiratory distress, reactive hemophagocytosis and 
multiple organ failure. There are evidences from fatal human cases infected with H5N1 
viruses that these viruses replicate in non-respiratory organs and, consequently, multiple 
organ involvement is indicative of dysregulated immune responses (de Jong et al., 2005a; 
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de Jong et al., 2006; Gu et al., 2007; Uiprasertkul et al., 2007; Uiprasertkul et al., 2005). 
Furthermore, the 1918 pandemic was characterized by an unusually high mortality rate in 
healthy adults ranging from 15 to 34 years of age, which may reflect immune-mediated 
pathology. Hemophagocytosis, a disorder characterized by excessive activation of 
mononuclear phagocytosis of erythrocytes, platelets, and leukocytes, is one of the most 
prominent and severe manifestations in both 1918 pandemic flu and HPAI H5N1 cases. 
Hemophagocytosis is thought to be cytokine-driven, with elevated levels of soluble IL-2r, 
IL-6, IFN-γ and TNF-α associated with disease exacerbation and poor prognosis (Akashi 
et al., 1994; Imashuku et al., 1996). 
 
2.5.2   The “Cytokine Storm Theory”- Cytokines and Chemokines in Influenza 
Immunopathology 
            Severe respiratory disease and immunopathology together with a high case-
fatality rate have become a hallmark of highly pathogenic avian influenza virus infection 
in humans as well as in other mammalian species. However, the underlying mechanisms 
accounting for the severe immunopathology are not fully understood yet. In fact, 
histological and pathological indicators strongly suggest a key role for an excessive host 
response in mediating at least some of the extreme pathology associated with highly 
pathogenic influenza viruses. Cytokine storm, characterized by dysregulated and 
exaggerated production of inflammatory cytokines by unchecked or excessive stimulation 
of the innate immune response, has been reported to correlate with fatal outcome of 
experimental animals infected with 1918 and H5N1 influenza viruses (Kash et al., 2006; 
Kobasa et al., 2007; Simon et al., 2001; Tumpey et al., 2005a) as well as in humans 
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(Beigel et al., 2005; de Jong et al., 2006; Peiris et al., 2004; Uiprasertkul et al., 2007) 
succumbing to H5N1 infection. Indeed, cytokine storm has been associated with massive 
pulmonary edema, primary and secondary pneumonia, and alveolar haemorrhage with 
acute bronchopneumonia. However, some studies suggest that a high viral load in the 
respiratory tract is primarily responsible for the disease severity in influenza infection, 
and that severe immunopathology is secondary and the consequence of an inability to 
resolve the viral infection (de Jong et al., 2006; de Jong et al., 2005b). The discrepancy in 
the proposed mechanisms involved in influenza infection illustrates that the relationship 
between mortality, viral clearance and immunopathology during influenza infection 
remains elusive and has yet to be fully understood. A study using IL-1R knock-out mice 
showed increased mortality associated with delayed viral clearance but less severe 
pathology, indicating competing roles for this cytokine in pathogenesis and efficient viral 
clearance (Schmitz et al., 2005). Reduced inflammatory cell infiltration and pulmonary 
damage but with delayed viral clearance was also observed in mice with a disrupted MIP-
1α gene (Cook et al., 1995). Studies investigating the role of IL-6 in influenza infection 
demonstrated both positive and negative effects of this cytokine (Kozak et al., 1997; 
Larsen et al., 1998; Lee et al., 1999). A study using CCR5 (receptor for MIP-1a, MIP-1b 
and RANTES)- and CCR2 (primary receptor for MCP-1)-deficient mice revealed that 
CCR5-deficient mice showed decreased survival rate associated with a dramatic 
inflammatory immune response and lung damage, while CCR2-deficient mice displayed 
reduced mortality but a significantly elevated viral burden associated with decreased 
pulmonary cell infiltration and tissue damage (Dawson et al., 2000). In another study, the 
intratracheal administration of the sphingosine analog AAL-R significantly reduced lung 
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immunopathology caused by influenza virus by decreasing the release of a variety of 
cytokines and chemokines known to contribute to the cytokine storm effect while no 
change in lung viral titers was observed even when AAL-R was given at high dose 
(Marsolais et al., 2009). Taken together, these data suggest that influenza-induced 
mortality is not necessarily a direct function of viral burden, highlighting the role of 
immune-mediated pathology in this disease.        
 
            Although multiple studies suggest that proinflammatory cytokine responses 
correlate with disease severity, the use of gene knockout mice failed to place any single 
cytokine including TNF-α, IL-6 and CC chemokine ligand 2 (CCL2) in a key role in fatal 
H5N1 virus infection (Salomon et al., 2007). A better understanding of the complex 
interplay between the virus and the host, and the consequences for disease outcome, will 
undoubtly help develop improved methods to identify rapidly a possible genetic basis for 
disease, and develop appropriate intervention strategies. 
 




 in Influenza Immunopathology 




 T cells can potentially 
mediate pulmonary immunopathology following influenza virus infection.  
 
            As discussed in section 2.4.2, CD4
+ 
T cells can be classified into two subsets, Th1 
which preferentially produce IFN-γ and IL-2, and Th2 which preferentially produce IL-4 
and IL-5. Adoptive transfer of influenza-specific Th1 CD4
+ 
T cell clones has been shown 
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both to protect BALB/c mice following lethal influenza virus infection and decrease 
influenza induced immunopathology. IFN-γ produced by Th1 cells was shown to play a 
role in promoting IgG2a class-switched antibody responses and may therefore ameliorate 
the immunopathology. In contrast, adoptive transfer of influenza-specific Th2 CD4
+
 T 
cell clones failed to protect the mice against lethal influenza challenge where the animals 
showed delayed viral clearance and extensive lung congestion. The enhanced 
immunopathology was thought to be caused by IL-4 and IL-5 secreted by the adoptively 
transferred Th2 cells as a marked pulmonary eosinophilia was observed (Graham et al., 
1994).  
 
            CD8
+
 T cells functions are critical for efficient control of influenza virus infection 
via either direct lysis of infected cells or the production of proinflammatory cytokines 
such as IFN-γ and TNF-α. Important as they are, these protection mechanisms could also 
contribute to lung immunopathology and damage. As suggested by previous studies, this 
immunopathology effect generally occurs when the CD8
+ 
T cell response is unable to 
control the viral load and the virus clearance is delayed (Bender et al., 1995; 
Moskophidis & Kioussis, 1998). Prolonged expression of IFN-γ by CD8+ T cells may 
indirectly exacerbate immunopathology mediated by macrophages (Hsieh & Chang, 
2006). Production of TNF-α by CD8+ T cells was also shown to mediate lung damage in 
several in vivo and in vitro studies (Liu et al., 1999; Small et al., 2001; Zhao et al., 2001). 
A member of the TNF receptor superfamily, OX40, expressed on activated T cells, B 
cells, dentritic cells (DCs) and vascular endothelium has been found to be involved in the 
activation of influenza specific CD8
+
 T cells and the subsequent immunopathological 
CHAPTER 2 SURVEY OF LITERATURE 
31 
 
damage; Functioning as a co-stimulatory molecule, OX40 has been implicated in T-cell 
migration, proliferation and cytokine production (Gramaglia et al., 1998; Kopf et al., 
1999). OX40 expressed on activated T cells interacts with OX40 ligand (OX40L) on 
antigen presenting cells. Blocking of OX40-OX40L interaction by OX40-Ig treatment 
resulted in significant amelioration in weight loss and reduced sickness in infected 
animals associated with reduced CD8
+
 T cells, CD4
+
 T cells and  neutrophils infiltration 
in the lungs, as well as diminished TNF-α production by  the CD8+ T cells (Humphreys et 
al., 2003).  
 
2.5.4   Alveolar Macrophages and Neutrophils in Influenza Immunopathology 
            Recruitment of monocytes/macrophages into the lung parenchyma and alveolar 
spaces is a hallmark of the initial response to influenza infection. Upon influenza virus 
infection, alveolar macrophages (AMs) can release proinflammatory cytokines (TNF-α, 
IL-1β, IL-6 and type I interferon) and chemokines (MCP-1, MIP-1, RANTES and IP-10). 
Production of proinflammatory cytokines by virus-infected AMs can potentially 
contribute to exacerbate inflammation-mediated lung pathology by inducing the 
activation and migration of additional blood monocytes and neutrophils, as well as T and 
B cells to the infected lungs. A second wave of cytokines released from infiltrating 
macrophages undergoing virus-induced apoptosis would indeed further amplify the 
inflammatory response, leading to high concentrations of cytokines in the circulation 
which may have destructive, multi-organ consequences. On the other hand, there are 
evidences showing that AMs also play important roles in inhibiting influenza virus 
infection; depletion of AMs led to uncontrolled virus growth and 100% mortality 
CHAPTER 2 SURVEY OF LITERATURE 
32 
 
following a sublethal 1918 HA/NA:Tx/91 influenza virus infection (Tumpey et al., 
2005b).  Therefore, although the presence of large numbers of these cells may exacerbate 
clinical symptoms and contribute to the lung pathology through the production of pro-
inflammatory cytokines, chemokines and reactive oxygen species or nitric oxide 
metabolites (La Gruta et al., 2007), the infiltration of monocytes/macrophages into the 
lung tissue upon infection is essential for host protection and recovery. In addition, 
alveolar macrophages have been demonstrated to display suppressive effects on the 
inflammation reaction by regulating T-cell function (Strickland et al., 1993), and by 
suppressing dendritic cells maturation (Bilyk & Holt, 1993; Holt et al., 1993; Stumbles et 
al., 2003) and migration to the mesenteric lymph nodes (Jakubzick et al., 2006). 
Furthermore, alveolar macrophages have recently been demonstrated to display high 
basal expression of CD200R that was rapidly up-regulated during influenza infection 
(Snelgrove et al., 2008). CD200R expression was shown to be critical for lung 
macrophage immune homeostasis in the resting state, and limits inflammatory amplitude 
and duration during pulmonary influenza infection. CD200R-mediated regulation of AMs 
involves the ligand CD200 which is expressed on the luminal aspect of the airway 
epithelium. Mice lacking CD200 had more macrophage activity and enhanced sensitivity 
to influenza infection, which led to delayed resolution of inflammation and, ultimately, 
death. Furthermore, administration of agonists that bind CD200R prevented 
inflammatory lung disease (Snelgrove et al., 2008).  
 
            Neutrophils may also contribute to the release of cytokines, and although they 
traditionally have been viewed as being important in fighting bacterial infections, these 
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cells can be involved in virally induced pathology. Uncomplicated human influenza virus 
infections of the H1 or H3 subtype usually results in viral replication in the respiratory 
epithelium and leads to the induction of an inflammatory infiltrate comprised mainly of 
mononuclear leukocytes such as AMs, with lower levels of PML (neutrophils) (Ada & 
Jones, 1986).  However, predominant neutrophil infiltrate increase into the mouse lungs 
has been shown to be associated with the immunopathology and pathogenesis of the 
enhanced disease induced by reconstructed highly pathogenic 1918 influenza virus and 
1918 HA/NA:Tx/91 virus infections (Kash et al., 2006; Tumpey et al., 2005b). A heavy 
inflammatory infiltration marked by a predominance of neutrophils associated with an 
increase of AMs and cytokines shortly before the death of the mice was observed in the 
mice infected with 1918 HA/NA:Tx/91. In addition, overproduction of proinflammatory 
cytokines, such as TNF-α and IFN-γ, upon infection with highly pathogenic influenza 
virus, can also stimulate more neutrophils into the inflamed tissues. TNF-α was found to 
be able to enhance neutrophilic infiltration into the lung tissue (Kips et al., 1992). 
Neutrophils can elicit numerous responses in the presence of IFN-γ, including increased 
oxidative burst, induction of antigen presentation and chemokine production (Ellis & 
Beaman, 2004; Farrar & Schreiber, 1993). Taken together, although increased numbers 
of neutrophils in the lungs contribute to the inhibition of virus replication as part of the 
host innate immune response, they might also contribute to the enhanced 
immunopathology and, therefore, be partially responsible for the lethality of highly 
pathogenic influenza virus infections. 
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2.6   OPTIONS FOR PANDEMIC CONTROL 
2.6.1   Antivirals Treatment: Effectiveness and Limitations 







) and its analogue rimantadine 
(Flumadine
®
), and the neuraminidase inhibitors zanamivir (Relenza
®
) and oseltamivir 
(Tamiflu
®
). These drugs interfere with specific steps in the replication cycle of influenza 
virus, either at the level of virus entry (neuraminidase inhibitors) or at the level of virus 
assembly or release from the infected cell (M2 inhibitors). 
 
            Amantadine and rimantadine were the first generation of influenza antiviral 
agents. These compounds specifically block the ion channel function of the M2 protein of 
influenza A virus, thus interfering with corresponding specific steps in the viral life cycle.  
Both amantadine and rimantadine are active at low doses against various subtypes of 
influenza A viruses whereas they have no activity against influenza B viruses. Like 
amantadine, rimantadine is also effective for the prevention of infection and illness 
caused by seasonal influenza A viruses (Couch, 2000). When used as prophylactic 
treatment, either drug can prevent about 50% of infections or 70–90% of morbidity. 
Notably, prophylactic treatment does not increase the emergence of resistances (Couch, 
2000; Monto, 2006). Moreover, the therapeutic use of amantadine or rimantadine reduced 
the duration of symptoms by approximately 1 day when administered within 48 h of 
onset of symptoms (Couch, 2000). However, these drugs have not been shown to reduce 
the rate of influenza A virus-associated complications (Monto, 2003). 
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            Neuraminidase inhibitors zanamivir and oseltamivir are analogues of sialic acid. 
These compounds specifically inhibit all nine NA subtypes in nature, including the 
subtypes contained in the avian strains of influenza A H5N1, H7N7 and H9N2 that have 
infected humans (Moscona, 2005). Zanamivir exhibits better in vitro antiviral activity 
against influenza B viruses, whereas oseltamivir is more effective against influenza A 
isolates (Boivin & Goyette, 2002). Clinical trials demonstrated that NA inhibitors are 
highly effective in the treatment of seasonal influenza. Moreover, NA inhibitor treatment 
reduced complications associated with influenza infection both in adults and children 
(Lalezari et al., 2001) thus providing an important advantage over M2 ion channel 
inhibitors. 
 
            The most common side effects of the M2 inhibitors are central nervous system 
(CNS) complaints such as anxiety, difficulty concentrating, insomnia, dizziness, 
headache and jitteriness (Couch, 2000). While the CNS complaints are minor in younger 
adults, these symptoms may be very prominent in the elderly, particularly with the use of 
amantadine. In addition, both amantadine and rimantadine can exaggerate gastrointestinal 
symptoms, including nausea and vomiting in influenza A patients (Couch, 2000). 
Importantly, in contrast to prophylactic treatment, adamantine resistance emerges rapidly 
following therapeutic use in human influenza A infection. Adamantine-resistant viruses 
are fully transmissible and pathogenic (Abed et al., 2005; Hayden et al., 1989). 
Widespread adamantine resistance has been documented among seasonal H1N1 and 
H3N2 strains, in addition to a majority of clade 1 and some clade 2 H5N1 isolates from 
Southeast Asia (Bright et al., 2005; Cheung et al., 2006).  
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            In general, neuraminidase inhibitors have fewer adverse effects than the M2 
channel blockers and they are less prone to select for resistant influenza viruses. Both 
influenza A H1N1 and H3N2 isolates are highly susceptible to NA inhibitors. However, 
oseltamivir-resistant H5N1 and H1N1 isolates (de Jong et al., 2005b; Le et al., 2005; 
Sheu et al., 2008) had also been identified in patients during oseltamivir treatment. 
 
            Taken together, the use of antiviral drugs early in the pandemic would buy time 
until a vaccine against the pandemic strain can be produced and available in sufficient 
quantities for mass vaccination. However, many issues related to the use of antivirals in 
pandemic control remain. Firstly, as discussed above, the relatively rapid induction of 
resistance to the M2 inhibitors when used for the treatment of influenza illness would 
quickly limit the efficacy of this class of antiviral drugs for preventing influenza illness 
and ameliorating the impact on pandemic influenza. Although neuraminidase inhibitors 
have many advantages over M2 inhibitors, the development of H5N1 disease raised 
concerns about the potential for induction and spread of antiviral-resistant H5N1 strains. 
In addition, the efficacy of these drugs in the absence of vaccination in the very young 
and the very old also remains in question in pandemic influenza seasons. 
 
 
2.6.2   Licensed and Trial Vaccines 
            Vaccination is considered as the primary and single most cost-effective method 
for preventing influenza. Influenza vaccination with current licensed influenza vaccines 
(inactivated or live attenuated virus vaccines) results in significant reduction in influenza-
related respiratory illness, hospitalization rates and deaths among the elderly and patients 
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at risk of serious complications of influenza. Furthermore, these vaccines have an 
excellent safety record. However, limitations remain (to be discussed in 2.6.2.1.3). 
Therefore, novel and efficacious influenza vaccine modalities are highly in demand.  
 
2.6.2.1 Current licensed vaccines 
            Current licensed influenza vaccines can be categorized into two different groups- 
inactivated virus vaccines and live attenuated virus vaccines.  Both kinds of vaccines 
contain three virus strains, two influenza A subtype-H1 and H3, and influenza B type. 
The components of the vaccine (currently two influenza virus A subtypes, H1N1 and 
H3N2, and one influenza B subtype) are determined each year by an international 
surveillance system coordinated by the World Health Organization (WHO).    
 
2.6.2.1.1 Inactivated virus vaccines 
            Inactivated virus vaccines are in one of three forms: whole virus, split-product 
vaccines, and surface antigen vaccines. Whole virus vaccines are the initial licensed 
formulations which were first introduced in the 1940s. These vaccine formulations 
consist of virus particles chemically inactivated through formaldehyde or β-propiolactone 
treatment. Whole virus vaccines are usually quite immunogenic as the entire virus 
proteins are present and stimulate effectively the host immune system. However, despite 
improvements in techniques for virus purification, local reactogenicity and systemic side 
effects still pose problems in the use of these vaccines, particularly in young children 
(Wilschut, 2006). These side effects prompted the development of split virus vaccines in 
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which the virus has been detergent-treated and highly purified. Split vaccines were first 
licensed in the USA in 1968 and are among the most widely used formulations to date. 
They turned out be to almost equally immunogenic as the whole virus vaccines primed 
people but with significantly fewer side effects (Wood, 1998). However, a disadvantage 
of split vaccines is that they are comparatively less immunogenic than whole virus 
vaccines in naïve population (such as young children) without prior exposure to flu virus 
or vaccine (Bresson et al., 2006; Nicholson et al., 1979; Stephenson et al., 2004). The 
third formulation, surface antigen vaccines with the name Trivalent Inactivated Vaccines 
(TIV vaccines), consist of a better improvement and refinement of the previous two 
formulations. They are made of two major partially purified influenza virus surface 
proteins, HA and NA. Because of their relatively high purity, TIV vaccines are well 
tolerated with very few side effects compared to whole virus and split product vaccines 
(Beyer et al., 1998). However, they are not optimally immunogenic and require multiple 
doses together with inclusion of an adjuvant to ensure strong antibody responses. 
 
 2.6.2.1.2 Live attenuated virus vaccine- Cold attenuated vaccine (CAV) 
            Current live attenuated virus vaccines, FluMist
®
, are trivalent cold adapted 
vaccines (CAV); like the inactivated influenza vaccines, CAV include influenza A virus 
H3N2 and H1N1 subtypes, and influenza B virus. They were licensed for human use in 
2003 in USA for individuals from 5 to 49 years of age. This vaccine induces an immune 
response that more closely resembles natural immunity than the response elicited by 
inactivated vaccines (Cox et al., 2004). Studies have shown that CAV induce a strong 
long term local cellular and humoral response, providing protection at the systemic and 
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mucosal levels (Cinatl et al., 2007; Cox et al., 2004). Among young children, CAV had 
significantly better efficacy than inactivated vaccines (Cinatl et al., 2007). Moreover, 
CAV can stimulate immune responses in influenza A virus-naïve individuals following a 
single dose of administration (Cinatl et al., 2007). These properties make CAV attractive 
candidates for the prevention of pandemic influenza in humans. The main problem of 
CAV lies in their reliance on “cold chain” for vaccine stability. Safety wise, CAV appear 
to be quite safe but have potential risk in immunocompromised people (Lewis, 2006). For 
this reason, CAV-treated health-care workers have been advised not to be in contact with 
HIV patients for up to 3 weeks post-vaccination (Harper et al., 2004). In addition, risks in 
virus shedding and generation of reassortant viruses that are sufficiently infectious, as 
well as the risk of reassortment with circulating human influenza viruses have refrained 
the use and development of CAV for mass vaccination against influenza (Subbarao & 
Joseph, 2007). 
 
 2.6.2.1.3 Limitations of Current Licensed Vaccines 
            In summary, currently licensed influenza vaccines are highly effective in primed 
children and adults (70%-90%), but not in the very young children and the elderly (≤5 
and ≥65 years of age). Moreover, due to influenza antigenic drift and shift, the efficacy of 
current vaccines for influenza A is highly dependent on the accuracy to predict every year 
the strains that will circulate during the next epidemic.   
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2.6.2.2 Alternative approaches to pandemic influenza vaccine development  
            Due to the limitations of currently available influenza vaccines, there is an urgent 
need for the development of novel, more efficacious influenza vaccines. Various 
innovative and promising approaches have been reported. 
2.6.2.2.1   Virosome-based influenza vaccines 
            Virosomes, which are virus-like particles lacking their viral genetic material, are a 
presentation form that closely mimics the naïve virus so that the immune response to 
inactivated viral vaccines is improved by modification of the way in which the antigen is 
presented to the immune system. They are generated through a reconstitution procedure 
by treating influenza virus with an appropriate detergent such that the viral envelope is 
selectively solubilized. Functionally reconstituted virosomes preserve the receptor-
binding and membrane fusion activity of the viral HA, implying that these virosomes, 
like the native virus, are internalized by cells via receptor-mediated endocytosis and 
fusion within acidic endosomes. 
 
            Currently, there are two virosome-based influenza vaccines available on the 




. Both vaccines have excellent safety and 
immunogenicity records (de Bruijn et al., 2004; Kanra et al., 2004). In comparative trials, 
the MF59-adjuvanted vaccine Fluad and the two virosome vaccine formulations were 
shown to have similar efficacy and immunogenicity (de Bruijn et al., 2006; Ruf et al., 
2004). Moreover, the MF59-adjuvanted vaccine was found more reactogenic than the 
virosomal vaccines. 
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2.6.2.2.2   DNA Vaccines 
            DNA vaccines are non-infectious, non replicating E. coli plasmids that encode 
only protein(s) of interest to which immune responses are induced. This feature makes it 
possible to vaccinate individuals multiple times without induction of immune-dampening 
vector specific responses. The production of DNA vaccines in E. coli enables large-scale 
production and yields a highly pure and stable vaccine. DNA vaccines present a 
promising new approach to vaccination, evoking a full range of immune responses, 
including antibody, cytotoxic, and helper-T-cell responses.  
 
            DNA vaccines with constructs encoding influenza NP, HA, NA, M1, M2 and NS1 
proteins elicited protective and long-lasting immune responses in different animal models 
and conferred protection against challenge with homologous as well as heterologous 
virulent influenza virus in mice, chicken and ferrets (Liu et al., 1997; Pertmer et al., 1995; 
Robinson et al., 1993; Tompkins et al., 2007; Ulmer et al., 1993; Ulmer et al., 1998). The 
protective potential of DNA vaccines against H5N1 influenza virus has also been 
explored (Epstein et al., 2002; Kodihalli et al., 2000). 
 
            DNA vaccine encoding HA from the influenza H5N1 isolate 
A/HongKong/156/97 (HK156) provided immunity against H5N1 infection of mice 
whereas DNA vaccine encoding HA from A/Ty/Ir/1/83 (H5N8) virus, which differ from 
HK156 virus by 12% in HA1, prevented death but not H5N1 infection in mice (Kodihalli 
et al., 1999). DNA vaccination in mice with plasmids expressing conserved NP and M 
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genes from an H1N1 influenza subtype protected against lethal challenge with HK156 
virus.  
 
            Although DNA immunization has given promising results in some animal models, 
a study in pigs vaccinated with M2/NP DNA vaccine exhibited exacerbation of disease 
upon challenge rather than protection (Heinen et al., 2002). Moreover, the initial results 
of a phase I study that evaluated intramuscular delivery of an influenza HA DNA vaccine 
trial were quite disappointing (Cinatl et al., 2007), indicating that further investigation is 
required to determine the efficacy of DNA immunization in humans. 
 
2.6.2.2.3   Recombinant Vectored Subunit Vaccines  
            Recombinant vectored subunit vaccines are composed of recombinant influenza 
proteins that are expressed by antigen delivery vectors. This means influenza subunit 
vaccines can be prepared without prior growth of the entire influenza virus.            
Several viral vectors have been developed to express recombinant influenza virus 
vaccines. These include replication defective adenoviral vectors, recombinant baculovirus 
vectors, poxvirus vectors and Newcastle disease virus vectors.  
 
            The immunogenicity and protective efficacy of two replication defective 
adenoviral vectors expressing full-length H5 HA were tested in mice and poultry by Gao 
WT et al. and Hoelscher MA et al, respectively (Gao et al., 2006; Hoelscher et al., 2006). 
These recombinant vaccines elicited both humoral and cellular immune responses in mice 
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and were able to protect against wild-type homologous and antigenically heterologous 
H5N1 viruses challenge after two doses of immunization. The authors proposed that 
cross-protection against heterologous challenge was mediated by the cellular immune 
response. Despite the promising data achieved by adenoviral vectored vaccines, a major 
limitation may exist for the use of adenoviral vectors in humans because of the pre-
existing immunity to human adenovirus in human populations, which could limit 
generation of immune response against a foreign gene of interest. 
 
            Recombinant baculovirus has also been used for expressing HA and/or NA 
proteins from influenza virus. A recombinant H3-HA (from H3N2 virus) subunit vaccine 
produced in baculovirus has been evaluated in Phase I and II clinical trials in human 
volunteers (Lakey et al., 1996). Other studies have also shown that baculovirus-based 
H3-HA vaccine induced a better serum antibody response than a conventional vaccine 
against HA of H3 subtype (Treanor et al., 2006; Wang et al., 2006). The safety and 
immunogenicity of recombinant baculovirus expressed H5-HA vaccine derived from 
H5N1 virus without adjuvant was also tested in a phase I clinical trial in humans (Treanor 
et al., 2001). However, the immunogenicity of this vaccine turned out to be suboptimally 
immunogenic in naïve adult populations compared to conventional influenza vaccines. 
 
            Other viral vectors tested for influenza vaccine purpose involved poxvirus and 
New castle disease virus (NDV) vectors. The poxvirus-vectored influenza vaccine 
expressing H5 HA derived from avian virus A/turkey/Ireland/ 1378/83 (H5N8) showed 
protection against challenge with homologous and heterologous wild-type highly 
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pathogenic H5N1 virus (AChicken/Indonesia/7/03) in a cat model (Karaca et al., 2005). 
NDV vectors expressing H5 HA derived from A/chicken/Italy/8/98 (H5N2) were shown 
to be able to protect chicken from both new castle disease and avian influenza (Veits et 
al., 2006). NDV was also used to express H5-HA from highly pathogenic avian strain 
A/Bar-headed goose/Qinghai/3/2005 (H5N1) and was shown to protect chickens and 
mice from challenge with a lethal dose of homologous and heterologous highly 
pathogenic H5N1 viruses (Ge et al., 2007).  
 
            In conclusion, recombinant vectored subunit vaccines appear to be the most 
promising vaccines against influenza. Recombinant vectored vaccines show several 
advantages over conventional influenza vaccines. Firstly, recombinant vector-based 
subunit vaccines may be delivered by mucosal route which eliminates the need of needles 
during vaccination. Secondly, recombinant vector-based delivery systems are able to 
induce strong immune responses without inclusion of adjuvants and their production is 
egg-independent. Last but not least, by including conserved neutralizing or CTL epitopes 
into the vector, recombinant vectored-based vaccines may be able to overcome the 
drawbacks of conventional vaccines by inducing strong cellular immunity as well as 
humoral immunity, and thus confer cross-protection against heterologous influenza 
viruses without the need to frequently update the vaccines to guess-match the virus 
strains that will cause the next pandemic. 
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2.6.3   Universal influenza virus vaccines 
            Due to the limitations of current anti-viral drugs and licensed flu vaccines, 
universal influenza vaccines using conserved influenza proteins may provide cross-
protection against different influenza virus subtypes. Because of their potential for 
broadening vaccine-mediated protection in humans, they have been studied extensively in 
animals and found to be mediated predominantly by virus-specific memory T cells 
(Benton et al., 2001; O'Neill et al., 2000), antibodies (Epstein et al., 1997; Nguyen et al., 
2001), or a combination of both (Liang et al., 1994; Sambhara et al., 2001). Different 
conserved vaccine candidates will be reviewed and discussed in detail below.         
           
 2.6.3.1   Ecto-domain of Matrix protein 2 (M2e) as a Universal Vaccine Candidate 
            One of the most hotly pursued universal influenza vaccine candidate is the 
extracellular domain of Matrix protein 2 (M2e). The sequence of M2e has remained 
remarkably non-changed among human epidemic virus strains, even back to the 1918 
Spanish flu (Figure 2.3) (Reid et al., 2002).   
 
            The possibility that the M2e protein may serve as a vaccine target was first 
demonstrated in a study showing that mAb14C2 directed towards the extracellular part of 
M2 (M2e) considerably reduced the spread of different influenza virus strains and 
achieved the same effect as M2 antiviral drug amantadine (Zebedee & Lamb, 1988). 
Subsequent passive transfer experiment of 14C2 antibodies in mice was able to accelerate 
lung viral clearance following a sublethal influenza A virus challenge (Treanor et al., 
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1990). Slepushkin et al. subsequently demonstrated that immunization with baculovirus-
expressed recombinant full length M2 protein protected mice from both homologous and 
heterologous lethal challenge (Slepushkin et al., 1995). In 1999, Neirynck et al. reported 
in Nature Medicine that a vaccine made of M2e fused to a carrier protein, the core of the 
hepatitis B virus (HBc) significantly reduced flu-induced death in mice challenged with 
homologous and heterologous influenza A viruses (Neirynck et al., 1999). HBc proteins 
clumped into virus-like particles bristling with M2e that stimulated more antibodies to 
M2e than did the protein by itself. In their latest paper, nasal administration of the 
universal influenza vaccine M2e-HBc in combination with the adjuvant CTA1-DD 
completely protected mice from a lethal infection and significantly reduced morbidity 
(De Filette et al., 2006). Furthermore, a study in ferrets, the animal model considered 
most prognostic for human influenza, has demonstrated protective activity of M2e-
specific immunity, and sera from rhesus monkeys immunized with a M2e-carrier 
conjugate have been shown to exhibit protective activity upon transfer into mice (Fan et 
al., 2004). However, pigs vaccinated with recombinant M2e-HBc chimera or plasmid 
DNA encoding an M2e-NP fusion protein showed no protection or even more severe 
illness, respectively, after virus challenge (Heinen et al., 2002). 
 
            In summary, evidence from animal models shows that M2e specific immunity 
typically restricts virus replication and confers protection against homologous and 
heterologous influenza A virus challenge. However, a number of issues remain to be 
addressed before considering M2e a competent universal vaccine candidate to be used in 
humans; such as the emergence of escape mutant in the presence of anti-M2e antibodies 
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and the M2e-induced protective immunity depending on animal species. Moreover, 
additional conserved determinants for protective antibodies are likely to exist and deserve 
further study. 
 
 2.6.3.2   Nucleocapsid Protein (NP) as a Universal Vaccine Candidate 
Another approach to the search of universal flu vaccines uses conserved internal 
proteins such as nucleoprotein (NP) which elicit cytotoxic T lymphocytes (CTL), instead 
of antibodies that recognize and kill infected cells expressing viral antigens. 
 
            NP, the major viral protein, constitutes about 30% of virion protein content (Lamb, 
2001a). It is very well conserved and does not evolve much from one subtype to another 
(Shu et al., 1993). There is an abundance of data proving that this protein is capable of 
inducing homo- and heterosubtypic CTLs when used as a purified immunogen (Altstein 
et al., 2006; Gschoesser et al., 2002; Saha et al., 2006; Wraith et al., 1987) or via DNA 
immunization (Fu et al., 1998; Ulmer, 2002; Ulmer et al., 1998). 
 
            Moreover, since CTLs are specific to peptides rather than proteins, it thus might 
be advantageous to use an immunodominant CTL epitope as a universal vaccine 
candidate. Different factors, such as MHC binding affinity, antigen processing, and 
composition of the TCR repertoire appear to play an important role in the selection of the 
determinants recognized by T-cell responses. It has been well established that NP366-374 
/Db is one of the immunodominant CTL epitopes that can induce protection against 
influenza infection in mice carrying Db (Belz et al., 2000a; Belz et al., 2000b; Cerundolo 
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et al., 1991; Townsend et al., 1986; Zhong et al., 2003). CD8
+
 T cells specific for NP366-
374 are prominent during the primary response, but after secondary challenge, the NP336-
374-specific CD8
+
 T cells can be more than ten times „overdominant‟ (Marshall et al., 
2001). Ninomiya et al. showed that intranasal immunization with NP366-374 loaded 
lipsosomes effectively induced mucosal immunity to reduce influenza A virus replication 
in the lung (Ninomiya et al., 2002). Thus, besides full length NP, the immunodominant 
CTL epitope NP366-374 represents another promising universal influenza vaccine candidate. 
 
 2.6.3.3   Conserved Neutralizing Epitopes of HA protein as Universal Vaccine 
Candidates 
            As influenza HA is one of the main surface antigens that induce a protective 
neutralizing antibody response against influenza, one alternative to target the well-
conserved viral antigens such as M2e and NP, consists of identifying protective 
conserved epitopes within HA. One such conserved epitope includes the 11 amino acid 
(aa) in HA2 N-terminal moiety, termed fusion peptide. This fusion peptide is responsible 
for the insertion of HA2 into the target host membrane during the fusion process (Atassi 
& Webster, 1983). Hence, antibodies against this peptide are expected to exhibit fusion-
inhibition activity and protect against the viral infection. Indeed mAb CF2 raised against 
the 11aa fusion peptide proved to inhibit the fusion activity of HA effectively, and 
improved the survival of mice even after infection with a heterologous H3N2 virus 
(Vareckova et al., 2003). Two other studies showed that mice vaccinated with the fusion 
peptide exhibited less illness and reduced mortality upon virus challenge (Bianchi et al., 
2005; Horvath et al., 1998). Importantly, although the degree of HA sequence diversity 
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between subtypes is great, particularly in the HA1 polypeptides (34%–59% homology 
between subtypes), more conserved regions are found in HA2 (51%–80% homology 
between subtypes). Most notably, the 11aa fusion peptide is conserved among all 
influenza A subtypes and differs only by 2 conservative amino acid replacements in 
influenza B virus (Gerhard et al., 2006). Other conserved and neutralizing HA epitopes 
are aa 331-335 of HA1 and the conformational neutralizing epitope in the middle of the 
stem region of HA consisting of two regions (aa 318–322 of HA1 and aa 47–58 of HA2) 
(Okuno et al., 1993; Rajnavolgyi, 1992; Smirnov et al., 2000). A monoclonal antibody 
(mAb) C179 directed to the conformational epitope in the middle of the stem region was 
indeed shown to be efficient in the prevention and treatment of lethal influenza virus 
bronchopneumonia caused by H1, H2 and H5 viruses in mice (Okuno et al., 1993; 
Smirnov et al., 2000) 
 
Taken together, while the development of universal flu vaccines using 
conventional conserved viral proteins such as M2e or NP is being extensively pursued, 
approaches considering alternative conserved antigens appear promising and deserves 
further investigation.  
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(II) BORDETELLA PERTUSSIS AS A LIVE VEHICLE FOR HETEROLOGOUS 
VACCINE ANTIGENS DELIVERY THROUGH THE NASAL ROUTE 
 
2.7 MUCOSAL VACCINATION 
The majority of pathogens initiate infection by interacting with host mucosae. 
Thus, stimulation of mucosal defenses is very important for controlling infection and 
preventing disease. Induction of local responses is possible through the use of mucosal 
vaccines as parenteral vaccination elicits little or no IgA, the antibody isotype that is 
abundantly secreted in mucosal tissues and that is responsible for their defense (McGhee 
et al., 1992). 
 
2.7.1 Mucosal Immunity  
            The hallmark of the mucosal immune system is the production of secretory IgA 
(sIgA) antibodies. sIgA antibodies have multiple roles in mucosal defense (Lamm, 1997). 
They promote the entrapment of antigens or microorganisms in the mucus, preventing 
direct contact of pathogens with the mucosal surface, a mechanism that is known as 
„immune exclusion‟ (Phalipon et al., 2002). Alternatively, sIgA can neutralize bacterial 
products or viruses within the epithelial cells, during their transcellular transport 
(Fernandez et al., 2003; Yan et al., 2002). Furthermore, sIgA that are present in the 
lamina propria can capture antigens such as toxins and viruses, and are able to excrete 
them from the mucosal tissue by intracellular cycling (Kaetzel et al., 1991; Yan et al., 
2002). Although sIgA antibodies represent the predominant humoral defense mechanism 
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at the mucosal surfaces, locally produced IgM and IgG, as well as serum-derived IgG can 
also contribute significantly to immune defense (Holmgren & Czerkinsky, 2005). In 
addition, mucosal cytotoxic T lymphocyte (CTL) immune responses have also been 
described after oral, nasal, rectal, vaginal as well as transcutaneous immunization 
(Belyakov et al., 2004; Klavinskis et al., 1996; Staats et al., 2001). Mucosal CTLs have 
been shown to play a crucial role in the immune clearance of pathogens in several animal 
models infected with enteric or respiratory viruses and intracellular parasites (Buzoni-
Gatel et al., 1997; Franco & Greenberg, 1995). 
 
2.7.2 Vaccination via the Mucosal Route 
            Mucosal vaccination has several advantages over parenteral vaccination (De 
Magistris, 2006). First of all, mucosal immunization elicits antigen specific sIgA 
antibodies at the site of infection. This local pathogen-specific response is very important 
because most pathogenic microorganisms are either restricted to the mucosal membranes 
or transit via mucosae during the early stages of infection; therefore elicitation of immune 
responses at the mucosal level after immunization is highly desirable. Secondly, thanks to 
the expression of mucosa-specific homing receptors by mucosally primed lymphocytes, 
the immunization at one mucosal site can induce specific responses at distant sites. 
Thirdly, in addition to IgA responses, mucosal vaccination induces systemic IgG 
responses that represent a further defense against invasion by microorganisms or their 
products, and also cell mediated responses including helper CD4
+
 T cells and CD8
+
 
cytotoxic T lymphocytes which are important to combat intracellular pathogens. Thus, 
mucosal vaccines have the potential to activate all the different arms of the immune 
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system. In addition, mucosal administration of vaccines also offers a number of important 
practical and economical advantages such as easy and painless administration, absence of 
syringe-mediated contaminations, with reduced delivery-associated costs.  
 
2.7.3 Intranasal Vaccination 
            The nasal mucosa is an important arm of the mucosal immune system since it is 
often the first point of contact for inhaled antigens and as a consequence, intranasal 
immunization has emerged as possibly the most effective route for vaccination for both 
peripheral and mucosal immunity. Nasal vaccination is easily accessible and it is highly 
vascularized. Presence of numerous microvilli covering the nasal epithelium generates a 
large absorption surface. Moreover, intranasal vaccination can be used for the easy 
immunization of large population groups. In addition, intranasal immunization does not 
require needles and syringes, which are potential sources of infection. 
 
            Importantly, intranasal vaccination can provide both humoral and cell-mediated 
protection, not only at the relevant mucosal surface, but also throughout the body. In this 
regard, nasal vaccination has shown particular potential. Studies in mice, monkeys and 
also humans, have shown that nasal administration of vaccines induced specific mucosal 
IgA antibody responses in the salivary glands, upper and lower respiratory tracts, male 
and female genital tracts, as well as in the small and large intestines (Imaoka et al., 1998; 
Kozlowski et al., 2002; Rudin et al., 1999; Staats et al., 1997). In addition, nasal 
immunization studies in humans and mice produced greater systemic antibody responses 
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than other mucosal immunization routes (Kozlowski et al., 2002; Staats et al., 1997), 
presumably because antigens or APCs readily trafficked to draining lymph nodes from 
this site. The nasal route can also induce CTLs in distant mucosal tissues including the 
female genital tract (Gallichan & Rosenthal, 1998). Furthermore, nasal immunization in 
mice and monkeys with certain live viral vectors generated systemic antiviral CTLs and 
IgG at concentrations that were comparable to those induced upon parenteral vaccination 
(Egan et al., 2004; Enose et al., 2002).  
 
2.8 BORDETELLA PERTUSSIS MICROBIOLOGY 
2.8.1   Bordetella pertussis Pathogenesis and Whooping Cough 
            Bordetella pertussis is an aerobic, non-spore forming, Gram negative 
coccobacillus. It is a strict human pathogen and is the etiological agent of whooping 
cough in infants. Transmission of disease is postulated to occur via respiratory droplets. 
Bacteria pathogenesis occurs in two stages: the initial colonization stage and the 
following toxemic stage. In the colonization stage, the bacteria interact with the ciliated 
epithelium of the bronchi and trachea. During the following toxemic stage, a variety of 
soluble toxins are produced by the bacteria, such as PT and tracheal cytotoxin (TCT) 
(Preston, 2002). 
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2.8.2 Treatment and Pertussis Vaccines                     
            Treatment with antibiotics such as azithromycin and clarithromycin does not 
significantly shorten the clinical course in infected patients but aims to reduce 
transmission to other persons (Altunaiji et al., 2007).  
            The original pertussis vaccines were inactivated whole-cell vaccines (Pw) and 
were developed in the 1930s. Although Pw have prevented millions of deaths since their 
first use, several countries have interrupted their pertussis vaccination programmes 
because of adverse reactions that have been associated with Pw, such as local pain, 
redness, swelling, fever, drowsiness, and sometimes with irritability and anorexia.  
            The safety concerns surrounding the whole cell pertussis vaccines have led to the 
development of acellular pertussis vaccines (Pa) with less risk of adverse reactions.  
Nowadays, more than 10 different Pa are available (Storsaeter, 2007). They vary in 
antigen composition, ranging from one to five different B. pertussis antigens, and in the 
amounts of the antigens in a vaccine dose. All vaccines contain at least PT, detoxified by 
various methods, and most contain PT and FHA, sometimes with additional antigens, 
such as pertactin and fimbriae. In many countries pertussis antigens are now included in 
multivalent vaccines, which may contain diphtheria, tetanus, hepatitis B, Haemophilus 
influenzae type B, and poliovirus. Combination vaccines are preferred as they allow the 
infant to receive multiple immunizations with a single shot.  
            Despite having lower reactogenicity, the most significant shortcoming of acellular 
vaccines is their inability to sufficiently well protect neonates and infants, the most often 
the result of transmission from the adult reservoir, against severe pertussis. Thus, a 
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vaccine that can induce protection early in life, ideally after a single administration given 
at birth is highly desirable. Since natural infection with B. pertussis induces measurable 
antigen-specific Th1-type immune responses even in very young children (Mascart et al., 
2003), Live attenuated B. pertussis may represent an interesting approach for early and 
effective pertussis vaccination. A highly attenuated live B. pertussis vaccine BPZE1 has 
thus been constructed and was shown in preclinical studies to protect very effectively 
against pertussis (Mielcarek et al., 2006a) (see section 2.10.2 below). It has recently 
entered phase I safety trials in humans (http://www.child-innovac.org). 
 
2.8.3   Virulence Determinants of B.  pertussis 
            Based on in vitro adherence assays and in vivo (mice) colonization experiments, 
several surface-exposed and secreted factors have been proposed to play a role in 
Bordetella pathogenesis. These virulence determinants can be classically divided into two 
main groups: adhesins and toxins (Locht, 1999). Some of the better-studied adhesins 
include FHA, pertactin, fimbriae and the serum-resistance protein BrkA, while the toxins 
include exotoxins like PT, DNT, the adenylate cyclase toxin (ACT), the tracheal 
cytotoxin (TCT), and the heat stable endotoxin LPS (Figure 2.4).  All of these virulence 
factors are regulated by the BvgA/S two-component regulatory system, which comprises 
the histidine kinase sensor protein BvgS and the DNA-binding response regulator protein 
BvgA (Preston et al., 2004). Functions of these virulence factors are listed in Table 2.2. 
In this section only FHA will be developed; detailed discussions of other virulence 
determinants are beyond the scope of this thesis.  
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Table 2.2 Functions of B. pertussis virulence factors 
 Cell Localization Function References 
FHA Secreted and OM-
attached 
Host cell adhesion (Relman et al., 
1989) 
PT secreted Toxin; ADP-
ribosyltranferase 
(Tamura et al., 
1982) 
ACT secreted Adenylate cyclase 
and  haemolysin 
 










(Wilson et al., 1991) 
Dermonecrotic toxin 
(DNT) 





colonization factor  
Secreted Unknown - 
Pertactin (PRN) Secreted Host cell adhesin  
Fimbriae Secreted Attachment to host 
epithelia 
(Geuijen et al., 
1997; Geuijen et al., 
1996) 










CHAPTER 2 SURVEY OF LITERATURE 
58 
 
FHA is a highly immunogenic, hairpin-shaped molecule which serves as the 
dominant attachment factor for Bordetella in animal model systems (Relman et al., 1989). 
It has been included as a component in most acellular pertussis vaccines. Figure 2.5 
shows a schematic drawing of FHA and its functional domains. FHA is encoded by fhaB, 
one of the strongest BvgA/S-activated genes (Mattoo & Cherry, 2005). fhaB encodes a 
367-kDa precursor protein named FhaB, which undergoes a series of modifications 
before the mature 220-kDa FHA is secreted into the extracellular milieu or remain 
attached to the cell surface.  
 
            The mature FHA contains three distinct binding sites that are thought to 
contribute to its adhesion property: an N-terminal glycosaminoglycan-binding site, an 
Arg-Gly-Asp (RGD) sequence and a carbohydrate recognition domain (CRD). The 
glycosaminoglycan-binding site allows B. pertussis to bind to heparin and dextran 
sulphate (Hannah et al., 1994; Menozzi et al., 1994). The ability to bind heparin has also 
been exploited in the one-step purification of FHA using heparin sepharose (Menozzi et 
al., 1991). The Arg-Gly-Asp (RGD) triplet stimulates adherence to 
monocytes/macrophages and possibly other leukocytes via the leukocyte response 
integrin/integrin-associated protein (LRI/IAP) complex and complement receptor type 3 
(CR3) (Ishibashi et al., 1994; Relman et al., 1990; Saukkonen et al., 1991). Specifically, 
the RGD motif of FHA has been implicated in binding to very late antigen 5 (VLA-5; an 
α5β1 integrin) of bronchial epithelial cells (Relman et al., 1990). FHA also possesses a 
carbohydrate recognition domain (CRD) which mediates attachment to ciliated 
respiratory epithelial cells as well as to macrophages in vitro (Prasad et al., 1993). The N-
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terminus of FhaB contains an atypical signal peptide (SP), which is cleaved from the 
molecule prior to export (Jacob-Dubuisson et al., 1996). In addition, the C-terminal third 
of the precursor is also removed (Renauld-Mongenie et al., 1996a). Although the C-
terminal is not part of the mature protein, it is important in the secretion of full-length 
FHA (but not truncated analogs), probably as an intramolecular chaperone to stabilize the 
protein and prevent incorrect folding (Renauld-Mongenie et al., 1996a).  
 
            FHA is exported across the cytoplasmic membrane by a Sec signal peptide-
dependent pathway. Secretion of FHA in the external environment has been shown to be 
essential for optimal colonization (Coutte et al., 2003). Although efficiently secreted, a 
significant amount of FHA remains associated with the cell surface.  The translocation 
and secretion of FHA across the outer membrane requires a specific accessory protein, 
FhaC. FhaC transporter belongs to the outer membrane protein 85-two-partner secretion 
B(Omp85-TpsB) superfamily. FhaC is composed of a 16-stranded β barrel that is 
occluded by an N-terminal α helix and an extracellular loop and a periplasmic module 
composed of two aligned polypeptide-transport–associated (POTRA) domains in the 
periplasm (Clantin et al., 2007; Guedin et al., 2000; Meli et al., 2006). Upon FHA 
secretion, FhaC folds into a transmembrane β-barrel that facilitates secretion by serving 
as an FHA-specific pore in the outer membrane (Guedin et al., 2000; Jacob-Dubuisson et 
al., 1999). Functional data reveal that FHA binds to the POTRA 1 domain via its N-
terminal domain and likely translocates the adhesin-repeated motifs in an extended 
hairpin conformation, with folding occurring at the cell surface (Clantin et al., 2007). 
This Fha/FhaC secretion belongs to the Two-Partner Secretion (TPS) pathway, 
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commonly used in Gram-negative bacteria for the secretion of large virulence proteins 
(Barenkamp & St Geme, 1994; Jacob-Dubuisson et al., 2004). Besides FhaC, recent data 
has shown the periplasmic chaperone/protease DegP chaperones the extended FHA 





















Mature FHA: 220 kDa 
Precursor FhaB: 367 kDa 
SP 
Figure 2.5  Schematic drawing of mature FHA and its precursor FhaB.  
The N-terminal signal peptide (SP) and C-terminal one-third of the precursor is 
cleaved in the maturation and translocation process of FHA to release the 220-kDa 
mature protein into the extracellular milieu. The various domains and binding sites 
of mature FHA are labeled. RGD, Arginine-Glycine-Aspartate tripeptide motif; 
CRD, carbohydrate recognition domain. 
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2.9   IMMUNITY TO B. PERTUSSIS  
All of B. pertussis virulence factors are known to contribute to pertussis 
pathogenesis and many of them are involved in immune protection or immune subversion. 
It also produces a range of adhesins which aid bacterial colonization in the respiratory 
tract by mediating adherence to ciliated epithelial cells, macrophages and neutrophils (see 
section 2.8.3). In addition, B. pertussis not only binds to epithelial cells and multiplies 
extracellularly, but is also taken up and survives within macrophages and other cell types 
(Steed et al., 1992). This provides evidence of a role for cell-mediated as well as humoral 
immunity in protection.  
 
 2.9.1   Humoral  and Cell-mediated Immunity 
            Direct evidence of the protective role for antibodies in humans was provided 
through the demonstration that passive immunization with B. pertussis specific anti-sera 
reduced the severity of disease in infected individuals (Granstrom et al., 1991). Further 
information on the role of antibodies was provided by studies using Ig-defective (Ig
–/–
) 
mice. B. pertussis respiratory challenge of naïve Ig
–/–
 mice resulted in the development of 
a chronic infection; mice failed to clear the bacteria from their lungs for at least 6 months 
after challenge, whereas the wild-type C57BL/6 mice cleared the infection after 8–10 
weeks (Mahon et al., 1997). Antibodies may function either by neutralizing bacterial 
toxins, inhibiting extracellular bacteria from binding to cells in mucosal tracts or by 
enabling bacterial uptake and destruction by macrophages and neutrophils.  
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Athymic or severe combined immunodeficient (SCID) mice failed to clear B. 
pertussis bacteria whereas in normal BALB/c mice clearance occurs after 35 days; this 
was the first evidence of the importance of T cells in immunity to B. pertussis (Mills et 
al., 1993). Furthermore, evidence for a role of CD4
+
 T cells was provided by the 
demonstration that CD4 KO mice could not be protected by intranasal (in.) immunization 
with inactivated bacteria and depletion of CD4
+
 T cells in wild type mice prior to 
challenge of mice immunized with killed bacteria, which did not affect antibody 
production, abrogated protection (Leef et al., 2000). In contrast, CD8-depleted mice were 
protected against B. pertussis by immunization with inactivated bacteria (Leef et al., 
2000) and adoptive transfer of immune CD8
+
 T cells did not confer protection to 
sublethally irradiated mice (Mills et al., 1993). Taken together, these data suggest that 
CD4
+
 T cells, but not CD8
+
 T cells, mediate protection against B. pertussis. While help 
for antibody production is an obvious mechanism whereby CD4
+
 T cells may mediate 
protection, it is not the only mechanism. In adoptive transfer experiments with CD4
+
 T 
cells (Mills et al., 1993) and in B-cell reconstituted Ig
–/–
 mice immunized with inactivated 
bacteria (Leef et al., 2000), protection was demonstrated in the absence of specific IgG, 
suggesting a role for CD4
+
 T cells in direct cell-mediated immunity. 
Recently, several studies have shown that TLR-4 and IL-1 mediates vaccine-
induced protective cellular immunity to B. pertussis and that immunization with Pw but 
not Pa, induced IL-17 production by a recently described subset of T lymphocytes termed 
Th17 cells (Banus et al., 2008; Higgins et al., 2006). Th17 cells are considered important 
for the host immune response against extracellular pathogens in the airways (Aujla et al., 
2007), but are also associated with chronic inflammation and autoimmunity (Steinman, 
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2007). IL-17 induces the production of inflammatory chemokines and cytokines and 
contributes to neutrophil recruitment and activation of innate immune cells (Yu & Gaffen, 
2008). IL-17 is mainly produced by T cells but it can also be produced by neutrophils 
(Ferretti et al., 2003) and NK cells (Michel et al., 2007). Studies on the role of Th17 
response in protection against B. pertussis infection are limited. However, Higgins et al. 
(2006) showed that a possible role for IL-17 in protective immunity to B. pertussis was 
enhancing bacterial killing by macrophages (Higgins et al., 2006). Moreover, a recently 
study demonstrated that CyaA promoted the induction of Ag-specific Th17 cells in wild-
type but not IL-1RI(-/-) mice and the bacterial load was enhanced in IL-17-defective 
mice (Dunne et al., 2010). Thus, it appears that the Th17 response may play a significant 
role in protective immunity elicited by natural B. pertussis infection or Pw. 
Antibody and cell-mediated responses to B. pertussis and pertussis vaccines are 
summarized in Table 2.3. 
 
Table 2.3 Antibody and cell-mediated responses to B. pertussis and pertussis 
vaccines 
 Antibodies Th Responses References 
B. pertussis  
and Pw 
IgG2a, sIgA Predominantly Th1 
and Th17  
(Mills et al., 
1998) 
Pa IgG1 Predominantly Th2 or 
Mixed Th1/Th2 
(Mills et al., 
1998; Ryan et 
al., 1998) 
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2.9.2   Immune Subversion and Immunomodulatory Effects of B. pertussis  
            B. pertussis virulence factors, regulated by the bvg locus, contribute to adherence 
of the organism to ciliated epithelial cells, macrophages and PMNs and mediate local 
pathology and systemic reactions, but also contribute to bacterial persistence by 
modulating or subverting the host protective immune response. 
 
            In addition to its role in adherence, B. pertussis FHA has been shown to have 
immunosuppressive and immunomodulatory activities. It can stimulate IL-10 and inhibit 
TLR-induced IL-12 production by macrophages and dendritic cells (DCs), resulting in 
the development of IL-10-secreting type 1 T-regulatory (Tr1) cells (McGuirk et al., 2002). 
In addition, anti-FHA antibodies in convalescent human serum were found to reduce 
neutrophil phagocytosis of the bacteria (Mobberley-Schuman et al., 2003). Furthermore, 
injection of mice with FHA suppressed LPS-induced IL-12 and IFN-γ levels in the serum 
in a classical murine model of septic shock. The suppressive effect of FHA was shown to 
be mediated by IL-10 (Bassinet et al., 2000). Interestingly, the systemic administration of 
FHA was found to reduce intestinal inflammation in a T-cell-mediated model of colitis 
(Braat et al., 2007). This effect was most likely achieved through the anti-inflammatory 
Tr1 responses induced by FHA. Importantly, as well as subverting immune responses to 
B. pertussis, it has been demonstrated that FHA may also exert an immunomodulatory 
effect on immune responses to an unrelated pathogen; intranasal administration of FHA 
to mice infected with influenza virus suppressed the virus-specific Th1 response in the 
local lymph nodes (McGuirk et al., 2000). These findings are consistent with the 
demonstration of suppressed antigen-presenting to CD4
+
 T cells specific for tetanus 
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toxoid by human monocytes infected with B. pertussis, an effect that was abrogated in 
mutant B. pertussis defective in FHA (Boschwitz et al., 1997). Thus, FHA may make a 
significant contribution to the suppressed immune responses to B. pertussis and to other 
pathogens during whooping cough in children. It may also contribute to the reduced 
immune responses to other antigens of combination vaccines that include FHA as one of 
the pertussis vaccine antigens. 
 
            Adenylate cyclase toxin (ACT) has also been involved in some modulatory 
activities of the host immune system. This toxin was shown to be able to upregulate 
MHC class II and costimulatory molecules on DCs, inducing a semi-mature state that 
induces IL-10 production and decreases proinflammatory cytokine production (Ross et 
al., 2004; Skinner et al., 2004). Incubation of human dendritic cells with B. pertussis 
induced ACT-dependent expression of IL-23, a cytokine important for the expansion and 
maintenance of Th17 cells, but not of the Th1-inducing cytokine IL-12 (Fedele et al., 
2005; Spensieri et al., 2006). ACT has recently been shown to promote innate IL-1β-
production and polarize T cell response towards Th17 subtypes, thus promoting clearance 
of the bacteria from the respiratory tract (Dunne et al., 2010).  
 
            Moreover, pertussis toxin (PT) was found to inhibit early neutrophil influx to the 
airways after infection by suppressing the early production of the neutrophil-attracting 
chemokines KC, LIX and MIP-2 by airway macrophages and epithelial cells (Andreasen 
& Carbonetti, 2008). The same authors subsequently showed that following this early 
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inhibitory phase, a second wave of neutrophil recruitment in response to B. pertussis 
infection occurs and this second wave of neutrophil recruitment is stimulated through PT 
activity by upregulation of cytokines including IL-17, which then upregulates neutrophil-
attracting chemokine gene expression (Andreasen et al., 2009).  Since ACT and the type 
III secretion system may contribute to induction of a Th17 response to Bordetella 
infection (Siciliano et al., 2006), PT and ACT may have a synergistic effect on the 
induction of Th1 and Th17 cytokines. In addition, PT can exert its inhibitory effects on 
the protective role of resident airway macrophages to promote B. pertussis infection of 
the respiratory tract (Carbonetti et al., 2007). PT has also been found to have multiple 
suppressive effects on the immune system beyond those observed on innate immune cells, 
such as the suppression of serum antibody responses to B. pertussis antigens such as FHA 
after infection (Carbonetti et al., 2004; Mielcarek et al., 1998), the reduction of MHC 
class II molecules on the surface of human monocytes (Shumilla et al., 2004) and the 
modulation of surface markers on DCs (Martino et al., 2006).  
 
            Finally, different from the LPS of E. coli which induces strong pro-inflammatory 
immune responses, LPS of B. pertussis, was shown to induce IL-10 production through 
TLR-4 signaling and inhibit inflammatory responses and limit pathology in the airways 
(Higgins et al., 2003). This is because that Bordetella LPS molecules differ in chemical 
structure from the well-known smooth-type LPS expressed by members of the family 
Enterobacteriaceae. Specifically, B. pertussis LPS lacks a repetitive O-antigenic 
structure and is therefore more similar to rough-type LPS (Peppler, 1984). B. pertussis 
infection was found more severe in TLR4-defective mice. LPS could also act 
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synergistically with ACT to induce IL-10 production and modulate other responses by 
DCs (Ross et al., 2004). LPS signaling through TLR4 also contributes to Th17 responses 
in mixed cell culture (Fedele et al., 2008) or after B. pertussis infection and pertussis 
vaccination (Banus et al., 2008; Higgins et al., 2006). 
 
2.10 ATTENUATED B. PERTUSSIS FOR HETEROLOGOUS ANTIGEN 
DELIVERY 
2.10.1 Live Bacteria as Vaccine Delivery System 
A range of delivery systems have been developed that allow effective stimulation 
of mucosal immune responses upon mucosal vaccination. Enzymatic degradation at 
mucosal surfaces, poor absorption and exposure to low pH in the gastrointestinal tract are 
the possible reasons why sometimes mucosal delivery of antigen results in very poor 
immune responses. One approach used to improve absorption and protect against 
degradation is to encapsulate antigens in biodegradable microspheres (Gupta et al., 1998) 
or liposomes (Wassef et al., 1994). An alternative approach is the use of live bacteria as 
vectors to deliver antigens from other pathogens (Thole et al., 2000).  
 
            Live recombinant vaccines can be broadly classified into two categories:  1) 
“generally recognized as safe” (GRAS) bacteria as vectors, and 2) attenuated pathogenic 
bacteria as vectors (Locht, 2000). GRAS bacteria are mainly human commensals or those 
commonly used in the food industry, such as Lactococcus lactis, Lactobacillus and 
Streptococcus gordonni. A major disadvantage of these food-grade bacteria is their 
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limited capacity to replicate and persist in the human host, hence a lower ability to elicit 
protective immunity towards their passenger antigens (Mielcarek et al., 2001b). In 
contrast, pathogenic bacteria are able to stimulate mucosal as well as systemic immune 
responses, as these organisms enter hosts via mucosal surfaces where they can replicate 
effectively. To date, live attenuated mutants of several pathogenic bacteria have been 
evaluated as potential vaccine vector candidates following mucosal administration. Those 
most studied include attenuated strains of Salmonella spp., Shigella flexneri, Listeria 
monocytogenes, Vibrio cholerae, Yersinia enterocolitica, Bordetella pertussis and 
Mycobacterium bovis Bacille Calmette-Guerin (BCG) as well as live attenuated B. 
pertussis which will be developed in greater detail in the next section. 
 
2.10.2   Attenuated B. pertussis as a Live Recombinant Nasal Delivery Vector 
            Live recombinant B. pertussis is particularly attractive and promising as a nasal 
vaccine delivery vector to protect against respiratory pathogens. As a highly contagious 
agent, it colonizes the human respiratory tract very efficiently and induces both local and 
systemic immune responses. It can be easily genetically manipulated with a variety of 
genetic tools available. Moreover, the completion of Bordetella genome sequencing 
project has make it possible to analyze Bordetella pertussis in depth 
(http://old.genedb.org/genedb/pert/). Importantly, this organism possesses various 
bacterial protein secretion systems, which make it possible to secrete or surface expose 
foreign antigens. Last but not least, B. pertussis can serve as a potent adjuvent when 
delivered as live recombinant vaccine vector (Rijpkema et al., 2005; Tournier et al., 
2002). 
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            The detailed knowledge of the molecular mechanisms of B. pertussis virulence 
has led to the design of attenuated strains that may be safe enough as a live recombinant 
vaccine vector administered by the nasal route.  B. pertussis aroA mutants, which is 
inactivated in the genes involved in amino acid biosynthesis (Roberts et al., 1990), was 
the first generation of attenuated B. pertussis. Such mutations affecting the aromatic 
pathway gave rise to highly attenuated strains (Hernanz Moral et al., 1998; Simmons et 
al., 1997) that still express all the virulence determinants. However, the mutants were 
greatly impaired in their colonization efficiency and thus turned out to be poor 
immunogens, requiring at least three doses for protection (Roberts et al., 1990). The 
second generation of attenuated B. pertussis was represented by the BPRA strain which 
had its pertusis toxin-encoding gene deleted (Mielcarek et al., 1998).  BPRA was found 
to be attenuated in flammation. However, BPRA was still able to colonize the mouse 
respiratory tract almost as efficiently as the wild-type strain and a single intranasal 
administration provided protection against subsequent challenge with the wild-type strain. 
BPRA was also successfully used as a vector for several heterologous antigens fused to 
FHA or its truncated derivative Fha44 (Coppens et al., 2001; Mielcarek et al., 1998; 
Reveneau et al., 2002). However, since PT is known to be highly antigenic and it also has 
adjuvant properties, its absence may impair the host immune response to the heterologous 
antigens. Moreover, deletion of PT only may not be safe enough for BPRA to be used in 
humans. Hence, this has led to the recent development of the third generation of 
attenuated B. pertussis in the name of BPZE1 strain (Mielcarek et al., 2006a). BPZE1 is 
deleted for the dermonecrotic (DNT)-encoding gene, produces an enzymatically inactive 
pertussis toxin (PTi) and overexpresses E.coli ampG gene to reduce tracheal cytotoxin 
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(TCT) release in the extracellular milieu. Although highly attenuated as evidenced by a 
markedly reduced lung inflammation in the infected animals, BPZE1 bacteria still 
maintain the ability to colonize the mice lungs efficiently and induce protective immunity 
against pertussis infection (Mielcarek et al., 2006a). These features make BPZE1 strain 
not only an attractive live pertussis vaccine candidate but also a potential vehicle for 
vaccine delivery via the nasal route (Ho et al., 2008). 
 
 2.10.3   FHA as an Antigen Carrier 
FHA is both secreted and surface-exposed by B. pertussis. It is highly 
immunogenic, inducing high levels of mucosal and systemic antibodies upon B. pertussis 
infection in mice (Cahill et al., 1995) and humans (Isacson et al., 1995). This has led to 
the inclusion of FHA in most acellular pertussis vaccines. In addition, its different 
functional domains play important roles in adherence to the respiratory mucosa and 
stimulation of the host immune responses (see section 2.8.3).Thus, heterologous antigens 
genetically fused to FHA may also benefit from the various binding activities and 
stimulatory properties of the carrier protein. Targeting antigens to mononuclear 
phagocytes including macrophages would be expected to improve antigen presentation to 
the T helper cells thereby facilitating the development of antibody responses. Together 
with its adjuvant properties (Poulain-Godefroy et al., 2003; Poulain-Godefroy et al., 
1998), FHA is thus an attractive candidate for use as a carrier to secrete foreign antigens 
into the extracellular milieu or to present foreign antigens at the bacterial surface of B. 
pertussis-based live recombinant vaccines. Three heterologous antigens fused to FHA 
include the Schistosoma mansoni 28-kDa glutathione S-transferase (Sm28GST) 
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(Mielcarek et al., 1998), Haemophilus influenzae HtrA (Alonso et al., 2005) and SP70 
from Enterovirus 71 (Ho et al., 2008). Significant systemic and/or local (respiratory tract) 
antibody responses against the foreign antigens were measured in mice upon intranasal 
administration of the live recombinant bacteria. 
A truncated form of FHA corresponding to the first 80-kDa N-terminal half of the 
mature protein (Fha44), has been described and was found to be produced in higher 
amounts and secreted more efficiently by B. pertussis than full-length FHA (Renauld-
Mongenie et al., 1996a). It has been used as a carrier for the transferrin-binding protein B 
(TbpB) from Neisseria meningitidis (Coppens et al., 2001). The genetic fusion of TbpB 
to Fha44 resulted in much more production and secretion of the hybrid protein (Coppens 
et al., 2001) than those induced by a fusion of Sm28GST to full-length FHA, which was 
barely detectable in the culture supernatants of the recombinant strains (Renauld-
Mongenie et al., 1996b). Subsequently, TTFC from V. cholera (Reveneau et al., 2001) 
and HtrA from nontypeable Haemophilus influenzae (Alonso et al., 2005) were expressed 
in recombinant B. pertussis using Fha44 as a carrier. Although Fha44 was more 
efficiently expressed, it was found to be much less immunogenic than FHA, stimulating 
anti-FHA IgG production only in the presence of an adjuvant (Alonso et al., 2005). FHA-
HtrA chimera was found to elicit higher anti-HtrA serum antibody levels than the Fha44-
HtrA chimera, suggesting that the C-terminal moiety in mature FHA contains 
immunodominant/adjuvant activity. 
            Importantly, as discussed in section 2.8.3, FHA binds FhaC via its N-terminal 
domain and likely translocates the adhesin-repeated motifs in an extended hairpin 
conformation (Clantin et al., 2007). Therefore, FHA is thought to transit through the 
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periplasm in an extended conformation. In agreement with this hypothesis FhaC 
recognizes only the unfolded, but not the native TPS domain of FHA (Hodak et al., 2006). 
In addition, a chimeric protein carrying a heterologous globular domain at the C-terminus 
of an FHA fragment is blocked at the outer membrane (Guedin et al., 1998). So an 
extended form of FHA is required for its efficient secretion. Therefore, any foreign 
antigen with disulfide bonds will not be efficiently secreted when fused to FHA which 
limits the use of FHA as carrier. 
 
2.10.4   Other Antigen Carriers 
            Besides FHA, other virulence factors of B. pertussis have been used as carrier 
systems to present foreign antigens, including adenylate cyclase toxin (ACT) and 
autotransporter BrkA. ACT targets the αMβ2 integrin (CD11b/CD18) receptor expressing-
myeloid cells such as macrophages, neutrophils and dendritic cells (Guermonprez et al., 
2001) and internalize the enzymatic moiety into the host cells. The ability of ACT to 
specifically bind to antigen presenting cells and translocate its catalytic domain into the 
cell cytosol has been exploited for the delivery of vaccine candidates from various 
pathogens, using both major histocompatibility (MHC) class I and II pathways for 
activation of the adaptive immune system (Fayolle et al., 2001; Loucka et al., 2002; Tartz 
et al., 2008). Permissive sites within the ACT catalytic domain have been identified for 
insertion of heterologous antigens leading to the inactivation of the toxin activity but 
without affecting its cell-invasive capacity (Fayolle et al., 2001; Ladant et al., 1992; 
Osicka et al., 2000). Moreover, ACT has displayed a high tolerance for the insertion of 
large polypeptide fragments in its catalytic domain ranging from 8 to 206 amino acids 
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(Gmira et al., 2001; Simsova et al., 2004). So far only purified B. pertussis ACT chimera 
produced in E.coli have been reported and used for vaccine purposes. The expression of 
heterologous vaccine candidates in B. pertussis using ACT as carrier system has never 
been described. 
 
            Autotransporters have been successfully used in E. coli and Salmonella species to 
present heterologous antigens at the bacterial surface (Kjaergaard et al., 2002; Kramer et 
al., 2003; Lattemann et al., 2000; Zhu et al., 2006). Among all the autotransporters B. 
pertussis encodes, BrkA has been most studied and characterized. A truncated form of 
BrkA, with a substantial deletion in the passenger domain has been shown to be 
efficiently translocated and exposed at the cell surface (Oliver et al., 2003), thus making 
it possible to use BrkA to present heterologous antigens of bigger size. In addition, the 
passenger domain of BrkA has been shown to be immunogenic and possesses adjuvant 
properties (Cainelli Gebara et al., 2007). Recently, our laboratory has demonstrated that 
BrkA can successfully be used as a carrier system to present heterologous vaccine 
candidates at the bacterial surface. Three copies of the neutralizing B cell epitope SP70 
from Enterovirus 71 were fused to BrkA, and the chimera was expressed in BPZE1 strain, 
the third generation of attenuated B. pertussis (Ho et al., 2008). Significant amounts of 
SP70-specific antibodies were triggered in mice upon intranasal administration of the live 
recombinant bacteria and these antibodies were able to neutralize Enterovirus 71. 
Importantly, the levels of neutralizing antibodies measured were higher than that 
measured in mice immunized with live recombinant bacteria producing a FHA-(SP70) 
chimera. 
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CHAPTER 3 MATERIALS AND METHODS 
 
(I)   ESCHERICHIA COLI WORK 
3.1   BACTERIAL STRAINS, PLASMIDS AND GROWTH CONDITIONS 
3.1.1   E. coli Strains and Plasmids 
 The E. coli strains and plasmids used in this study are listed in the table below. 
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; pBR322 derivative with SalI-SalI- ptx1-ptx2 













































; pBRLR13 derivative with SalI-SalI-ptx1-ptx2-






; pBRLR13 derivative with SalI-SalI-ptx1-ptx2-

















a. Ampr, Kanr, Tetr, Gmr refer to resistance to ampicillin, kanamycin, tetracycline and gentamicin respectively. Sms 
refers to sensitivity to streptomycin. 
 
3.1.2   Growth Conditions 
 All E. coli strains were grown at 37
o
C overnight in 3 ml fresh Luria-Bertani (LB) 
broth (Difco, Detroit, Mich.) with shaking at 220 rpm, or on LB agar (Difco). When 
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appropriate, 50 or 100 g/ml ampicillin, 50 g/ml kanamycin or 10 g/ml gentamicin 
were added to select for antibiotic-resistant strains. 
 
3.2   MOLECULAR BIOLOGY 
3.2.1   Oligonucleotides and Primers 
3.2.1.1   List of oligonucleotides and primers 
The sequences of the oligonucleotides and primers (Sigma) are shown in Table 
3.2. When necessary, restriction sites (in bold) were included at the 5‟ ends of the primers 
to facilitate cloning. The annealing temperature (TA) of the primers are calculated as 
follows: 
4 × N(G/C) + 2 × N(A/T) - 5 
where N(G/C) and N(A/T) represent the number of G & C bases, and A & T bases 
respectively. 
 
3.2.1.2   Hybridization of oligonucleotides  
Ten μl of 50 M of each of the sense and anti-sense oligonucleotides were mixed 
in a boiling water bath and left to cool slowly to room temperature, allowing 
hybridization of the complementary DNA strands.  
  




Table 3.2   Oligonucleotides and primers used for E. coli work. 
Name Sequence 5’to 3’ 




























Primers for  FHA-(M2e)3, FHA-(HA1-1)7,  FHA-(HA2-1)3 and  FHA-(HA2-2)3 





















CHAPTER 3 MATERIALS AND METHODS 
79 
 
3.2.2   Plasmid Extraction 
Plasmid DNA was isolated and purified using the QIAprep Spin Miniprep Kit 
(Qiagen, Mississauga, Ont.) following the manufacturer‟s instructions. High and low 
copy number plasmids were eluted with 50 l and 30 l of deionised water, respectively.  
 
3.2.3   Polymerase Chain Reaction (PCR) 
3.2.3.1   DNA amplification 
The HotStarTaq
®
 PCR Kit (Qiagen) was used to carry out all PCR reactions 
according to the manufacturer‟s instructions, and using the GeneAmp® PCR System 
2400 thermal cycler (PE Applied Biosystems, Foster City, CA). The PCR reaction was 
initiated at 95ºC for 15 min, followed by 25 to 35 cycles of DNA denaturation at 95ºC for 
45s, primer annealing at TA for 50 s and extension at 72ºC for 1 to 2 min (~1 min per 1 kb 
DNA). Finally, an elongation time of 10 min at 72ºC was included to allow complete 
extension of the PCR products. 
 
3.2.3.2   Colony PCR screening 
A loopful of bacteria was dissolved in 30 μl of ultrapure water, heated at 95ºC for 
10 min and centrifuged at 13,000 rpm for 5 min. PCR was performed as described in 
Section 3.2.3.1 for 35 cycles, using 5 μl of the supernatant as template.  
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3.2.4   Restriction Enzyme Digestion 
 DNA digestion was carried out with the appropriate restriction enzymes (RE) in 
their corresponding buffers (New England Biolabs, Ipswich, MA) following the 
manufacturer‟s protocol. When only one RE was involved or when two REs shared 
buffer compatibility, a single-step digestion of 1 to 2 h at 37
o
C was performed. When two 
or more REs with incompatible buffers were involved, sequential digestion was carried 
out; after the initial digestion, the first RE was heat inactivated according to the 
manufacturer‟s instructions, followed by membrane dialysis (Millipore, Billerica, MA) 
against deionized water for 10 min before setting up the second digestion reaction. 
Analysis of the restriction profile was conducted by DNA gel electrophoresis (Section 
3.2.5). 
 
3.2.5   Agarose Gel Electrophoresis 
3.2.5.1   Gel migration 
DNA/RNA electrophoresis was performed using 0.8% to 1.5% agarose in 1x Tris-
acetate (TAE) running buffer [0.04 M Tris-acetate and 0.001 M ethylenedinitrilo 
tetraacetic acid (EDTA), pH 7.8]. Each DNA/RNA sample to be analyzed was mixed 
with 1/5 volume of 6x loading dye (0.25% bromophenol blue, 0.25% xylene cyanol and 
25% Ficoll in water) before being loaded into the gel wells. 5 l of 1 kb or 100 bp DNA 
ladder (Promega) were used as markers for estimation of band size.  Electrophoresis was 
carried out at 80 V for 45 min, after which the gel was stained in 0.5 g/ml of ethidium 
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bromide solution (Invitrogen) for 15 min before viewing under an ultra-violet (UV) 
transilluminator (ChemiGenius, Syngene, UK). 
 
3.2.5.2   Gel extraction 
After agarose gel electrophoresis, the DNA fragments of interest were cut under 
low UV light (366 nm) (to avoid DNA damage and/or mutations) and gel-extracted using 
the QIAquick Gel Extraction and PCR Purification Kit (Qiagen) according to the 
manufacturer‟s instructions.  
 
3.2.6   DNA Cloning 
Digestion (Section 3.2.4) with the appropriate RE(s) was performed on plasmid 
DNA to open up the vectors and generate the inserts. Both digested vectors and inserts 
were electrophoresed on agarose gel and the DNA bands of interest were excised and 
purified from the gel as described in Section 3.2.5. Cloning of inserts into the TOPO
® 
vector was performed using the TOPO
®
 TA Cloning Kit (Invitrogen, Carlsbad, CA), 
while DNA inserts were ligated into the pBR322 and pJQ vectors using the Fast-Link
TM
 
DNA Ligation Kit (Epicentre Technologies, Madison, WI). Recircularization of vectors 
digested with a single RE was prevented by dephosphorylation with alkaline phosphatase 
(New England Biolabs) according to the manufacturer‟s instructions. 
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3.2.7   Transformation of Chemically Competent E. coli 
Chemically competent One Shot
®
 TOP10 E. coli (Invitrogen) were transformed 
according to the manufacturer‟s protocol with slight modifications. Half volume of 
ligation mix was added to one vial of chemically competent TOP10 cells and mixed 
gently. The tube was incubated on ice for 30 min, followed by a heat shock at 42ºC for 
45s. The tube was then immediately transferred to ice and 500 μl of LB medium without 
antibiotics was added to the mixture. After incubation at 37ºC for 1 h, 100 μl of 
transformation mixture was plated on LB agar supplemented with the appropriate 
antibiotic or on imMedia
TM
 Amp Blue ready-mix agar (Invitrogen) for blue/white 
screening. The plates were incubated at 37ºC overnight. 
 
3.2.8   DNA Sequencing 
 Plasmids from the recombinant clones were sent for DNA sequencing (Research 
Biolabs, Singapore) with suitable primers (Table 3.2). Alignment of the obtained 
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(II)   BORDETELLA PERTUSSIS WORK 
 
3.3   BACTERIAL STRAINS AND GROWTH CONDITIONS 
3.3.1   B. pertussis Strains 
 The B. pertussis strains used in this study are summarized in the following table.  




BPZE1 Attenuated TohamaI derivative, mutant rpsL, ptx 
gene mutated (inactive pertussis toxin), 
dermonecrotic toxin gene deleted, ampG gene 
overexpressed (reduced tracheal cytotoxin 
production); Sm
r 
Pasteur Institute of 
Lille 
BPDY2 BPZE1 derivative with ptx gene deleted This lab 
BPLR1 BPZE1 derivative expresssing FHA-(M2e)1 chimera
 
This study 
BPLR2 BPZE1 derivative expresssing FHA-(M2e)2 chimera This study 
BPLR3 BPZE1 derivative expresssing FHA-(M2e)3 chimera This study 
BPLR4 BPZE1 derivative expresssing FHA-(HA1-1)7 
chimera 
This study 
BPLR5 BPZE1 derivative expresssing FHA-(HA2-1)3 
chimera 
This study 
BPLR6 BPZE1 derivative expresssing FHA-(HA2-2)3 
chimera 
This study 
BPLR7 BPZE1 derivative expresssing PfhaB-NP chimera This study 
BPLR8 BPZE1 derivative expresssing PfhaB-ΔNA chimera This study 
     a. Smr refers to resistance to streptomycin. 
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3.3.2   Growth Conditions 
All B. pertussis strains were grown at 37ºC on pre-warmed sterile Bordet-Gengou 
(BG) agar (Difco) supplemented with 1% glycerol and 10% defibrinated sheep blood 
(England) or in pre-warmed sterile modified Stainer-Scholte (SS) medium containing 1 
g/L 2,6-O-dimethyl-ß-cyclodextrin (Sigma) as described previously (Menozzi et al., 
1991). When appropriate, 10μg/ml gentamicin or 100 μg/ml streptomycin (Sigma) were 
added to select for antibiotic-resistant strains. 
 
3.4   MOLECULAR BIOLOGY 
3.4.1 List of Primers  
The primers (Sigma) used for B. pertussis work are listed in the table below. 
Table 3.4   Primers used for B. pertussis work. 
Name Sequence 5’ to 3’ 
















3.4.2   Construction of Recombinant B. pertussis Strains  
3.4.2.1 Construction of Recombinant B. pertussis Strains Expressing M2e, HA1-1, 
HA2-1 and HA2-2 
3.4.2.1.1 Design and synthesis of optimized m2e (opm2e), ha1-1(opha1-1), ha2-1(opha2-1) 
and ha2-2(opha2-2) 
The M2e peptide covers nucleotides 689-750 of the M2 protein of the influenza A 
virus H5N1 (A/chicken/Nakorn-Patom/Thailand/CU-K2/2004(H5N1)). The HA1-1, 
covers nucleotides 331-335 of HA1 protein, and HA2-1 and HA2-2 covers nucleotides 1-11 
and 47-58 of HA2 protein, respectively. To prevent any problems in protein translation 
due to codon usage (Yazdani et al., 2006), the m2e, ha1-1, ha2-1 and ha2-2 DNA sequence 
was optimized to B. pertussis codon usage preference as shown in Table 3.2 and Table 
3.5. For the FHA-(M2e)1, 2, 3 and FHA-(HA1-1)7, FHA-(HA2-1)3, FHA-(HA2-2)3 chimera, 
the forward and reverse strands of opm2e, opha1-1, opha2-1 and opha2-2  named opm2e-
upper and opm2e-lower,  opha1-1-upper and opha1-1-lower, opha2-1-upper and opha2-1-
lower, opha2-2-upper and opha2-2-lower respectively, were synthesized and  annealed to 
give double stranded opm2e, opha1-1, opha2-1 and opha2-2 with BglII-compatible ends to 
clone the 1, 2, 3  copies of m2e, 7 copies of HA1-1, 3 copies of HA2-1 and HA2-2 into FHA.  
 











opha1-1-upper 5‟- gATC- ACC- ggC- CTg- CgC- AAC- ACC- ggC- CTg- 
CgC- AAC- ACC- ggC- CTg- CgC- AAC- ACC- ggC- CTg- 
CgC- AAC- gA-3‟ 
opha1-1-lower 5‟- gATCTC- gTT- gCg- CAg- gCC- ggT- gTT- gCg- CAg- 
gCC- ggT- gTT- gCg- CAg- gCC- ggT- gTT- gCg- CAg- 
gCC- ggT- 3‟ 
opha2-1-upper 5‟- gATC- ggC- CTg- TTC- ggC- gCC- ATC- gCC- ggC- 
TTC- ATC-gAg- ggC- CTg- TTC- ggC- gCC- ATC- gCC- 
ggC- TTC- ATC- gAg- gA-3‟ 
opha2-1-lower 5‟- gATCTC- CTC- gAT- gAA- gCC- ggC- gAT- ggC- 
gCC- gAA- CAg- gCC- CTC- gAT- gAA- gCC- ggC- gAT- 
ggC- gCC- gAA- CAg- gCC- 3‟ 
opha2-2-upper 5‟- gATC- ggC- gTg- ACC- AAC- AAg- gTg- AAC- TCg- 
ATC- ATC- gAC- AAg- ggC- gTg- ACC- AAC- AAg- gTg- 
AAC- TCg- ATC- ATC- gAC- AAg- gA- 3‟ 
opha2-2-lower 5‟- gATCTC- CTT- gTC- gAT- gAT- CgA- gTT- CAC- 
CTT- gTT- ggT- CAC- gCC- CTT- gTC- gAT- gAT- CgA- 
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3.4.2.1.2 Cloning opm2e, opha1-1, opha2-1 and opha2-2 into fhaB 
The cloning strategy will take m2e for example. Three copies of m2e were cloned 
in tandem into FHA as follows: A 1620-bp fhaB fragment encompassing the unique BglII 
site in FHA was PCR-amplified from B. pertussis BPZE1 chromosomal DNA using the 
primers FHA1-F and FHA2-R (Figure 3.1). The PCR product was then sequenced and 
transferred into pBR322 plasmid (Bolivar et al., 1977) to obtain pBRSY0 (Figure 3.2). A 
first copy of opm2e was cloned into BglII-digested pBRSY0 such that only the 3‟ 
terminal BglII site was restored. A second and third copy of opm2e were then 
sequentially added using the same procedure. The respective constructs in pBRSY0 were 
named pBRLR1, pBRLR2, pBRLR3 (Figure 3.2). Finally, the entire fhaB-(m2e)1, fhaB-
(m2e)2, fhaB-(m2e)3 fragment was cloned into the suicide vector pJQ200mp18-rpsl 
(Quandt & Hynes, 1993) to give pJQLR1, pJQLR2, pJQLR3 (Figure 3.2). RE digestion 
analysis and colony PCR screening were used to screen for and verify the E. coli 




























Figure 3.1 Schematic diagram showing the 1620-bp HindIII-HindIII fhaB 
fragment cloned into pBRSY0. 
The fragment spanning nucleotide 5221 to 6840 of fhaB gene was PCR 
amplified from B. pertussis BPZE chromosomal DNA using primers FHA1-F 
and FHA2-R with HindIII sites incorporated at the two ends. 
fhaB gene Unique BglII site 


















Figure 3.2 Overview of cloning strategy for FHA-(M2e)1,2,3 
HindIII 
digestion 
Insertion of opm2e 1
st
 
copy by BglII digestion 
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nd
 
copy by BglII digestion 
Insertion of opm2e 3
rd
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3.4.2.1 Construction of Recombinant B. pertussis Strains Expressing ∆NA and NP 
A 1858bp ptx fragment in PTX was PCR-amplified from B. pertussis BPZE1 
chromosomal DNA using the primers ptx1-F and ptx1-R for amplification of ptx1 
fragment, and ptx2-F and ptx2-R for amplification of ptx2 fragment (Figure 3.3). After 
ptx1 and ptx2 were being cloned into pCR2.1
®
-TOPO vector, they were then 
subsequently transferred into pBR322 plasmid resulting in pBRLR13. Next, the promoter 
region of fhaB was PCR-amplified from B. pertussis BPZE1 chromosomal DNA using 
the primers PfhaB-F and PfhaB-R (Figure 3.3) and cloned into TOPO vector and then 
transferred into pBR322 plasmid to obtain pBRLR14. The Regions for the truncated NA 
amino acid sequences (120-366AA) were selected by identifying the most immunogenic 
regions shown by the immunogenicity index analyzed using DNASTAR software. The 
corresponding cDNA sequences spanning 358-1098bp were obtained by PCR 
amplification of the viral na cDNA sequence AY679513 Thailand strain. The PCR 
product were then cloned into TOPO vector and subsequently transferred into the 
pBRLR14 to obtain pBRLR15. The pFHAB-∆na fragment was then digested and purified 
from pBRLR15 and transferred into pBRLR13, resulting in pBRLR17. Finally, the entire 
ptx1-ptx2-pFHAB- Δna fragment was cloned into the suicide vector pJQ200mp18-rpsl to give 
pJQLR5 (Figure 3.4). RE digestion analysis and colony PCR screening were used to 
screen for and verify the E. coli transformants obtained at each step of the cloning. The 
same strategy was used to clone full length np. 
 
 


















Figure 3.3 Overview of cloning strategy for PFHA-∆NA 
 
SalI + SmaI 
digestion 
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3.4.2   Transformation of B. pertussis 
3.4.2.1   Preparation of electrocompetent cells 
Ten ml of bacteria exponentially grown (OD600 4 to 5) in SS medium were 
centrifuged at 7,000 rpm for 10 min at room temperature, and the pellet was washed three 
times in 10 ml sterile 10% glycerol. After the final wash, the pellet was resuspended in 1 
ml 10% glycerol and the cells were immediately used for electroporation. 
 
3.4.2.2   Electroporation of plasmid DNA into B. pertussis 
Between 100 ng to 1 g of plasmid DNA was mixed with 200 l of 
electrocompetent B. pertussis cells in an electroporation cuvette (0.2 cm) (Biorad 
Laboratories, Hercules, CA), and an electrical pulse of 2.5 kV, 800  resistance and 25 
F capacitance was applied. One ml of pre-warmed SS medium without antibiotics was 
then added to the cells and the bacteria were incubated for 5 h at 37
o
C with shaking, 
before plating 200 l of cells onto pre-warmed BG agar plates containing the appropriate 




3.4.3   Selection of Transformants upon electroporation with pJQ derivatives 
plasmid constructs 
            Gentamicin-resistant (Gm
r
) colonies obtained upon transformation were patched 





 clones were identified as transformants that had 
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successfully undergone the first event of recombination. These intermediate strains were 
streaked onto a streptomycin plate to allow select the clones for which the second event 
of recombination had occurred. After incubation at 37ºC for 5-7 days, 10 isolated Sm
r
 





clones were identified as having undergone the second event of recombination. 
 
3.4.4   Screening for True Recombinants 




 clones to genotypically 
distinguish true recombinants from revertant clones. Preparation of the template DNA 
was performed as described in Section 3.2.3.2 except that the dissolved bacteria were 
heated for 30 min instead of 10 min. PCR was carried out as described in Section 3.2.3.1 
for 35 cycles using the appropriate primers (Table 3.4) followed by agarose gel 
electrophoresis to analyze the PCR products (Section 3.2.5.1).  
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3.5   PROTEIN EXPRESSION STUDIES 
 
3.5.1   Preparation of B. pertussis Samples 
3.5.1.1   Supernatant 
Ten ml of exponentially-grown B. pertussis liquid culture were centrifuged at 
7,000 rpm for 10 min at room temperature. The pellet was stored at –80oC until further 
use and the supernatant was subjected to further spinning for 10 min at maximum speed 
(13,000rpm), to remove any remaining cell debris. An equal volume of 2x protein loading 
buffer (1 M Tris-HCl at pH 6.8, 100% glycerol, -mercaptoethanol, bromophenol blue, 
SDS) was then added to 500 l of the clarified supernatant and the mixture was heated at 
95
o
C for 15 min, and stored at –20oC until further analysis. When necessary, the 
supernatant was concentrated up to 10 times using the Ultra-4 Centrifugal Filter Device 
(Amicon) following the manufacturer‟s instructions before adding the protein loading 
buffer and heat- denaturing. 
 
3.5.1.2   Cell extract 
The bacterial pellet was thawed and resuspended in 500 μl of RNAse-free water, 
after which an equal volume of protein loading buffer was added and the mixture heated 
at 95ºC for 30 min. The chromosomal DNA was sheared by passing the suspension 10 
times through a 27G needle followed by heating at 95ºC for 15 min and stored at -20ºC 
until further analysis. 
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3.5.2   Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
           (SDS-PAGE) 
Protein separation was conducted under denaturing conditions via SDS-PAGE 
using a vertical slab gel unit (Hoefer, San Francisco CA, USA) according to the 
manufacturer‟s instructions. The slab gel was made up of a 4% polyacrylamide stacking 
gel and a 8% or 12% polyacrylamide separating gel, both containing 10% SDS. Cell 
extract and supernatant samples were heated at 95ºC for 5 min immediately before 
loading into the wells. 15 μl of BenchMarkTM Pre-Stained Protein Ladder (Invitrogen) 
was used as the molecular weight standard. Electrophoresis was conducted in 1x Novex 
Tris-Gly SDS Running Buffer (Invitrogen) at 25 mA/ gel for 45 min.  
  
3.5.3   Coomassie Blue Staining 
To visualize the protein bands after electrophoresis, the SDS-gel was soaked in 
Coomassie Staining Solution (0.2% Coomassie Billiant Blue, 45% ethanol, 10% acetic 
acid) for 1-2 h with constant gentle shaking. The gel was then soaked in Destaining 
Solution (25% ethanol, 10% acetic acid) with constant shaking until the protein bands 
could be visualized as sharp blue bands against a clear background. The gel was then 
rinsed in water and dried between a piece of 3M Whatman™ filter paper and a piece of 
clear cellophane in a BioRad Gel Dryer (Hercules, CA, USA) for 2 h at 80ºC. 
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Figure 3.4   Western blot transfer sandwich. 
2 pieces 3M Whatman
TM
 filter paper 
Nitrocellulose membrane 
Gel 
2 pieces 3M Whatman
















3.5.4   Western Blot 
After SDS-PAGE, the separated proteins were electro-transferred onto a 
nitrocellulose membrane (Bio-Rad) at 65 mA for 2-4 h using a semi-dry transfer system 
(OWL). Prior to assembly (Figure 3.4), the gel, membrane and filter papers were soaked 
in Transfer Buffer containing 1x Towbin Buffer (Bio-Rad) and 20% methanol for 15 min. 
After transfer was complete, the membrane was blocked overnight in blocking buffer 
(1% BSA, 1x TBS, 0.1% Tween20) at 4ºC. The membrane was then incubated with the 
appropriate primary antibody (Table 3.6) diluted in blocking buffer for 1 h, with gentle 
shaking at room temperature, followed by 3 washings in an excess of washing buffer (1x 
TBS, 0.1% Tween20) for 10 min. The appropriate AP-conjugated secondary antibody 
diluted in blocking buffer (Table 3.6) was then added to the membrane and incubated for 
1 h, with gentle shaking at room temperature, followed by washing as described above. 
Finally, the antibody-reactive bands were revealed by chromogenic detection upon 
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Table 3.6   Antibodies used in Western Blot. 
 
 




Primary Antibody Dilution Secondary Antibody 
(Alkaline phosphataseconjugated) 
Dilution 
Mouse anti-M2e antiserum 
(Raised in this study) 
1:500 Goat anti-mouse IgG (H+L) 
(Sigma) 
1:3,000 
Anti-FHA monoclonal antibody 
(Kind gift from Renauld-
Mongenie et al., 1996b) 
1:250 Goat anti-mouse IgG (H+L) 
(Sigma) 
1:3,000 
Anti-influenza NP monoclonal 
antibody 
(Chemicon) 
1:1000 Goat anti-mouse IgG (H+L) 
(Sigma) 
1:3,000 
Rabbit anti-influenza NA 
peptide polyclonal antibodies 
(Prosci-inc) 
1:2,000 Goat anti-rabbit IgG (H+L) 
(Sigma) 
1:3,000 
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(III)    ANIMAL WORK 
3.6 MOUSE STRAINS 
 Ten-weeks-old female CD1 outbred mice and 6-weeks-old female BALB/c mice 
were purchased from Biological Resource Center, Biopolis, Singapore. The mice were 
kept under specific pathogen-free (SPF) conditions in individual ventilated cages (IVCs). 
All the animal experiments were carried out upon approval and under the guidelines of 
the National University of Singapore animal study board. 
 
3.7 PRODUCTION OF POLYCLONAL ANTI-M2E IMMUNE SERA 
            Anti-M2e immune sera were raised by immunizing BALB/c mice with KLH-
conjugated M2e peptide (Mimotopes Pte Ltd, Clayton Victoria, Australia). Ten 6- to 8-
weeks old BALB/c mice were first primed intraperitoneally with 50 µg/mouse in 400 µl 
KLH-M2e peptide mixed with complete Freund‟s adjuvant (Sigma) and then boosted 
intraperitoneally with equal amount of peptide mixed with incomplete Freund‟s adjuvant 
(Sigma) two weeks later. Two weeks after the last immunization, blood was collected 
from the sedated mice by retro-orbital plexus puncture and allowed to clot overnight at 
4ºC. The sera were recovered after centrifugation at 4,000 rpm for 10 min, transferred to 
a clean Eppendorf tube and stored at -80ºC until use. Anti-M2e antibody titer was 
determined using unconjugated M2e peptide as coating antigen by ELISA. 
 
CHAPTER 3 MATERIALS AND METHODS 
99 
 
3.8 INTRANASAL B. PERTUSSIS INFECTION 
 B. pertussis bacteria grown on BG agar were resuspended in sterile PBST 
(1×PBS, 0.05% Tween80) and adjusted to a concentration of 2.5 × 10
8
 colony forming 
units (cfu) / ml. Infection of mice was performed by the intranasal route with 20 μl of 
bacterial suspension deposited in the nostrils of each animal, sedated with an anaesthetic 
cocktail (6% valium, 10% atropine, 20% ketamine, 64% 1x sterile PBS) administered 
intraperitoneally (150 μl per 20 g of body weight). 
 
3.9 LUNG COLONIZATION STUDY 
Four CD1 mice per group were sacrificed at the indicated time points after 
intranasal infection with the various B. pertussis strains. The lungs from each mouse were 
aseptically removed and homogenized in 2.5 ml or 5 ml of sterile PBST using the High 
Shear homogenizer (Omni International). Serially diluted in PBST lung homogenates 
from individual mice were then plated onto BG agar and the total cfu per lung was 
determined after 4-5 days incubation at 37ºC. Each colonization experiment was repeated 
twice independently. 
 
3.10 IN VIVO STABILITY STUDIES 
            To study in vivo stability of B. pertussis expressing ΔNA and NP proteins, the 
recombinant strains were first streaked onto commercial blood agar plates to obtain 
individual colonies. After 5 to 7 days incubation at 37ºC, 10 individual colonies were 
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picked and undergone PCR screening using ΔNA and NP specific primers (see section 
3.4.4). The positive colonies (two were selected) were then plated onto BG agar and 
incubated at 37ºC for 2 to 3 days. Four BALB/c mice were then nasally infected with 
each bacterial suspension deriving from the individual colonies identified positive by 
PCR. At 3 days post-infection, the mice were sacrificed, and their lungs were harvested, 
and homogenized. Appropriate dilutions were plated onto blood agar plates in order to 
obtain individual colonies after 5 days incubation at 37
o
C. Ten colonies were then 
randomly picked and undergone PCR screening using specific primers. All the colonies 
identified positive by PCR were then further grown in SSA+B (S100) medium and 
undergone western blot analysis using anti-NA or anti-NP specific antibodies. 
 
3.11 STUDY OF THE IMMUNE RESPONSES 
3.11.1 Immunization Schedules 
            Six per group BALB/c mice were intranasally infected with BPZE1 or 
recombinant B. pertussis strains as described in section 3.8,  and then boosted for the first 
time four weeks later and boosted for the second time three weeks later with equal 
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3.11.2 Broncho-alveolar Lavage Fluids (BALFs) and Serum Collection 
            Ten days after the boost, bronchoalveolar lavage fluids (BALFs) were recovered 
from each euthanized mouse by flushing 1 ml of sterile 1x PBS twice into the lungs using 
a 1 ml syringe introduced into the trachea. BALFs were centrifuged at 2,000 rpm for 10 
min at 4 ºC and then kept at -80ºC until further analysis. Two weeks after each boost, 
blood was collected from the sedated mice by retro-orbital plexus puncture and allowed 
to clot overnight at 4ºC. The sera were obtained after centrifugation at 4,000 rpm for 10 
min, transferred into a fresh Eppendorf tube and stored at -80ºC until further use. 
 
3.12 INFLUENZA VIRUS INFECTION 
           Sedated BALB/c mice were nasally administered with approximately 2 × 10
6
 
TCID50 of mouse-adapted H3N2 virus passage 10 (P10) (Narasaraju et al., 2009) or 4 
lethal dose (LD50) of H1N1 influenza virus in 20 µl sterile PBS supplemented with 
penicillin and streptomycin. Ten mice per group were used to determine the survival rates 
based on body weight loss and the mice were euthanized when body weight loss 
exceeded 20% of the original body weight. 
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3.13 HISTOPATHOLOGY  
3.13.1 Histopathology of Mouse Lungs  
            Four mice per group were sacrificed and their lungs were harvested 3 days post-
viral challenge. The lungs were removed and fixed in 10% formalin in PBS. After 
fixation, the lungs were embedded in paraffin, sectioned, and stained with H&E. 
 
3.13.2 Cellular Infiltrates in Bronchoalveolar Lavage Fluids (BALFs) 
            Individual BALFs were recovered as described in section 3.11.2. and then 
centrifuged at 400g for 10 min. The supernatant was removed and stored at -80°C for 
cytokine detection. The cell pellet was resuspended in 200 µl RBC lysis buffer (Promega) 
to remove blood cells. Total BALF cell number was determined using a hemocytometer. 
The cells were spotted onto a glass slide using a Cytospin device (Thermo Shandon), and 
were stained with a modified Wright staining procedure (Bao et al., 2007). Identification 
of the different cell types was performed using standard morphological criteria. Results 
are expressed as the percentage of each cell type in the total cell population. A total of 
500 cells were considered per slide. Four mice per group were individually assessed. 
 
3.14 PASSIVE TRANSFER PROTECTION STUDY  
            A high titer anti-B. pertussis immune serum was generated in 10 adult BALB/c 
mice nasally infected twice at a 4-week interval with 5 x 10
6
 cfu of live BPZE1 bacteria. 
Another group of 10 adult naïve BALB/c mice were injected intraperitoneally (ip.) with 





TCID50 of heat-inactivated human /Aichi/2/68 (H3N2) virus (HI-H3N2) in complete 
Freund‟s adjuvant and boosted with the same amount of HI-H3N2 virus in incomplete 
Freund‟s adjuvant 2 weeks later. The immune sera from each mouse group were collected 
2 weeks after the boost, pooled, and the anti-pertussis and anti-influenza antibody titers 
were measured by ELISA (Section 3.18). Moreover, HI-H3N2 serum was tested for the 
presence of neutralizing antibodies by neutralization assay (Section 3.17). The immune 
sera were filter-sterilized, heat inactivated at 56
o
C for 30 min and stored at -80
o
C until 
further use. Sera from control naïve mice were also collected as negative control.  Six to 
8 week-old recipient BALB/c mice were ip. injected with 200µl of naïve, anti-BPZE1 or 
anti-H3N2 immune serum 1 day prior viral challenge with mouse-adapted H3N2 virus. 
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(IV)   VIRUS WORK 
3.15   VIRUS STRAINS 
            Adaptation of H3N2 influenza A virus were obtained by serial lung-to-lung 
passaging of human influenza A virus strain A/Aichi/2/68 (H3N2) in BALB/c mice 
(Narasaraju et al., 2009) and Passage 10 (P10) virus was used in this study. Influenza A 
virus strain H1N1 (A/PR/8/34) influenza virus (ATCC# VR-95) were purchased from the 
American Type Culture Collection (ATCC). 
 
3.16   VIRUS TCID50 QUANTIFICATION 
            The virus titer was expressed as 50% tissue culture infective dose (TCID50) in 
Madin-Darby Canine Kidney (MDCK) cells based on a typical cytopathic effect (CPE) 
produced by influenza virus infection. The infected mouse lungs were harvested and 
homogenized using mechanical disruption (Omni homogenizer), and tested for the 
presence of viable virus by TCID50 assay using a modified method reported by the WHO 
(WHO, 2002). Briefly, 90% confluent MDCK cells in 96-well plates were inoculated 
with 100 µl of 10-fold serially diluted in RPMI medium lung homogenates. Plates were 
incubated at 35°C in a humidified incubator and 5% CO2 for 3 days. TCID50 was 
determined by a reduction in CPE of 50%, and the log TCID50/lung was derived. Five 
mice per group per time point were individually assessed. 
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3.17     IN VITRO MICRO-NEUTRALIZATION ASSAY 
            MDCK cells (5×10
4
) were seeded the day before assay into 96 well flat bottom 
plates. On the day of assay, 25 μl of two-fold serial dilutions of heat-treated (56 ºC, 30 
min) sera or neat BALFs were mixed with equal volumes of 10
2
 TCID50 of virus in a 
sterile 96-well microtiter plate and incubated at 37ºC with 5% CO2. One hour later, the 
antibody-virus mixtures were transferred to MDCK cell monolayer that had been washed 
twice with serum free DMEM (Gibico) and incubated at 37ºC for 1 hr with 5% CO2. The 
antibody-virus mixture was then flicked out and, the monolayers were washed twice with 
DMEM and 200 µl DMEM were added into each well. Three days later, the cells were 
observed for CPE and the neutralizing antibody titer was read as the highest dilution of 
serum that inhibited virus growth and prevented CPE. Each dilution was assayed in six to 
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(V)   IMMUNOLOGY WORK 
3.18   ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)  
3.18.1   Coating Antigens  
            The titers of anti-B. pertussis, anti-M2e, anti-HA1-1, anti-HA2-1, anti-HA2-2 
antibodies and anti-H3N2 influenza virus were measured by ELISA using BPZE1 total 
cell lysate, unconjugated M2e, HA1-1, HA2-1, HA2-2 peptide (Mimotopes Pte Ltd, 
Clayton Victoria, Australia) and purified inactivated whole H3N2 influenza virus as 
coating antigens, respectively. To prepare the BPZE1 total cell lysate, 10 ml of 
exponentially grown BPZE1 liquid culture was centrifuged at 7,000 rpm for 15 min at 
room temperature. The pellet was washed three times with 5 ml of sterile 1x PBS and 
resuspended in 1 ml of 1x PBS. The suspension was sonicated on ice 15 times for 15s 
each, with intervals of 15s (Model 150V/T Ultrasonic Homogenizer, BioLogics Inc., 
Manassas, VA). Total protein concentration of the lysate was measured using the 
NanoDrop® ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). 
 
3.18.2   Determination of Antibody Titer 
            Flat 96-well microtiter plates (Corning NUNC) were coated overnight at 4ºC with 
100 μl of coating buffer (0.1 M Na2CO3-NaHCO3, pH 9.6) containing 5 μg/ ml of BPZE1 
total cell lysate, 3 μg/ ml of unconjugated M2e, HA1-1, HA2-1, HA2-2 peptide, or 5 μg/ 
ml of H3N2 influenza virus. The wells were washed three times with wash buffer (1x 
PBS, 0.1% Tween20), before blocking with blocking buffer (1x PBS, 0.1% Tween20, 2% 
BSA) for 1 h at 37°C. The wells were then washed three times with wash buffer and 100 
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μl of diluted mouse serum in blocking buffer or neat BALFs were added to each well. For 
detection of anti-B. pertussis antibodies, the mouse serum was diluted at 1:1,000. For 
detection of anti- M2e, HA1-1, HA2-1, HA2-2 peptide antibodies, the mouse serum was 
diluted at 1:40. For detection of anti-H3N2 influenza virus antibodies, anti-BPZE1 mouse 
serum was diluted at 1:40 and anti-H3N2 influenza virus mouse serum was diluted at 
1:1,000. After incubation at 37ºC for 2 hrs, the plate was washed thrice before adding 100 
μl of 1:3,000 diluted horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG 
(H+L) secondary antibody (Bio-rad) or 1:2,000 diluted anti-mouse IgA secondary 
antibody (Chemicon). The plates were again incubated at 37ºC for 1 h followed by 3 
washes. The ELISA was developed by adding 100 μl of o-phenylenediamine 
dihydrochloride (OPD) substrate (Sigma) to each well and incubating at room 
temperature for 20 min in the dark. To stop the reaction, 50 μl of 1 M sulphuric acid was 
added to each well and absorbance at 490 nm was measured using the Biorad model 680 
Microplate Reader and recorded with the Microplate Manager 5.2 software (Biorad). 
IgG isotyping was carried out by adding 100 µl 1:250 diluted biotinylated anti-
mouse IgG1 and IgG2a (BD Pharmingen) after incubating samples 1.5 hr at 37ºC. The 
plates were incubated at room temperature for 1hr followed by 6 times washes before 
adding 100 µl 1:1,000 diluted avidin-HRP (BD Pharmingen). The plates were then 
incubated at room temperature for 45 mins and washed 6 times again before adding 50 µl 
TMB substrate (Biorad) and incubating in dark at room temperature for 30 mins. The 
reaction was stopped by adding 50 μl of 1 M sulphuric acid to each well and absorbance 
at 490 nm was measured using the Biorad model 680 Microplate Reader and recorded 
with the Microplate Manager 5.2 software (Biorad). 
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3.19     IN VITRO RE-STIMULATION EXPERIMENTS 
3.19.1   T-Cell Proliferation assay 
            Lymphocyte proliferation was measured by incorporation of tritiated (
3
H) 
thymidine as described elsewhere (Kimman et al., 1995). Briefly, spleens from naïve and 
BPZE1-treated mice (6 mice per group) were collected under aseptic condition and 
pooled. Single-cell suspensions were prepared and centrifuged on Ficoll-Paque
TM
PLUS 
(GE) for 20 min at 600g at room temperature.  The splenocytes were seeded in 96-well 
round-bottom plates (NUNC) at a density of 2 × 10
5
 cells/well in 100 µl medium 
(RPMI640 supplemented with 10% FCS, 5 × 10
-5
 M β-mercaptoethanol, 2 mM L-
glutamine, 10 mM HEPES, 200 U/ml penicillin, 200 µg/ml streptomycin). 100 µl 
medium containing 20 µg/ml of BPZE1 whole cell lysate or heat-inactivated 10
5
 TCID50 
HI-H3N2 (test antigen) were added to the splenocytes. 100ul of non-infected egg 
amniotic fluid and 100 ul of medium containing 5 µg/ml concanavalin A (conA) were 
used as mock and vitality controls, respectively. After 3 days incubation at 37
o
C with 5% 
CO2, the cultures were pulsed with 0.4 µCi [
3
H]thymidine in 20 µl RPMI complete 
medium for 18 hrs incubation.  The cells were then harvested, washed and the 
incorporated radioactivity was measured in TopCount NXT™ Microplate Scintillation 
and Luminescence Counter (PerkinElmer). Results are expressed as stimulation index (SI) 
corresponding to the ratio between the mean of [
3
H]thymidine uptake in the presence of 
test antigen and the mean of [
3
H]thymidine uptake in the absence of test antigen. A SI>2 
was considered positive. Each sample was assayed in quadruplicate. 
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3.19.2   IFN-γ ELISPOT 
            The frequency of antigen-specific IFN-γ-producing splenocytes was determined 
by ELISPOT assay using BD mouse ELISPOT set (BD PharMingen) according to the 
manufacturer‟s instructions. Briefly, single-cell suspensions of individual spleen from 
naïve and BPZE1-treated mice were prepared and plated in 96-well microplates 
(Millipore, Bedford, MA) pre-coated with 100 µl of 5 µg/ml anti-IFN-γ antibody in 
sterile PBS overnight at 4
o
C, washed three times and blocked for 2 hrs at room 
temperature with RPMI 1640 containing 10%  FCS. Cells were then incubated with 20 
µg/ml of BPZE1 whole cell lysate, 10
5
 TCID50 HI-H3N2 or 5 µg/ml ConA for 12-20 hr 
at 37
o
C with 5% CO2. The plates were then washed followed by addition of biotin-
conjugated anti-mouse IFN-γ antibody for 2 hrs at room temperature. After washing, 
streptavidin-HRP conjugate was added and incubated at room temperature for 1 hr. Wells 
were washed again and developed with a 3-amino-9-ethyl-carbazole (AEC) substrate 
solution until spots were visible. After drying, spot-forming cell numbers were counted 
by Bioreader
®
 4000 (Biosystem). Six animals per group were individually assayed. 
 
3.20 MULTI-PLEX CYTOKINE AND CHEMOKINE ANALYSIS 
            Cytokine and chemokine production in the BALFs supernatants was measured 
using Procarta cytokine profiling kit, according to the manufacturer‟s instructions 
(Panomics). After incubation with Ab-conjugated beads, detection Abs and streptavidin-
PE complexes, samples were run on Bio-Plex instrument (Bio-Rad). Levels of the 
following growth factors, cytokines, and inflammatory mediators were evaluated: GM-
CSF, KC, IL-1β, IL-6, IFN-γ and TNF-α, IFN-α, MCP-1 RANTES, IL-10. In addition, 
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TGF- levels were measured using a Human/Mouse TGF1 ELISA kit (eBioscience) 
according to the manufacturer‟s instructions.  
 
3.21 FACS ANALYSIS 
            Mice were sacrificed, their lungs were harvested and single cell suspensions were 
prepared by digesting the lungs at 37°C for 15 min in 2 ml digestion buffer containing 0.5 
mg/ml Liberase (Roche) in RPMI with 1 %  FCS and 2 U/ml DNaseI (Qiagen), followed 
by centrifugation on Ficoll-Paque
TM
PLUS (GE) for 20 min at 600g and room temperature. 
Cells were collected and washed twice with sterile FACS buffer (2% FCS, 5 mM EDTA 
in PBS). 10
6
 cells were stained with FITC-labeled anti-mouse CD3 antibody (eBioscience) 
and analyzed on CyAn
TM
 ADP cytometer (Dako). Five mice per group per time point 
were individually assessed. 
 
(VI)   STATISTICAL ANALYSIS 
            Bars represent the means ± standard deviations (SD), and averages were 
compared using a bidirectional unpaired Student‟s t test with a 5% significance level with 
* P≤0.05, **P≤0.01 and ***P≤0.001. 
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CHAPTER 4: STUDY OF THE MECHANISMS INVOLVED IN THE 
PROTECTION OF ATTENUATED B. PERTUSSIS BPZE1 AGAINST LETHAL 




4.1.1 A Single Nasal Treatment with B. pertussis BPZE1 Protects Against Lethal 
Challenge with Mouse-Adapted H3N2 Virus 
            Adult BALB/c mice were nasally inoculated once with 5×10
6
 cfu of live B. 
pertussis BPZE1 and challenged 3 or 6 weeks later with 2 lethal dose 50% (2LD50) of 
mouse-adapted H3N2 virus, obtained after 10 successive lung-to-lung passages of the 
A/Aichi/2/68 (H3N2) virus (Narasaraju et al., 2009). Survival rates (Figure 4.1A) and 
body weight changes (Figure 4.1B) indicated that the mice challenged 6 weeks after nasal 
BPZE1 treatment were significantly protected (60% protection rate), whereas mice 
challenged at 3 weeks post-BPZE1 treatment were not protected. A protection rate of 60% 
was still observed when the viral challenge was performed 12 weeks post-BPZE1 
treatment (Figure 1C). In contrast, nasal administration of the same amount of heat-killed 
bacteria did not provide any significant protection against H3N2 lethal challenge (Figure 
1D), suggesting that bacterial colonization of the mouse lung which typically lasts for 4 
weeks (Mielcarek et al., 2006a) is necessary for protection. Typical colonization profile 
of BPZE1 in the mouse lungs is shown in Figure 4.2. BPZE1 displayed a slight peak of 
multiplication at day 3 followed by a progressive clearance of the bacteria from the lungs. 
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           To further explore the protective efficacy of live BPZE1 bacteria, 10-fold serially 
diluted BPZE1 suspensions were administered nasally to the mice prior to lethal 
challenge with H3N2 virus performed 6 weeks later. The mouse group who received 
5×10
5
 cfu of BPZE1 was not significantly protected whereas mice administered with 
either 5×10
6
 cfu or 5×10
7
 cfu were significantly protected with 50% and 62.5% survival 
rates, respectively (Figure 4.3A). Interestingly, the animals immunized with the highest 
bacterial dose (5×10
7
 cfu) displayed significantly smaller body weight losses compared to 
the animal group administered with 5×10
6
 cfu (Figure 4.3B). Concurrently, the lung 
colonization profiles of BPZE1 were determined for each bacterial dose, and showed that 
the bacterial load present in the lungs during the colonization period directly depends on 
the initial bacterial dose administered (Figure 4.3C). 
 
           Taken together, these results indicate that the protective efficacy of BPZE1 against 
lethal challenge with H3N2 virus depends on the bacterial dose administered, and that the 
ability of the bacteria to colonize effectively the mouse respiratory tract is necessary to 
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Figure 4.1(A-D) Protection rates of BPZE1-treated mice against lethal challenge 
with influenza A viruses.  
Mice were nasally administered once with 5×10
6
 cfu of BPZE1 and challenged with 
2LD50 of mouse-adapted H3N2 influenza A virus. The survival rates were compared 
to infected control mice (solid lozenge). Body weights were monitored daily and 
mice were sacrificed when the body weight loss exceeded 20% of the original body 
weight. (A, B) Viral challenge was performed at either 3 weeks (solid square) or 6 
weeks (solid triangle) after BPZE1-treatment. (C) Viral challenge was performed at 
12 weeks post-BPZE1 treatment (solid triangle). (D) Mice were nasally administered 
with live (solid triangle) or dead (solid square) BPZE1 bacteria, and challenged 6 
weeks later with H3N2 virus. Ten animals per group were monitored. Ten animals 
per group were assessed. Results are representative of at least two independent 
experiments. 
 







































Figure 4.2 Lung colonization profile of BPZE1.  
CD1 mice were infected intranasally with 5×10
6
 cfu of BPZE1 at 0 h. The lungs were 
harvested at the indicated time points and viable bacteria in the lungs were counted 
after plating appropriate dilutions of the lung homogenates onto blood agar plates. 4 
mice per time point were assessed individually. Bars represent the means ± standard 
deviations (SD). 
 



















































































Figure 4.3 Effect of the bacterial dose on BPZE1 protective efficacy against 
lethal challenge with H3N2 virus.  
Survival rate (A) and average body weight changes (B) of mice nasally administered 
once with 5×10
5
 (open square), 5×10
6
 (solid square) or 5×10
7
 (open circle) cfu of live 
BPZE1 bacteria, were compared to non-treated infected mice (solid lozenge). Lethal 
viral challenge (2LD50) was performed 6 weeks post-BPZE1 treatment with mouse-
adapted H3N2 virus. Mice were sacrificed when body weight loss exceeded 20% of 
the original body weight. Ten animals per group were monitored. (C) Lung 





 (solid square) or 5×10
7
 (open circle) cfu. Four animals per group per 
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4.1.2 Booster Effect 
The effect of a second nasal BPZE1 treatment was addressed. Live BPZE1 
bacteria were nasally administered twice at a 4-week interval prior to lethal challenge 
with mouse-adapted H3N2 virus performed 2 weeks after the last BPZE1 treatment. A 
survival rate of 100% was obtained (Figure 4.4A) with minimal body weight changes in 
contrast to the infected control mice (Figure 4.4B). These data demonstrate that a second 
nasal administration of BPZE1 not only enhances the protective efficacy, but also 













































































Figure 4.4 Booster effect 
Mice were administered twice at a 4-weeks interval with 5×10
6
 cfu of live BPZE1 
bacteria (solid square) and lethally (2LD50) challenged 2 weeks after the last 
administration with H3N2 virus. Survival rate (A) and body weight loss (B) were 
compared to non-treated infected animals (solid lozenge). Mice were sacrificed when 
body weight loss exceeded 20% of the original body weight. Ten animals per group 
were assessed.  
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4.1.3 BPZE1 Protects Against H1N1 Virus 
The protective potential of BPZE1 against a different influenza A virus subtype 
was explored. A single nasal administration of 5×10
6
 cfu of live BPZE1 bacteria was 
shown to protect the mice at 20% against lethal challenge with H1N1 A/PR/8/34 virus, 
whereas two administrations of live BPZE1 provided 40% protection (Figure 4.5A). 
These observations indicate that BPZE1 is able to protect against different influenza A 
virus subtypes although with variable efficacy. In this experiment, a 4LD50 dose of 
H1N1 was administered to mice, whereas H3N2 challenge was performed with a 2LD50 
dose; one can thus argue that the differential protective efficacy of BPZE1 against both 
virus subtypes may be due to the different lethal dose used for the challenge. However, 
we found that the survival rates, time of death and body weight losses of naïve mice 
infected with either 2LD50 or 10LD50 of H1N1 A/PR8/34 virus were comparable 
(Figure 4.5B&C), indicating that a higher initial viral dose does not worsen the disease 
severity based on survival rate, time of death and body weight loss. Therefore, the 
differential ability of nasal BPZE1 treatment to protect against H1N1 or H3N2 subtypes 
is likely not attributable to the different lethal doses used for the viral challenge, but 
rather suggests differences in the virulence mechanisms developed by both virus subtypes, 

















































































Figure 4.5 Protective efficacy of BPZE1 against H1N1 A/PR8/34 influenza virus. 
(A) Mice were nasally administered once (open triangle) or twice (solid triangle) with 
5×10
6
 cfu of live BPZE1 bacteria and challenged 2 weeks after the last BPZE1 
treatment with 4LD50 of H1N1 A/PR8/34 virus. The survival rate was compared to 
non-treated infected animals (solid lozenge). Ten animals per group were assessed. 
(B, C) Naïve mice were nasally infected with 2LD50 (open lozenge) or 10LD50 
(solid lozenge) of H1N1 A/PR8/34 virus. Survival rates (B) and body weight losses 
(C) were monitored over time. Ten animals per group were used. 
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4.1.4 BPZE1 Treatment Protects Mice from Influenza-induced Immunopathology 
and Lymphocyte Depletion 
            Lung immunopathology was examined by histology of lung sections from 
infected BPZE1-treated and non-treated animals. As expected and as described 
previously (Narasaraju et al., 2009), the infected non-treated mice displayed signs of 
severe bronchopneumonia and interstitial pneumonitis, characterized by necrosis of the 
bronchiolar epithelium, presence of necrotic debris in the bronchioles and alveoli, as well 
as significant pulmonary emphysema and moderate edema (Figure 4.6A). In contrast, 
only mild inflammation, minimal airway and alveolar damage, and mild perivascular- or 
peribronchiolar damage together with minimal edema were observed in the lungs of the 
protected BPZE1-treated mice. 
 
            The cell populations present in the broncho-alveolar lavage fluids (BALFs) 
recovered from protected and non-protected animals were also examined. Whereas the 





), a significantly higher proportion of macrophages but a lower 
proportion of neutrophils were found in the infected BPZE1-treated, compared to the 
non-treated mice (Figure 4.6B). 
 
            Lymphocyte depletion has been reported in mice infected with highly pathogenic 
H1N1 (1918) and H5N1 influenza viruses (Kash et al., 2006; Lu et al., 1999; 
Uiprasertkul et al., 2007), as well as in mice infected with the mouse-adapted H3N2 virus 
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strain used in this study (Narasaraju et al., 2009). The lymphocyte populations present in 
the lungs of protected and non-protected mice were thus compared. At 3 days post-viral 
challenge, the percentages of CD3
+
 T-lymphocytes in the infected control and BPZE1-
treated mice were comparable to that found in the animals before challenge (Figure 4.6C). 
However, significant CD3
+ 
T-cell depletion was observed in the infected control animals 
at 5 days post-viral challenge. In contrast, the T-cell population remained constant before 
and after challenge in the protected BPZE1-treated animals, indicating that nasal 




























































































a b c d e f 
Figure 4.6 (A-C) Lung histology, cellular infiltrates and CD3
+
 T-cell population in 
the lungs of BPZE1-treated versus control mice.  
Mice were nasally administered once with 5×10
6
 cfu of live BPZE1 bacteria and 
challenged 6 weeks later with 2LD50 of mouse-adapted H3N2 virus. (A) Lung histology. 
At 3 days post-viral challenge, infected control mice displayed pulmonary edema (black 
arrow) and necrotizing bronchitis with necrotic cell debris (open arrows). 40 fields were 
analyzed per group (>5 fields/section, 2 sections/mouse and 4 mice/group). (B) Cellular 
infiltrates. Non-treated (a,b) or BPZE1-treated (c,d) mice were left un-infected (a,c) or 
were challenged with H3N2 virus (b,d), and their macrophage, neutrophil and 
lymphocyte counts were determined in their broncho-alveolar lavage fluids (BALFs) 3 
days post-challenge. Four animals per time point per group were individually assessed. 
(C) Analysis of the CD3
+
 T-cell population. Non-treated (a,c,e) and BPZE1-treated mice 
(b,d,f) were left un-infected (a,b) or were challenged with H3N2 virus (c-f). Three (c,d) 
or 5 (e,f) days after viral challenge, the CD3
+
 T-cell population was analyzed in the 
mouse lungs. Four animals per time point and per group were individually assessed. 
Results are expressed as the means ± SD of the percentages of CD3
+
 T-cells in the total 
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4.1.5 B. pertussis-specific Adaptive Immunity is Not Involved in Protection against 
Influenza A Virus 
            The presence of cross-reactive and virus-neutralizing antibodies and T-cells in the 
BPZE1-treated animals was examined. A BLAST search failed to identify any matching 
epitopes between B. pertussis and H3N2 or H1N1 influenza A viruses (data not shown). 
 
Moreover, the sera and BALFs from BPZE1-treated mice did not react with 
whole H3N2 viral antigens in an ELISA assay (Figure 4.7A&B), and did not neutralize 
virus infectivity in vitro (Figure 4.7C). Consistently, high-titer anti-BPZE1 immune sera 
did not confer any significant protection against H3N2 lethal challenge in an in vivo 
passive transfer experiment, whereas immune sera raised against heat-inactivated H3N2 
virus provided 100% protection (Figure 4.8A). Finally, proliferation and IFN-γ ELISPOT 
assays revealed that splenocytes from BPZE1-treated mice did not proliferate and did not 
produce IFN-γ 
and IFN-γ production was seen upon stimulation with BPZE1 extracts (Figure 4.8B & C). 
Altogether, these data indicated that B. pertussis-specific adaptive immunity is not likely 
























Mouse group Mouse serum Serum dilution* BALFs 
Naïve  Pooled No protection No protection 
BPZE1 M1 1/4 No protection 
 M2 1/4 No protection 
 M3 1/4 No protection 
 M4 1/4 No protection 


























a b c d e f a b c d e f 
A B 
C 
Figure 4.7 (A-C) Cross-reactive antibodies in ELISA and neutralization assays.  
(A&B): 6 Mice per group were nasally administered twice at a 4-weeks interval with 
5×10
6
 cfu live BPZE1 or first primed with heat inactivated (HI-H3N2) virus in 
incomplete Freund‟s adjuvant and boosted with HI-H3N2 in complete Freund‟s 
adjuvant. Sera and BALFs were collected two weeks after the last administration. 
ELISA assay was performed using purified heat-inactivated H3N2 viral particles as 
coating antigen and the anti-BPZE1 immune sera (diluted 1/40), anti-H3N2 immune sera 
(diluted 1/1000) or BALFs (neat) as primary antibody. IgG (A) and IgA (B) antibody 
responses were measured. Results are expressed as the optical density at 490nm 
(OD490nm). Legend: a, naïve serum; b, anti-BPZE1 serum; c, anti-H3N2 serum; d, 
naïve BALFs; e, anti-BPZE1 BALFs; f, anti-H3N2 BALFs. (C): in vitro neutralizing 
activity of the anti-pertussis immune sera and BALFs. Two-fold serial dilutions of the 
sera (starting at 1/2) or neat BALFs were incubated with H3N2 influenza virus before 
infecting MDCK cells, and the cytopathologic effect (CPE) was observed 72 h later. A 
high titer anti-H3N2 influenza virus immune serum was used as positive control. Sera or 
BALFs from naïve mice were pooled, while those from mice treated with BPZE1 were 
tested individually. * Highest dilution for which total protection was observed. Results 
are representative of two independent experiments. 
*** 
* 
















































































Figure 4.8 (A-C) Cross-protective antibodies and T-cells.  
(A) Passive transfer of immune serum. Naive (open triangle), anti-H3N2 (solid circle) or 
anti-BPZE1 (open circle) immune sera were ip. injected to naive mice one day prior to 
lethal challenge with mouse-adapted H3N2 virus. Survival rates were compared to non-
treated mice (solid triangle). Ten animals per group were assessed. (B) Re-stimulation 
assays. Pooled spleens from 6 BPZE1-treated (grey bar), HI-H3N2 virus immunized 
(black bar) or untreated (open bar) animals were stimulated with either BPZE1 lysate or 
heat-inactivated H3N2 viral particles, and [
3
H]-thymidine incorporation assay were 
performed. (C). IFN-γ ELISPOT assay. Individual spleens from 6 BPZE1-treated (grey 
bar) or untreated (open bar) animals were stimulated with either BPZE1 lysate or heat-
inactivated H3N2 viral particles and IFN-γ ELISPOT assay were performed. Results are 
representative of two independent experiments and expressed as the mean ± SD. *, 
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4.1.6 The Viral Load is Not Significantly Reduced in BPZE1-treated Mice 
            To further characterize BPZE1-induced protection against influenza A viruses, the 
viral loads were quantified by TCID50 quantification assay (see section 3.16) in the lungs 
of mice either treated or not treated with BPZE1, and infected with mouse-adapted H3N2 
virus. No significant difference in the viral loads was observed between the two groups, 
neither at 3 nor at 5 days post-viral challenge (Figure 4.9). This result indicates that the 
BPZE1-induced protective mechanism does not directly target the virus particles and/or 
infected cells and demonstrates that effective protection against influenza A virus-
induced pathology and mortality can be achieved without affecting the virus titer in the 
lungs. 
 




























Figure 4.9 Viral load quantification in the lungs of protected and non-protected 
mice.  
Mice were nasally administered with live BPZE1 bacteria and challenged 6 weeks later 
with a lethal dose of mouse-adapted H3N2 virus. At 3 and 5 days post-viral challenge, 
the viral loads were measured in the lungs of BPZE1-treated and non-treated mice by 















































CHAPTER 4 BPZE1 PROTECT AGAINST INFLUENZA A VIRUSES 
128 
 
4.1.7 The Production of Major Pro-inflammatory Cytokines and Chemokines is 
Dampened in the Protected BPZE1-treated Mice  
The levels of 8 major pro-inflammatory cytokines and chemokines as well as 
TGF-β and IL-10 were measured before and 3 days after lethal challenge with H3N2 in 
the BALFs from BPZE1-treated and non-treated mice. A significant up-regulation of 6 
out of the 8 pro-inflammatory cytokines/chemokines was observed in the non-treated 
infected mice compared to the levels measured in naïve animals (Figure 4.10A). IFN-γ 
and IL-12p70 production was unchanged in the infected mice compared to the naïve 
group. Interestingly, the level of TGF-β was found strongly reduced in the infected mice 
whereas IL-10 levels were higher compared to the naïve control (Figure 4.10A). In mice 
treated once with BPZE1, the level of 3 out of 8 pro-inflammatory cytokines and 
chemokines, namely IL-1β, IL-6, and GM-CSF was significantly lower compared to that 
measured in the non-treated infected controls (Figure 4.10B). In mice treated twice with 
BPZE1, the production of all the 8 pro-inflammatory cytokines and chemokines was 
either strongly reduced or completely suppressed compared to the non-treated infected 
control group (Figure 4.10B). Thus nasal treatment with live BPZE1 prior to viral 
challenge suppresses the influenza-induced cytokine storm, strongly suggesting a 
correlation between protection and reduced lung inflammation. 
Interestingly, no significant difference was detected in the levels of TGF-β 
between BPZE1-treated mice and the infected controls (Figure 4.10B), whereas IL-10 
production was found to be reduced in the BPZE1-treated animals.  
  









































































































Figure 4.10 Pro- and anti-inflammatory cytokine and chemokine profiles.  
Adult BALB/c mice were nasally administered once or twice at a 4-weeks interval with 
5×10
6
 cfu of live BPZE1 bacteria and were lethally challenged with 2LD50 of mouse-
adapted H3N2 virus at 6 and 4 weeks after the last BPZE1 administration, respectively. 
Three days post-viral challenge, 5 mice per group were sacrificed and their BALFs 
were collected. Ten inflammation-related cytokines and chemokines were measured in 
the individual BALF samples. (A) Cytokine levels in naïve (black bar) or non-treated 
infected (open bar) mice. (B) Cytokine levels in non-treated infected mice (black bar), 
or in mice treated once (open bar) or twice (grey bar) with BPZE1 prior to challenge 
with H3N2 virus. Results are expressed in pg/ml. *, p≤0.05; **, p≤0.01; ***, p≤0.001. 














CHAPTER 4 BPZE1 PROTECT AGAINST INFLUENZA A VIRUSES 
131 
 
4.2  DISCUSSION 
            Severe respiratory disease and immunopathology resulting in high case-fatality 
rates are hallmarks of highly pathogenic influenza virus infections in humans as well as 
in other mammals. However, the underlying mechanisms of the severe 
immunopathological effects have yet to be fully elucidated. Cytokine storm, 
characterized by excessive levels of chemokines and cytokines in the serum and lungs, 
has been linked to fatal outcome in humans (Beigel et al., 2005; de Jong et al., 2006; 
Peiris et al., 2004; Uiprasertkul et al., 2007) and in experimental animals infected with 
reconstructed 1918 H1N1 and H5N1 influenza viruses (Kash et al., 2006; Kobasa et al., 
2007; Simon et al., 2001; Tumpey et al., 2005a). Furthermore, histological and 
pathological indicators strongly suggest a key role for an excessive host response in 
mediating at least some of the extreme pathology associated with highly pathogenic 
influenza viruses. Thus, although cytokine production may be important for viral 
clearance, their inflammatory properties can also lead to tissue damage (La Gruta et al., 
2007). In this study, we found that administration of live attenuated B. pertussis BPZE1 
protected mice against lethal challenge with two different influenza A viruses by strongly 
decreasing lung immunopathology and reducing the production of major pro-
inflammatory cytokines and chemokines without affecting the viral load. These findings 
thus indicate a direct link between protective efficacy and reduction of the cytokine-
mediated inflammation, and strongly argue for an important role of the over-production 
of pro-inflammatory cytokines in influenza disease severity and mortality.  
            These conclusions are in line with those of a recent study in which the intra-
tracheal administration of the sphingosine analog AAL-R significantly reduced lung 
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immunopathology caused by influenza virus by decreasing the release of cytokines and 
chemokines known to contribute to the cytokine storm effect, while no change in lung 
viral titers was observed (Marsolais et al., 2009). However, other studies have suggested 
that the severe immunopathology observed in infected animals is a consequence of the 
inability to resolve a high viral load in the respiratory tract (de Jong et al., 2006; de Jong 
et al., 2005b). Moreover, reduced inflammatory cell infiltration and pulmonary damage 
but delayed viral clearance was observed in MIP-1α gene knock-out mice (Cook et al., 
1995). Likewise, CCR2 (primary receptor for MCP-1)-deficient mice displayed reduced 
mortality with decreased pulmonary cell infiltration and tissue damage, but a significantly 
elevated viral burden, compared to control mice (Dawson et al., 2000). The relationship 
between viral load, immunopathology and disease severity thus appears complex and 
involves a variety of host factors playing different roles during influenza infection and 
whose disruption or inactivation leads to different outcomes.  
 
            The reduced production of pro-inflammatory cytokines and chemokines in the 
respiratory tract of the protected BPZE1-treated animals likely impacted on cellular 
infiltration and immune cell activation. Lower neutrophil counts were observed in BALFs 
of the protected animals, consistent with lower levels of KC and TNF-α, two cytokines 
that are involved in the recruitment and activation of neutrophils in the infected tissues 
(Headley et al., 1997; Kips et al., 1992; La Gruta et al., 2007). Neutrophils can elicit 
numerous responses in the presence of IFN-γ, including an increased oxidative burst, and 
the induction of antigen presentation and chemokine production (Ellis & Beaman, 2004; 
Farrar & Schreiber, 1993). Therefore, although increased numbers of neutrophils in the 
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lungs contribute to the inhibition of virus replication as part of the host innate immune 
response, they may also play a role in the enhanced immunopathology induced upon 
infection with highly pathogenic influenza viruses. 
 
            Interestingly, a higher number of macrophages were observed in the BALFs of 
protected BPZE1-treated mice. Alveolar macrophages (AMs) constitute the predominant 
macrophage population recovered in BALFs (Jakubzick et al., 2006) and display 
suppressive effects on the inflammatory reaction by regulating T-cell function (Strickland 
et al., 1993) and by suppressing dendritic cell maturation (Bilyk & Holt, 1993; Holt et al., 
1993) and migration to the mesenteric lymph nodes (Jakubzick et al., 2006). The 
increased number of AMs present in the BPZE1-treated animals upon influenza challenge 
may thus contribute to the control of lung inflammation.  
 
            In addition, treatment with BPZE1 prevented influenza virus-induced CD3
+
 T-cell 
depletion. Lymphocyte depletion during highly pathogenic influenza infection has been 
previously reported (Kash et al., 2006; Lu et al., 1999; Narasaraju et al., 2009; 
Uiprasertkul et al., 2007), and apoptosis has been proposed as a potential mechanism 
(Hinshaw et al., 1994; Lu et al., 1999; Uiprasertkul et al., 2007). Since in this study no 
difference in viral load was observed between protected and non-protected animals, 
virus-induced lymphocyte apoptosis is likely not a direct cytotoxic effect of the virus 
itself. Instead, consistent with previous studies on H5N1-infected humans and mice 
(Maines et al., 2005; Uiprasertkul et al., 2007), lymphocyte apoptosis is likely to be 
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attributed to cytokine dysregulation and over-activation of the host immune response. In 
particular, TNF-α and related TNF-superfamily members including TNF-related 
apoptosis-inducing ligand (TRAIL) are known to induce T-cell apoptosis (Simon et al., 
2001; Wang et al., 2001). Consistently, lower levels of TNF-α were measured in the 
BALFs of protected BPZE1-treated mice upon influenza challenge, thus potentially 
translating into diminished T-cell apoptosis. 
 
            Aspecific protection against influenza viruses has previously been reported. Nasal 
administration of Autographa californica nuclear polyhedrosis baculovirus (AcNPV) 
protected mice from lethal A/PR/8/34 (H1N1) influenza A virus challenge (Abe et al., 
2003). Reduced immunopathology together with lower level of IL-6 production, but also 
with reduced viral loads were observed in the protected mice compared to control mice. 
Also, prophylactic intranasal treatment with chitin microparticles enhanced the local 
accumulation of NK cells and suppressed hyper-induction of cytokines, resulting in 
protection against infection with HPAI virus (Ichinohe et al., 2007). However, in both 
studies, the prophylactic treatment had to be performed less than a few days prior to virus 
challenge in order to be protective, resulting in a transient short-term down-regulation of 
the host inflammatory response. In contrast, BPZE1-induced protection required more 
than 3 weeks to develop, as mice treated once with BPZE1 and challenged 3 weeks later 
were not significantly protected. However, a high protection rate was observed when the 
virus challenge was performed at 6 weeks after BPZE1-treatment, and was sustained up 
to at least 12 weeks post-treatment.  
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There are also studies showing infection with virulent B. pertussis does not 
protect against bronchial hyper-reactivity, but rather exacerbates the allergic asthma 
(Ennis et al., 2004; Kavanagh et al., 2010). On the other hand, unlike virulent strains, 
infection with the attenuated B. pertussis strain BPZE1 did not exacerbate but reduced 
OVA-driven pathology (Kavanagh et al., 2010). However, in their cases, OVA 
sensitization was performed at the peak of B. pertussis infection (10 days) which is quite 
different from our influenza challenge performed at 3 weeks and 6 weeks post B. 
pertussis infection. So the underlying mechanisms for the protection in the above studies 
and our study may be different. 
 
            The lack of T and B cell cross-reactivity between B. pertussis and influenza A 
virus, as well as the inability to confer protection by passive transfer of T cells or 
antiserum from BPZE1-treated mice demonstrate that B. pertussis-specific adaptive 
immunity is not involved. The observation that live but not heat-killed BPZE1 bacteria 
induce protection, indicates that bacterial lung colonization, i.e. a prolonged exposure to 
the host immune system, is necessary. Moreover, a second BPZE1 treatment shortened 
the time necessary to induce protection and enhanced the protection rate, suggesting that 
some type of memory has been triggered upon first exposure to BPZE1 and can be 
boosted by a second encounter with BPZE1 bacteria. 
 
            Many activities of B. pertussis virulence factors are dedicated to 
immunomodulation in order to suppress, subvert and evade the host defense system 
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(Carbonetti, 2007). The immune response to B. pertussis is initiated and controlled 
through toll-like receptor 4 (TLR-4) signaling, inducing the production of the anti-
inflammatory cytokine IL-10 to inhibit inflammatory responses and limit pathology in the 
airways (Higgins et al., 2003). Filamentous hemagglutinin (FHA), the major B. pertussis 
adhesin, can stimulate IL-10 production and inhibit TLR-induced IL-12 production, 
resulting in the development of IL-10 secreting Tr1-cells (McGuirk et al., 2002). 
However, we found no difference in the production of TGF-β and reduced levels of IL-10 
in the BPZE1-treated mice compared to those in the infected control mice, thus excluding 
the potential involvement of FHA-mediated induction of Tr1 cells as a mechanism of 
BPZE1-mediated protection against influenza A virus. The involvement of other types of 
regulatory mechanisms is thus likely at play and will be the subject of further 
investigation. 
 
           In conclusion, regardless the precise mechanism, our study supports the use of 
attenuated live B. pertussis BPZE1 to be administered nasally as a novel, highly effective 
prophylactic agent, with long-lasting effects, against severe and lethal pneumonitis 
induced by H3N2 and H1N1 influenza A virus. Phase I safety trials in humans has 
recently started in 2010. In addition, attenuated B. pertussis is particularly well-adapted 
for the nasal delivery of heterologous vaccine antigens and represents an attractive 
mucosal vaccine delivery system (Alonso et al., 2005; Coppens et al., 2001; Ho et al., 
2008; Mielcarek et al., 2001a; Mielcarek et al., 1997; Renauld-Mongenie et al., 1996a; 
Reveneau et al., 2002). The construction of BPZE1-derivatives producing viral antigens, 
thereby combining the anti-inflammatory properties with the ability to induce adaptive 
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anti-influenza immune responses, may thus constitute an interesting approach for future 
development. 
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5.1 RESULTS 
5.1.1 STUDIES OF RECOMBINANT B. PERTUSSIS STRAINS EXPRESSING 
THE ECTODOMAIN OF MATRIX PROTEIN 2 (M2E) 
5.1.1.1 Construction of Recombinant B. pertussis Strains Producing FHA-(M2e)1,2,3 
Chimera 
            One, two or three copies of M2e peptide were fused in frame to full-length FHA 
as described in the M&M section. Each DNA construct was introduced by allelic 
exchange into the chromosomal fhaB locus of attenuated B. pertussis BPZE1 strain, 
giving rise to recombinant strains BPLR1, BPLR2 and BPLR3 strains, respectively. The 
secretion of the FHA-M2e, FHA-(M2e)2, and FHA-(M2e)3 chimera in the culture 
supernatant of each recombinant strain was analyzed by SDS-PAGE and Coomassie 
staining, and by Western blot analysis using monoclonal anti-FHA or polyclonal anti-
M2e antibodies. The results showed that the FHA-(M2e)1,2,3 chimera are secreted into the 
culture supernatant of the recombinant strains, and that the intensity of the signal 
observed upon Coomassie staining or Western blot analysis decreased as the number of 
M2e copies fused to FHA increased (Figure 5.1). Our data therefore indicated that the 
secretion efficacy of the chimera is inversely proportional to the number of M2e copies 
fused to the carrier FHA. 
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Figure 5.1 SDS-PAGE and Coomassie staining and Western blot analysis of M2e 
expressing recombinant B. pertussis.  
(A) SDS-PAGE and Coomassie staining  
(B) Western blot analysis using anti- M2e polyclonal immune serum  
(C) Western blot analysis using anti-FHA monoclonal antibodies of 10× concentrated 
culture supernatant from parental BPZE1 (lane 1), or recombinant BPLR1 (lane 2), 
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5.1.1.2 Lung Colonization by the Recombinant B. pertussis Strains 
            To investigate the ability of the recombinant B. pertussis strains to colonize the 
mouse respiratory tract, mice were nasally infected with each of them. The lung 
colonization profiles of BPLR1, BPLR2 and BPLR3 were compared to that of the 
parental BPZE1 strain. As described before (Mielcarek et al., 2006a), BPZE1 displayed a 
slight peak of multiplication at day 3 followed by a progressive clearance of the bacteria 
from the lungs (Figure 5.2). BPLR1 which produces the FHA-M2e chimera, colonized 
the mouse respiratory tract almost as efficiently as the parental BPZE1 strain, although no 
peak of multiplication was observed at day 3. In contrast, BPLR2 and BPLR3 which 
produce the FHA-(M2e)2 and FHA-(M2e)3 chimera respectively, were greatly impaired 
in their ability to colonize the mouse lungs; no peak of multiplication was observed and 
instead, the bacteria were rapidly cleared from the lungs. By day 17 post-infection, no 
BPLR2 and BPLR3 bacteria were detected whereas about 3 logs of bacteria were still 
present in the lungs of mice infected with either BPZE1 or BPLR1 strain.  
 
            These results thus suggested that the lung colonization ability of the recombinant 
B. pertussis strains is related to the secretion efficacy of the FHA-(M2e) chimera into the 
extracellular environment. Alternatively, the lower colonization efficacy displayed by 
BPLR2 and BPLR3 strains may also result from an impaired general bacterial fitness. To 
test this hypothesis, the in vitro kinetic profiles were determined. The results indicated 
that BPLR1 bacteria grew as well as the parental BPZE1 bacteria, whereas BPLR2 and 
BPLR3 displayed some impairment in their growth kinetic (Figure 5.3).  
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Figure 5.2 Lung colonization profiles of M2e expressing B. pertussis strains.  
CD1 mice were infected intranasally with 5×10
6
 cfu of parental BPZE1 (solid 
squares) or recombinant BPLR1 (open squares), BPLR2 (solid circles) and BPLR3 
(open circles) strains. The lungs were harvested at the indicated time points and 
viable bacteria in the lungs were counted after plating appropriate dilutions of the 
lung homogenates onto blood agar plates. 4 mice per group per time point were 
assessed individually. **, p<0.01, compared with the values of BPZE1. The dashed 
line represents the detection limit of the number of cfu present in the lungs. Bars 
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Figure 5.3 In vitro growth kinetic of M2e expressing B. pertussis strains.  
Exponential liquid pre-cultures of the parental BPZE1 (open circles), or recombinant 
BPLR1 (solid squares), BPLR2 (solid triangles) and BPLR3 (solid circles) strains 
were used to inoculate a fresh culture medium at an initial OD of 0.02. The 
absorbance at 600nm of the cultures was monitored over time at the indicated time 
points. 
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5.1.1.3 Specific Antibody Responses Elicited by the Recombinant B. pertussis Strains 
            Adult BALB/c mice were nasally administered with live recombinant BPLR1, 
BPLR2 and BPLR3, or parental BPZE1 B. pertussis bacteria. Three administrations were 
performed at 3 week-intervals. The sera and broncho-alveolar lavages fluids (BALFs) 
were collected 2 weeks after the last boost, and the anti-M2e and anti-B. pertussis 
antibody responses were analyzed.  
 
            All the B. pertussis strains triggered very strong and comparable systemic (IgG) 
and local (IgG and IgA) antibody responses against B. pertussis (Figure 5.4A, B &C). 
This observation indicated that despite weaker colonization ability, BPLR2 and BPLR3 
bacteria efficiently primed the host‟s immune system. Consistently, these two strains 
were found the best at inducing high local anti-M2e antibody responses (IgA and IgG) 
compared to BPLR1 (Figure 5.5A&B). Moreover, the highest systemic anti-M2e IgG 
response was triggered upon BPLR3 immunization, which produces the FHA-(M2e)3 
chimera (Figure 5.5C). Surprisingly, the sera and BALFs obtained from BPZE1-
immunized mice gave significant absorbance readings in ELISA when using the purified 
M2e peptide as coating antigen. This observation suggested the presence of cross-
reacting epitopes shared between M2e sequence from influenza A viruses and B. 
pertussis. However, no cross reacting antibodies against whole H3N2 viral antigens were 
detected in the sera and BALFs from BPZE1- immunized mice in the ELISA assay (see 
section 4.1.5). The apparent discrepancy between the two experiments is likely due to the 
fact that different coating antigens were used for the ELISA assays.  In section 4.1.5, 
purified whole H3N2 viral particles were used as the coating antigens for which M2 
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protein represents a minor fraction of the total viral proteins. Here instead, purified M2e 
peptide was used as the coating antigen thus allowing the capture and detection of cross-
reactive antibodies.  
            Taken together, our data indicated that the BPLR3 recombinant strain which 
produces the FHA-(M2e)3 chimera triggered the strongest anti-M2e antibody responses 
upon nasal vaccination. This finding suggested that the number of M2e copies fused to 
FHA is a key parameter to induce a strong specific immune response, even though the 
secretion efficacy of the chimera and the colonization ability of the recombinant strain 
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Naïve  BPZE1 BPLR1 BPLR2 BPLR3 
Figure 5.4 Detection of anti-B. pertussis local and systemic immune responses in 
mice immunized with M2e-expressing B. pertussis strains.  
Groups of 6 adult BALB/c mice were nasally administered thrice at 3-week intervals 
with 5×10
6 
cfu of BPZE1, BPLR1, BPLR2, or BPLR3. Two weeks after the last 
administration, sera were collected and broncho-alveolar lavages (BAL) were 
performed. Systemic anti-B. pertussis IgG (A), local IgG (B) and IgA (C) antibody 
responses were measured by ELISA on individual serum diluted 1/1,000 and neat 
BALFs, using BPZE1 whole cell lysate as coating antigen. Results are representative of 
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Figure 5.5 Detection of anti-M2e local and systemic immune responses in mice 
immunized with M2e-expressing B. pertussis strains.  
 
Groups of 6 adult BALB/c mice were nasally administered thrice at 3-week intervals 
with 5×10
6 
cfu of BPZE1, BPLR1, BPLR2, or BPLR3. Two weeks after the last 
administration, sera were collected and broncho-alveolar lavages (BAL) were 
performed. Local anti-M2e IgA (A) and IgG (B), and systemic IgG antibody responses  
(C) were measured by ELISA on individual serum diluted 1/40 and neat BALFs, using 
synthetic M2e peptide as coating antigen. *, p<0.05, **, p<0.01. Results are 
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5.1.1.4 Expression of the FHA-(M2e)3 Chimera in a dsbA Knockout B. pertussis 
Background 
            To further increase the anti-M2e antibody response, we sought to improve the 
secretion efficacy of the FHA-(M2e)3 chimera. The M2e sequence contains two cysteine 
residues and the presence of cysteine residues in the passenger domain fused to FHA has 
been previously shown to impair the secretion of the FHA-chimera (Guedin et al., 1998). 
The dsbA gene, encoding a periplasmic disulfide isomerase (Stenson & Weiss, 2002), 
was thus deleted in the BPLR3 strain, resulting in the recombinant B. pertussis strain 
BPST6. Western blot analysis using anti-M2e (Figure 5.6A) or anti-FHA (Figure 5.6B) 
antibodies showed that the secretion efficacy of the FHA-(M2e)3 chimera was indeed 
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Figure 5.6 Western blot analysis of 10× concentrated culture supernatant from 
BPLR3, BPST6 (ΔdsbA), and parental BPZE1.   
 
BPLR3 (lane 1), BPST6 (lane 2) and parental BPZE1 (lane 3) strains  
(A) Western blot analysis using anti-M2e polyclonal immune serum;   
(B) Western blot analysis using anti-FHA monoclonal antibody.  
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5.1.1.5 Colonization Efficacy, Bacterial Fitness and Immunogenicity of the dsbA 
BPST6 mutant 
            The ability of BPST6 bacteria to colonize the mouse lungs was then investigated 
and compared to parental BPLR3, the DsbA
+ 
counterpart. By day 7 post-infection, 
BPST6 bacteria were totally cleared from the lungs whereas 3 logs of BPLR3 bacteria 
were still detected (Figure 5.7A). We tested whether the drastic impairment in colonizing 
the mouse lungs is related to the overall fitness of BPST6 strain. The in vitro kinetic 
profile study indeed indicated that BPST6 bacteria are severely impaired in their growth 
ability (Figure 5.7B).  
 
            The immunogenicity of BPST6 strain was further evaluated in mice upon nasal 
administration and compared to the immunogenicity induced upon administration of 
BPLR3 strain. As described in the previous section, 3 nasal administrations were 
performed at 3 week-intervals. The sera and BALFs were collected 2 weeks after the last 
boost and the anti-M2e and anti-pertussis antibody responses were analyzed by ELISA. 
Although high, the anti-pertussis antibody responses obtained in the BPST6-immunized 
mice were significantly lower than the responses measured in the BPLR3-immunized 
animals (Figure 5.8A-C). Moreover, both systemic and local anti-M2e IgG and IgA 
antibody responses in BPST6-immunized animals were significantly lower than those 
measured in BPLR3-immunized mice (Figure 5.8D-F).  
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Days Post Infection 
            Altogether, these results indicated that deletion of dbsA, despite improving the 
secretion efficacy of the FHA-(M2e)3 chimera, affected other essential cellular functions 
which resulted in a poor bacterial fitness, translating into a poor colonization ability and 















Figure 5.7 A  Lung colonization ability of BPST6 strain.  
CD1 mice were nasally inolulated once with 5×10
6
 cfu of parental BPZE1 (solid 
squares) or recombinant BPLR3 (open squares) and BPST6 strains (solid triangles). 
At the indicated time points, the animals were euthanized and their lungs harvested. 
Appropriate dilutions of the lung homogenates were plating for colony counting. 
Four mice per group per time point were individually assessed. The dashed line 
represents the detection limit of the number of cfu present in the lungs. Bars represent 
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Figure 5.7 B In vitro growth kinetics of BPST6 strain. 
Exponential liquid pre-cultures of the parental BPZE1 (open circles), BPLR3 (solid 
circles) and BPST6 (open squares) strains were used to inoculate a fresh culture medium 
at an initial OD of 0.02. The absorbance at 600nm of the cultures was monitored over 
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Figure 5.8 Anti-pertussis (A, B and C) and anti-M2e (D, E, and F) local and 
systemic immune responses in mice immunized with BPST6 strains.  
Groups of 6 adult BALB/c mice were nasally administered thrice at 3-week intervals 
with 5×10
6 
cfu of BPZE1, BPLR3 or BPST6. Another group of BALB/c mice were 
immunized twice with KLH conjugated-M2e peptide (KLH-M2e) as a control. Two 
weeks after the last administration, sera were collected and broncho-alveolar lavages 
(BAL) were performed.  The anti-pertussis and anti-M2e antibody responses were 
measured by ELISA. 
A) Local anti-pertussis IgA immune responses. Neat BALFs were used for 
detection. 
B) Local anti-pertussis IgG immune responses. Neat BALFs were used for 
detection. 
C) Systemic anti-pertussis IgG immune responses. Immune sera were diluted 
1/2,000 prior to analysis. 
D) Local anti-M2e IgA immune responses. Neat BALFs were used for detection. 
E) Local anti-M2e IgG immune responses. Neat BALFs were used for detection. 
F) Systemic anti-M2e IgG immune responses. BPZE1, BPLR3 and BPST6 
immunized immune sera were pre-diluted 1/40 and KLH-M2e immunized 
immune sera were pre-diluted 1/5,000 prior to analysis. 
*, p<0.05, **, p<0.01. 
 
** 
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5.1.1.6 Protection Efficacy of Recombinant B. pertussis (BPLR3) Producing FHA-
(M2e)3 Chimera against Influenza Challenge 
            BPLR3 strain which produces the FHA-(M2e)3 chimera in a dsbA
+
 background, 
was found the best at triggering in mice strong anti-M2e immune responses both 
systemically and locally upon nasal administration. We therefore evaluated the protection 
efficacy of this recombinant strain upon challenge with H1N1 (A/PR8) influenza virus. 
Groups of 8 BALB/c mice were intranasally immunized with either BPLR3 or BPZE1 
bacteria following the same immunization schedule as described above. Moreover, two 
control groups of mice were injected twice intraperitoneally with either KLH conjugated-
M2e peptide (KLH-M2e) or heat-inactivated H1N1 (A/PR8) virus (HI-H1N1), both 
mixed with Freund‟s adjuvant. Two weeks after the last immunization, mice were 
challenged with 4 LD50 of H1N1 (A/PR8) virus. The mice body weight was monitored 
daily. The animals were sacrificed when body weight loss was greater than 20% of the 
body weight measured before challenge. 
 
            100% of the non-immunized challenged mice succumbed to H1N1 infection 
within 7 days while 100% of HI-H1N1-immunized and 60% of KLH-M2e-immunized 
animals survived the challenge (Figure 5.9A). Moreover, as expected (See chapter 4), 50% 
of the BPZE1-immunized mice were also protected against H1N1 challenge (see chapter 
4). Immunization with BPLR3 bacteria provided up to 56% protection, which is 
comparable to the protective efficacy obtained upon immunization with KLH-M2e and 
slightly superior to the protection obtained upon immunization with BPZE1.  
Consistently, the average body weight loss profiles further indicated that the BPLR3-
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immunized mice lost less weight and recovered faster than the mice immunized with 
KLH-M2e or with BPZE1 bacteria (Figure 5.9B).  However, there was no difference in 
the viral load between the mice immunized with BPLR3 and those immunized with 
BPZE1 both at day 3 and day 5 post-H1N1 influenza virus lethal challenge (Figure 5.10). 
 
            Taken together, our data showed that the nasal administration of live recombinant 
B. pertussis BPLR3 bacteria which produce the FHA-(M2e)3 chimera did not provide 
further protection against H1N1 influenza A virus challenge, although survival rate and 
body weight changes were slightly better in mice immunized with BPLR3 than those 
immunized with BPZE1. It is possible that anti-M2e antibody titers induced upon BPLR3 
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Figure 5.9 Survival rate (A) and average body weight changes (B) of naïve (solid 
circles), BPZE1 (solid triangles), BPLR3 (open circles), KLH-M2e (open 
squares) and HI-H1N1 virus (solid squares) immunized mice challenged with 4 
LD50 H1N1 viruses.  
5×10
6 
cfu of BPZE1 or BPLR3 in 20 µl were nasally administrated three times to 8 
adult BALB/c mice. Two additional mouse groups were primed with KLH-M2e or 
HI-H1N1 in complete Freund‟s adjuvant and boosted once with KLH-M2e or HI-
H1N1 in incomplete Freund‟s adjuvant two weeks later. Two weeks after the last 
immunization, mice were challenged with a lethal dose 4 LD50 of H1N1 (A/PR8) 
virus. The animals were monitored for body weight changes daily. Mice were 
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Figure 5.10 Viral load quantification in the lungs of naïve mice, BPZE1 immunized 
mice, BPLR3 immunized mice and KLH-M2e immunized mice challenged with 
H1N1 influenza virus. 
5×10
6 
cfu of BPZE1 or BPLR3 in 20 µl were nasally administrated three times to the 
mice. Two additional mouse groups were primed with KLH-M2e or HI-H1N1 in 
complete Freund‟s adjuvant and boosted once with KLH-M2e or HI-H1N1 in 
incomplete Freund‟s adjuvant two weeks later. Two weeks after the last immunization, 
mice were challenged with a lethal dose 4 LD50 of H1N1 (A/PR8) virus. At 3 and 5 
days post-viral challenge, the viral loads were measured in the lungs in the mice from 
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5.1.1.7 Isotyping of Systemic and Local anti-M2e IgG Antibodies in the Immunized 
Mice  
The isotype profiles of the systemic and local anti-M2e IgG antibodies measured 
2 weeks after the boost in the sera and BALFs of BPLR3-immunized mice were analyzed 
and compared with those of naïve, BPZE1- and KLH-M2e-traeted mice. Four to 6 mice 
were individually assessed.  
 
As shown in Table 5.1A, an obvious predominant IgG1 antibody response was 
observed in the serum of mice immunized with KLH-M2e compared to that of mice 
immunized with BPLR3 which showed mixed IgG1/IgG2a antibody response. Likewise, 
significant IgG1 immune response was found in the BALFs of KLH-M2e immunized 
mice whereas mixed IgG1/IgG2a immune response was detected in the BALFs of the mice 
immunized with BPLR3 (Table 5.1B). In conclusion, BPLR3 triggered a mixed 
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  Serum IgG1/IgG2a 
M1 M2 M3 M4 M5 M6 AVE 
Naïve 0.602 0.511 0.737 0.413 - - 0.566 
BPZE1 1.161 1.306 0.875 1.169 - - 1.128 
BPLR3 3.638 1.933 1.214 1.325 1.023 1.828 1.827 
KLH-
M2e 
6.252 15.452 9.597 8.846 7.713 - 9.572 
 
B 
 BALFs IgG1/IgG2a 
M1 M2 M3 M4 M5 AVE 
Naïve 1.462 1.059 1.118 0.914 - 1.138 
BPZE1 1.525 0.925 0.653 0.876 - 0.995 
BPLR3 0.900 1.667 1.431 0.942 - 1.235 
KLH-
M2e 




 Serum IgG1 Serum IgG2a 
M1 M2 M3 M4 M5 M6 M1 M2 M3 M4 M5 M6 
Naïve 0.050 0.045 0.042 0.043 - - 0.083 0.088 0.057 0.104   
BPZE1 0.354 0.363 0.210 0.200 - - 0.305 0.278 0.240 0.172   
BPLR3 0.713 0.402 0.539 0.506 0.449 0.265 0.196 0.208 0.444 0.383 0.439 0.145 
KLH-
M2e 
2.207 2.086 2.169 2.185 2.206 - 0.353 0.135 0.226 0.247 0.286 - 
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 BALFs IgG1 BALFs IgG2a 
M1 M2 M3 M4 M5 M1 M2 M3 M4 M5 
Naïve 0.174 0.144 0.104 0.149 - 0.119 0.136 0.093 0.163 - 
BPZE1 0.247 0.198 0.277 0.170 - 0.162 0.214 0.424 0.194 - 
BPLR3 0.604 1.05 0.909 0.524 - 0.671 0.630 0.635 0.556 - 
KLH-
M2e 














Table 5.1 Serum and BALFs anti-M2e IgG isotype  
Mice sera collected 2 weeks after the boost were analyzed by ELISA for the presence 
of specific anti-M2e IgG1 and IgG2a antibody isotypes. Sera and BALFs from 
individual mice from each group were tested individually. The IgG1/IgG2a ratio from 
the sera (A) and BALFs (B) was compared. The OD readings at 450nm were listed in 
table 5.1 (C) and (D). Sera from KLH-M2e immunized mice were diluted 1/10,000 
prior to testing whereas sera from naïve, BPZE1 and BPLR3 immunized mice were 
diluted 1/40 prior to testing. Neat BALFs were used for all the groups. 
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5.1.2 STUDIES OF RECOMBINANT B. PERTUSSIS STRAINS EXPRESSING 
EPITOPES FROM THE HAEMAGGLUTININ (HA)  
 
5.1.2.1 Production of FHA-(HA1-1)7, FHA-(HA2-1)3 and FHA-(HA2-2)3 Chimera by 
Recombinant B. pertussis 
            Expression of full-length HA was found to be toxic in B. pertussis (data not 
shown). An alternative strategy was therefore undertaken and consisted in expressing 
three distinct epitopes of H5 which were previously shown to be conserved among 
influenza A viruses and to trigger the production of neutralizing antibodies (Gerhard et 
al., 2006; Okuno et al., 1993; Rajnavolgyi, 1992; Smirnov et al., 2000). Several copies of 
each epitope were fused to full-length FHA and expressed in B. pertussis (See Materials 
& Methods chapter 3). Table 5.2 summarizes the characteristics of each construct. 
 
            The secretion of the FHA-(HA1-1)7, FHA-(HA2-1)3 and FHA-(HA2-2)3 chimera 
in the non-concentrated culture supernatant of the recombinant B. pertussis strains was 
analyzed by SDS-PAGE followed by Coomassie staining (Figure 5.11). The result 
showed that the chimeras are secreted into the extracellular milieu as efficiently as the 
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Number of copies  
inserted in FHA 




HA1-1 aa 331 to 335 of HA1 7 FHA-(HA1-1)7 BPLR4 
HA2-1 aa 1 to 11 of HA2 3 FHA-(HA2-1)3 BPLR5 











Figure 5.11 SDS-PAGE and Coomassie staining of non-concentrated culture 
supernatant from parental BPZE or recombinant B. pertussis strains. 
BPZE1 (lane 1), recombinant BPLR4 (lane 2), BPLR5 (lane 3) and BPLR6 (lane 4)  
220 kDa  
3 2  1  4 
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5.1.2.2 Specific Antibody Responses Elicited by the Recombinant B. pertussis    
Strains Expressing HA1-1, HA2-1 and HA2-2 Epitopes 
            Adult BALB/c mice were nasally administered with live recombinant BPLR4, 
BPLR5 and BPLR6, or parental BPZE1 B. pertussis bacteria. Three administrations were 
performed at 3 week-intervals. The sera and BALFs were collected 2 weeks after each 
boost, and the anti-HA epitopes and anti-B. pertussis antibody responses were analyzed. 
  
A significant anti-HA IgA response was found in the BALFs of mice infected 
with BPLR4 strain (secreting the FHA-(HA1-1)7 chimera) two weeks after the first boost 
(Figure 5.12). However, the 2
nd
 boost didn‟t improve the immune response, with IgA 
levels lower than the levels obtained after the first boost. The mice immunized with the 
recombinant strains BPLR5 and BPLR6 expressing FHA-(HA2-1)3 and FHA-(HA2-2)3 
chimera, respectively, did not display any significant local specific IgA antibody 
response (data not shown). None of these strains triggered a significant systemic IgG 
antibody response against the specific H5 epitopes both after the first and second boosts 
(data not shown). 
 
            However, BPLR4 BALFs failed to neutralize H1N1 and H3N2 influenza viruses 
in an in vitro neutralizing assay (data not shown). This strongly suggests that the 
concentration of anti-HA1-1 antibodies in the BALFs produced upon nasal administration 
of BPLR4 may not be high enough to provide neutralization activity against influenza 
viruses.         
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Figure 5.12 Local anti-HA1-1 IgA immune response in BALB/c mice upon 
nasal administration of BPLR4. 
5×10
6 
cfu of BPLR4 or BPZE1 strain were nasally administrated three times at 3 
weeks intervals to 6 adult BALB/c mice. Two weeks after 1
st
 boost and 2
nd
 boost, 
the mice were sacrificed and Broncho-alveolar lavages (BAL) were performed. The 
anti-HA1-1 secretory IgA (sIgA) antibodies were measured by ELISA using 
synthetic HA1-1 peptide as coating antigen. *, p<0.05 compared with the values of 
BPZE1 and naïve mice.  
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5.1.3 STUDIES OF RECOMBINANT B. PERTUSSIS STRAINS EXPRESSING 
NUCLEOCAPSID PROTEIN (NP)  
5.1.3.1 Detection of NP Expressed in Recombinant B. pertussis Strains 
            Full-length NP was expressed in the cytoplasm of B. pertussis BPZE1 under the 
strong promoter of the B. pertussis fhaB gene (PfhaB), encoding the filamentous 
hemagglutinin FHA. The PfhaB-NP construct was introduced in the bacterial chromosome 
by double homologous recombination at the ptx locus (see Materials and Methods). The 
production of full-length NP in the cytoplasm of two recombinant clones was detected by 
Western blot using anti-NP monoclonal antibody (Figure 5.13). The result showed that 
full-length NP protein was efficiently produced in both clones. Clone 1 was selected for 
further studies and was named BPLR7. B. pertussis BPDY2, a BPZE1 derivative with the 








Figure 5.13 Western blot analysis of whole cell extracts from parental strain 
BPDY2 and recombinant B. pertussis expressing NP.  
BPDY2 (Lane 1), NP producing recombinant clone 1 (lane 2) and clone 2 (lane 3). 
1.5 × 10
7
 and 3 × 10
7 
bacteria were loaded in lane 2 and lane 3, respectively.  
          1                                 2                                   3 
60.4 kDa 
47.2 kDa 
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5.1.3.2 In vivo Stability Studies 
            As the cytoplasmic expression of full length NA under PfhaB promoter was found 
unstable in vivo (see section 5.1.4 below), we decided to carry out an  in vivo stability 
study of the NP-producing BPLR7 strain before proceeding to the analysis of specific 
immune responses. Three days after the nasal inoculation of BPLR7, the mice lungs were 
harvested, and the lung homogenates were plated onto blood agar plates. After incubation 
at 37
o
C, 10 individual colonies were randomly picked, and PCR screening using NP 
specific primers was performed. All of the 10 colonies picked were found PCR positive 
(data not shown). Subsequently, 8 out of these 10 colonies were grown in liquid medium 
and the production of NP was tested by Western blot using anti-NP monocolonal 
antibody (Figure 5.14). As shown in Figure 5.14, all of the 8 colonies were positive with 
anti-NP antibody, indicating that full length NP was stably and efficiently expressed in 









     1              2            3             4            5            6              7            8            9 
Figure 5.14 In vivo stability studies of BPLR7.  
Western blot analysis of whole cell extracts from parental strain BPDY2 (Lane 1) or 
recombinant BPLR7-clone 1 to clone 8 (lane 2 to lane 9).  
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5.1.3.3 Immune Responses Elicited by Recombinant B. pertussis Strains Expressing 
NP  
NP is the major conserved internal viral protein and it can elicit CTLs instead of 
antibodies. There is sufficient data showing that NP as well as the immunodominant 
epitope NP366-374 is capable of inducing protective CTLs to homologous and heterologous 
virus (See chapter 2 section 2.6.3.2). Thus, instead of looking at antibody responses, we 
measured the specific T cell immune responses induced upon nasal administration of 
recombinant BPLR7. 
 
To study specific T cell immune responses upon administration of BPLR7 
expressing full length NP, adult BALB/c mice were nasally administered with live 
recombinant BPLR7 or the control BPDY2. Three administrations were performed at 4 
weeks and 3 weeks intervals. Individual spleens from each group were collected 2 weeks 
after the last immunization and single cell suspensions were prepared as described in the 
M&M section. T cell proliferation assay and IFN-γ ELISPOT assay were performed to 
assess the T cell responses of the splenocytes from immunized mice upon re-stimulation 
with either whole viral particles (heat-inactivated) or the immunodominant NP366 peptide. 
T cell proliferation assay showed that there was no significant proliferation of 
lymphocytes of mice immunized with BPLR7 compared to those immunized with control 
BPZE1 and the naïve mice upon stimulating with NP366 peptide or whole H3N2 influenza 
virus (Figure 5.15). Moreover, IFN-γ ELISPOT assay showed that no significant IFN-γ 
secreting T cells were detected in the mice (Figure 5.16). 
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These results thus suggest that the cytoplasmic expression of NP in B.pertussis 
does not lead to significant specific T-cell priming in mice upon nasal administration of 





































Figure 5.15 T-cell proliferation assay from mice immunized with BPLR7.   
Pooled spleens from 6 BPDY2- (grey bar), BPLR7-immunized (black bar) or naïve 
(open bar) mice were stimulated with NP366 peptide or heat-inactivated H3N2 viral 
particles, and [
3
H]-thymidine incorporation assay were performed. Results are 
expressed as the mean ± SD of triplicates.  
.  
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Figure 5.16 IFN-γ ELISPOT assay using splenocytes from mice immunized with 
BPLR7.   
Individual spleens from 6 BPDY2 (grey bar), BPLR7-immunized (black bar) or 
naïve (open bar) mice were stimulated with NP366 peptide or heat-inactivated H3N2 
viral particles, and IFN-γ ELISPOT assay were performed. Results are expressed as 
the mean ± SD of triplicates.  
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5.1.4 STUDIES OF RECOMBINANT B. PERTUSSIS STRAINS EXPRESSING 
TRUNCATED NEURAMINIDASE (ΔNA)  
 
5.1.4.1 Detection of ΔNA Expressed in Recombinant B. pertussis Strains 
            Full-length NA was expressed in the cytoplasm of BPZE1 under the control of 
PfhaB. However, this construct was found unstable and was lost after few replication 
rounds of the bacteria (data not shown). We therefore cloned and expressed a truncated 
version of NA protein (NA) in B. pertussis. This truncated NA corresponds to the most 
immunogenic part of full length NA protein analyzed by DNASTAR software (Figure 
5.17). Production of the NA protein in the cytoplasm of recombinant BPLR8 strain 
(clones 1 and 2) was confirmed by Western blot analysis of the whole bacterial extracts 
(Figure 5.18). However, the production is a bit low. In vivo stability study as described in 
section 5.1.3.2 demonstrated that NA was stably expressed and produced by the 
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358-1098 bp  (744 bp)       358ctg 
361 aatgacaagc actccaatgg gactgtcaaa gacagaagcc ctcacagaac attaatgagt 
421 tgtcctgtgg gtgaggctcc ctccccatat aactcaaggt ttgagtctgt tgcttggtca 
481 gcaagtgctt gccatgatgg caccagttgg ttgacaattg gaatttctgg cccagacagt 
541 ggggctgtgg ctgtattgaa atacaatggc ataataacag acactatcaa gagttggagg 
601 aataacatac tgagaactca agagtctgaa tgtgcatgtg taaatggctc ttgctttact 
661 gtaatgactg acggaccaag taatggtcag gcatcacata agatcttcaa aatggaaaaa 
721 gggaaagtgg ttaaatcagt cgaattggat gctcctaatt atcactatga ggaatgctcc 
781 tgttatcctg gtgccggcga aatcacatgt gtgtgcaggg ataattggca tggctcaaat 
841 cggccatggg tatctttcaa tcaaaatttg gagtatcaaa taggatatat atgcagtgga 
901 gttttcggag acaatccacg ccccaatgat ggaacaggta gttgtggtcc ggtgtcctct 
961 aacggggcat atggggtaaa agggttttca tttaaatacg gcaatggtgt ctggatcggg 
1021 agaacaaaaa gcactaattc caggagcggc tttgaaatga tttgggatcc aaatgggtgg 
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Figure 5.17 Selection of truncated NA by DNASTAR software. 
A)  Antigenic index profile of NA protein analyzed by DNASTAR software. B) 
DNA sequence of ∆NA. C) Amino acid sequence of ∆NA. 
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Figure 5.18 Detection of ∆NA in recombinant B. pertussis  
Western blot analysis was performed on whole cell extracts from parental BPDY2 
(lane 1) or recombinant BPLR8-clone 1 (lane 2) and BPLR8-clone 2 (lane 3), using 
anti-NA peptide polyclonal antibodies. A positive control (lane 4) consisted in a His-
NA construct expressed in E.coli. 5×10
7
 bacteria were loaded in lane 2 and lane 3.  
 
    1           2           3            4 
35.1 kDa 
24.9 kDa 
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5.1.4.2 Immune Responses Elicited by Recombinant B. pertussis 
Adult BALB/c mice were nasally administered with live recombinant BPLR8, or 
control strain BPDY2. Three administrations were performed at 4 week- and 3 week-
intervals. The sera and BALFs were collected 2 weeks after the last boost, and the anti-
∆NA antibody responses were analyzed by ELISA. 
 
 Although high anti-B. pertussis immune response was observed (Figure 5.19A), 
no significant local (Figure 5.19B) and systemic (Figure 5.19C) anti-ΔNA antibody 
response was detected in the mice immunized with the recombinant BPLR8 strain 
producing ΔNA protein. A possible explanation is a specific threshold for the amount of 
expressed antigen that is required to elicit an immune response might exist (Wells & 
Mercenier, 2008), thus, the low quantity of ΔNA may account for the poor specific 
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Figure 5.19 Detection of anti- ΔNA local and systemic immune responses in mice 
immunized with ΔNA -expressing B. pertussis strain BPLR8.  
Groups of 6 adult BALB/c mice were nasally administered thrice at 4-week and 3-
week intervals with 5×10
6 
cfu of BPDY2 and BPLR8. Two weeks after the last 
administration, sera were collected and broncho-alveolar lavages (BAL) were 
performed. Systemic anti-B. pertussis IgG antibody response (A) was measured by 
ELISA on individual mouse serum diluted 1/1,000, using whole B. pertussis lysate as 
coating antigen. Local anti- ΔNA IgA (B) and systemic IgG (C) antibody responses 
were measured by ELISA on individual neat BALFs and serum diluted 1/40, using 
pET-∆NA peptide as coating antigen. Results are representative of two independent 
experiments. 
 






5.2.1 POTENTIAL OF ATTENUATED B. PERTUSSIS BPZE1 AS LIVE 
VACCINE DELIVERY VECTOR AGAINST INFLUENZA A VIRUS: FHA AS A 
CARRIER FOR HETEROLOGOUS ANTIGEN TO BE SECRETED INTO THE 
EXTRACELLUAR MILIEU  
 
5.2.1.1 Recombinant B. pertussis Expressing M2e 
            Due to the increased risk for pandemic infections with classical or emergent 
highly pathogenic avian influenza (HPAI) virus strains, as well as the limitations of 
currently available influenza vaccines, there is need for the development of novel, more 
efficacious influenza vaccines. The characteristics of the immune responses induced 
through the mucosal route confer to mucosal vaccination several advantages over 
parenteral vaccination. Among them is the induction of not only systemic IgG antibodies 
but also local specific IgA antibodies that exhibits potential heterotypic cross-reactivity to 
influenza virus strains at the site of entry. In this study, we investigated the potential of a 
live recombinant B. pertussis strain expressing tandem repeats of M2e to trigger 
protective immune responses in mice against lethal influenza A virus challenge.  
 
            Attenuated Bordetella pertussis has been proven to be a promising and attractive 
candidate for vaccine delivery via the nasal route (Mielcarek et al., 2001a; Renauld-
Mongenie et al., 1996b). Several heterologous antigens from various bacterial pathogens 




have been successfully expressed in B. pertussis and the nasal administration of the 
recombinant strains have been shown to induce local and systemic immune responses 
against the foreign proteins (Alonso et al., 2005; Coppens et al., 2001; Ho et al., 2008; 
Mielcarek et al., 1997; Reveneau et al., 2001). The parental B. pertussis strain, BPZE1, 
used in this study is a novel, highly attenuated strain which has been recently engineered 
and has entered phase I clinical trial in humans as live pertussis vaccine (Feunou et al., 
2008; http://www.child-innovac.org; Mielcarek et al., 2006a; Skerry et al., 2009).  
Although highly attenuated, BPZE1 is still able to colonize the lungs efficiently, making 
it an attractive candidate for live vaccine development. The use of BPZE1 as live vehicle 
for the delivery of heterologous antigens was first reported by our laboratory where a B-
cell epitope from enterovirus 71 (EV71) was fused to FHA; a strong EV71 neutralizing 
systemic antibody response was induced upon the nasal administration of the live 
recombinant bacteria (Ho et al., 2008).  
 
            Here, one, two and three copies of M2e were genetically fused to full length FHA. 
To be efficiently secreted, an FHA chimera must be in an unfolded conformation, 
implying that the fusion of heterologous antigens containing cysteine residues susceptible 
to form intra- and/or intermolecular disulfide bonds may compromise the secretion 
efficacy of the chimera. Indeed, as M2e contains two cysteine residues, the number of 
M2e copies fused to FHA inversely correlated with the secretion efficacy of the chimera. 
However, despite great impairment in its secretion efficacy, BPLR3 expressing FHA-
(M2e)3 was more immunogenic than BPLR1 expressing FHA-(M2e)1 and BPLR2 
expressing FHA-(M2e)2. BPLR3 actually triggered the strongest local IgA and systemic 




IgG specific anti-M2e immune responses upon nasal administration to the mice. This 
observation is in agreement with previous studies which reported that high epitope 
density in fusion proteins are more immunogenic and significantly enhanced protective 
immunity (Eliasson et al., 2008; Kjerrulf et al., 1997; Liu & Chen, 2005; Liu et al., 2004; 
Zheng et al., 1993). Tandem repeats of epitopes in fusion proteins were shown to be more 
effective at stimulating T-cell immunity thanks to better antigen-processing and 
presentation (Eliasson et al., 2008; Kjerrulf et al., 1997; Zheng et al., 1993).  Specifically, 
epitope density in M2e fusion proteins was shown to impact on B cell recognition and the 
higher epitope density resulted in M2e–specific antibodies with higher average avidity, 
which is likely due to stronger helper function of M2e-specific CD4
+
 T-cells (Liu & Chen, 
2005).  When compared to the BPZE1-immunized control group, the protection efficacy 
of BPLR3 appeared only slightly better based on the body weight loss and survival rate. 
However, the viral loads data showed that immunization with BPLR3 did not provide 
further protection compared to BPZE1. It is highly possible that the local and systemic 
anti-M2e immune responses induced by BPLR3 were not high enough to confer further 
protection, probably due to the impaired secretion efficacy of the chimera and lung 
colonization ability. Further improvement to increase the secretion efficacy and lung 
colonization ability of BPLR3 may lead to the production of higher anti-M2e immune 
responses and thus better protection. 
 
            Furthermore, we found that the lung colonization ability is another critical 
parameter for the induction of an effective immune response upon nasal administration of 
live recombinant B. pertussis strains. Unexpectedly, although the secretion of FHA-




(M2e)3 chimera by BPST6 was greatly improved upon dsbA deletion , both anti-pertussis 
and anti-M2e specific immune responses triggered by BPST6 were significantly lower 
than those triggered by BPLR3, the dsbA parental counterpart. We thus concluded that 
the weak immunogenicity of BPST6 is likely due to inefficient priming of the host 
immune system due to dramatic impairment in its colonization ability.  One possible 
reason that could account for the impaired colonization of BPST6 is that the deletion of 
dsbA gene, as previously reported, also affects the production of other virulence factors 
which are critical for an efficient colonization, such as pertussis toxin (Stenson & Weiss, 
2002). Alternatively, the impaired bacterial fitness of the bacteria upon deletion of dsbA 
gene (Figure 5.3) may also lead to its impaired lung colonization ability. 
 
            M2e is highly conserved among human influenza A virus strains, including the 
H1N1 1918 Spanish strain as well as the pandemic H1N1 2009 strain 
(http://www.ncbi.nlm.nih.gov/genomes/FLU/SwineFlu.html), making it an appealing 
universal influenza vaccine target (Fiers et al., 2004). Moreover, Gerhard and co-workers 
demonstrated that in the presence of M2e-specific monoclonal antibodies, only two 
escape mutants emerged in influenza A strains that were propagated in SCID mice and 
none in BALB/c mice following 11 passages (Gerhard et al., 2006; Zharikova et al., 
2005). Various M2e-based vaccine approaches have been evaluated as part of a broad-
spectrum vaccine against influenza. Highly conserved as it is, mutations still occur in 
M2e sequences. Thus, it is important and relevant to study whether an M2e-based 
vaccine can still protect against influenza A virus strains which have different M2e 
sequences. The M2e sequence selected to be expressed in BPZE1 is originally from 




H5N1 virus (A/Thailand/LFPN-2004/2004(H5N1) whereas the influenza virus that we 
have used in our challenge experiments is from the H1N1 subtype. There are actually 
four amino acid variations in the M2e sequence between these two virus strains. This 
could explain why the immunization with KLH-M2e conferred only 50% protection 
which differs from previous studies which reported that KLH-M2e-immunized mice were 
fully protected from lethal H1N1 (A/P/R/8) homologous challenge (Tompkins et al., 
2007). 
 
Specific sIgA antibodies which abundantly exist in the upper respiratory tract 
were shown indeed to not only provide protection against homologous virus infection but 
also, very importantly, cross protect against heterologous virus infection, whereas serum 
IgG antibodies are weekly cross-protective and provide protection only against 
homologous virus infection (Liew et al., 1984; Renegar et al., 1998; Tamura et al., 1990; 
Tamura et al., 1991; Tamura & Kurata, 2004; Tamura et al., 2005; Yoshikawa et al., 
2004). This could therefore also explain why, although KLH-M2e immunization 
triggered very high anti-M2e systemic IgG immune response, only 50% protection was 
observed upon heterologous influenza challenge. In those mice, the levels of sIgA 
antibodies produced in the respiratory tract were indeed very low (See section 5.1.1.5 
Figure 5.8D). Although the viral load data showed that BPLR3 did not offer an improved 
protection compared to BPZE1 against influenza virus lethal challenge, the production of 
anti-M2e sIgA antibodies may account for the slightly better survival rate and body 
weight changes observed in BPLR3 immunized mice. Thus, our results suggest that 1) 
airway-associated immunity may play a very important role in the protection, and 2) the 




nature more than the titer of specific antibodies could make the difference in the 
protection against influenza virus infection.  
 
           To conclude this section, it is worth addressing that although M2e constitutes an 
appealing target for a universal influenza vaccine development, M2e-based vaccines are 
not intended to replace strain-matched vaccines that induce neutralizing antibodies and 
thus prevent infection. A major reason is that M2e-specific antibodies are able to inhibit 
viral replication and thus reduce symptoms whereas fail to prevent viral infection. 
However, it may be difficult to produce strain-matched vaccines in adequate quantities in 
short time periods. M2e-based vaccines may instead help decrease morbidity and 
mortality while strain-matched vaccines are being prepared and thus could represent a 
valuable backup for conventional vaccines. 
 
5.2.1.2 Recombinant B. pertussis Expressing HA Epitopes 
            Three different epitopes from H5, namely HA1-1, HA2-1 and HA2-2, which have 
been previously shown to be neutralizing and conserved among influenza A viruses were 
also fused to FHA and expressed in BPZE1, resulting in recombinant B. pertussis BPLR4, 
BPLR5 and BPLR6. In vivo immune responses showed that only BPLR4 (secreting the 
FHA-(HA1-1)7 chimera) triggered a significant anti-HA1-1 IgA specific immune 
response in the BALFs of BPLR4-infected mice whereas BPLR5 (secreting the FHA-
(HA2-1)3 chimera) and BPLR6 (secreting the FHA-(HA2-2)3 chimera) failed to induce 
any specific systemic or local immune responses in the immunized mice. One possible 




explanation is that since HA2-1 and HA2-2 are only 11 aa and 12 aa respectively whereas 
FHA is a 220-kDa monomeric protein, the size ratio between the carrier and the 
heterologous antigen is very small. Therefore, three copies of HA2-1 and HA2-2 may be 
insufficient to efficiently prime the immune system using FHA as a carrier.  In this case, 
more copies could be inserted in future work in order to trigger a better immune response. 
Another possible explanation is that FHA is known to be highly immunogenic (Alonso et 
al., 2002; Cahill et al., 1995; Shahin et al., 1995) and as such, has been included in most 
acellular pertussis vaccines. However, this feature, if too prominent, may instead 
represent a handicap for FHA as a carrier by skewing the host‟s immune response 
towards itself at the expense of its passenger antigen. In this case, FHA may not be an 
ideal carrier for heterologous antigen delivery. Other smaller antigen carriers with 
relatively lower immunogenicity such as the autotransporter BrkA are currently explored 
in our laboratory and their abilities to expose heterologous antigens to the host immune 
system is being compared to FHA (Ho et al., 2008).   
 
            Although significant anti-HA1-1 local immune responses were found in BPLR4-
immunized mice, the anti-HA1-1 antibodies from BALFs didn‟t show neutralization 
activity in vitro. It is likely that the anti-HA1-1 antibody titer in the BALFs was not high 
enough to neutralize the virus effectively.  
 
            Taken together, the above data further demonstrate that the successful use of FHA 
as a carrier to present heterologous antigens to the host immune system largely depends 




on the nature of the passenger protein, including its size, intrinsic immunogenicity, as 
well as the presence of cysteine residues susceptible to form dissulfide bonds. This 
observation has already been made previously by us and our collaborator in other studies 
(Alonso et al., 2002; Alonso et al., 2005; Ho et al., 2008; Mielcarek et al., 1997; 
Reveneau et al., 2001; Reveneau et al., 2002).   
 
5.2.2 CYTOPLASMIC EXPRESSION OF ∆NA AND NP IN B. PERTUSSIS  
            Unlike M2e and HA epitopes which were fused to FHA and were secreted into 
the extracellular milieu, NP and NA proteins were expressed in the cytoplasmic 
compartment of BPZE1 under the control of the promoter of fhaB (Pfha). Our data 
showed that despite a very strong expression of full length NP, no NP specific CTL 
immune responses were found in the BPLR7-immunized mice. These results suggest that 
the cytoplasmic expression of heterologous antigens in BPZE1 may not be an effective 
approach to prime the host immune system. Our results are in agreement with previous 
studies using other live bacteria as vector for the delivery of subunit vaccines. In those 
studies, cytoplasmic expression of the vaccine candidates appears to be the least 
immunogenic compared to secretion in the extracellular milieu and exposure at the 
bacterial surface. In the study of Reveneau et. al., the immunogenicity of recombinant 
Lactobacillus plantarum strains producing the tetanus toxin fragment C (TTFC) in three 
cellular locations, namely intracellular, secreted or cell-surface exposed was compared in 
mice (Reveneau et al., 2002). Although the L. plantarum recombinant strains  expressing 
TTFC in the secreted and cell-surface exposed form, respectively, produced signiﬁcantly 
less TTFC (i.e. 20 and 5 times less, respectively) than the L. plantarum strain expressing 




TTFC intracellularly, they induced higher immune responses.  Likewise, Norton and 
colleagues also reported that although antigen production at the bacterial surface is 
generally less efficient compared to intracellular production, equivalent or even higher 
immune responses were observed with the cell wall-anchored antigens (Norton et al., 
1996). In addition, studies using attenuated Salmonella sp.also showed that secretion of 
foreign antigens allowed improved immunogenicity and/or protection compared to 
recombinant bacteria producing the same antigens cytoplasmically (Gentschev et al., 
1998; Hess et al., 1997; Hess et al., 1996; Hess et al., 2000). In conclusion, secretion into 
the extracellular milieu or cell wall-anchored expression of heterologous antigens is 
superior to the cytoplasmic expression in the ability to prime effectively the host immune 
system; and it is proposed that secreted or cell wall-anchored expression allows direct 
processing of target antigen to the APCs, resulting in more efficient presentation and 
stronger immune responses. Thus, although strongly expressed in BPLR7, NP may not be 
efficiently processed or presented, and thus, as a consequence, the host immune system 
may not be properly primed. On the other hand, when delivering the recombinant 
vaccines through the oral or intragastric route, cytoplasmic expression may be more 
advantageous as surface-localized antigens might be more susceptible to degradation in 
the highly proteolytic environment of the digestive tract  (Wells & Mercenier, 2008).  
 
Hence, a number of parameters, including the identity/nature of the carrier, the 
cellular location of the vaccine candidate, the route of administration, are to be taken in 
consideration when designing live recombinant vaccines as they will critically influence 
the vaccine efficacy. 




Alternatively, our results may indicate that BPZE1 is not an effective vector to 
trigger CD8
+ 
T-cell responses. The magnitude and type of immune response induced 
against a live vaccine vector-expressed antigen may also be influenced by the cellular 
location of the bacterial vector after entering the host cells. The difference in intracellular 
location of these bacteria generally affects the T-cell response induced to the bacteria 
(Mollenkopf et al., 2001). Bacteria remaining in the phagosome are processed and 
presented via MHC class II molecules and are recognized by CD4
+ 
T cells, whereas 
bacteria located in the cytoplasm (such as Listeria which escapes the phagosome by 
producing the listeriolysin) are recognised by CD8
+
 T-cells following presentation by 
MHC class I molecules. B. pertussis is traditionally described as an extracellular 
pathogen, however, substantial evidence from cell culture studies argues that the 
immunomodulatory properties of several of its virulence factors enable the bacterium to 
persist and even multiply within epithelial cells and leukocytes (Abramson et al., 2008; 
Bassinet et al., 2000; Carbonetti, 2007; Lamberti et al., 2010; Masure, 1992; McGuirk & 
Mills, 2000), leading to speculation that the infection might also comprise an intracellular 
stage. The dual extra- and intracellular locations of B. pertussis makes it an ideal live 





 T-cells as well. However, the exact fate and cellular location of the 
attenuated strain used in this study, BPZE1, after entering the host cells is unknown and 
deserves future study. Indeed, a number of studies reported that avirulent B. pertussis 
mutants were impaired in entering into macrophages compared to the virulent parental 
strain, and did not survive intracellularly (Friedman et al., 1992; Hellwig et al., 1999). 
The internalization process, as well as intracellular survival, is dependent on the virulence 




factors, such as ACT, FHA and PT. Thus, the three genetic alterations performed in 
BPZE1, which resulted in less TCT activity, inactivation of PT and absence of DNT, may 
potentially lead to impaired intracellular survival of BPZE1 in the host cells. In addition, 
during infection with virulent B. pertussis, most of the virulence-associated effects result 
in suppression and modulation of the host immune response which is skewed towards 
Th17 profile (Carbonetti, 2007). Thus, although the host immune response to BPZE1 
infection may be different from the response triggered upon infection with its virulent 





As for full length NA protein, although it was successfully expressed in BPZE1 
strain (data not shown), the construct was found unstable in vitro and in vivo suggesting 
that the cytoplasmic expression of full length NA is toxic for the bacteria. NA being a 
multimeric membrane protein, it is likely that when expressed in the cytoplasm of BPZE1, 
it aggregated and the formation of insoluble protein aggregates may impair some 
essential bacterial functions. As a consequence, the bacteria‟s survival strategy is the 
complete or partial deletion of the genetic locus that is responsible for the toxicity.   
 
Instead, truncated NA was stably expressed in BPZE1. However, the production 
yield of ΔNA was rather low. The expression and maintenance of ΔNA in BPLR8 may 
induce a stress response which resulted in low expression of the foreign protein.  No 
significant anti-ΔNA systemic and local antibody response was detected in the mice 




immunized with the recombinant BPLR8 strain producing NA protein. Again, as 
suggested by Wells and Mercenier (2008), a specific threshold of the amount of 
expressed antigen that is required to elicit an immune response might exist(Wells & 
Mercenier, 2008), thus, the low production and/or the cytoplasmic localization of the 
vaccine candidate may account for the absence of specific anti-NA immune responses 
triggered in BPLR8-immunized mice. 
 
            As previous work by us and our collaborator has employed FHA as carrier to 
secrete and surface-expose foreign antigens, this study represents the first attempt to 
produce heterologous vaccine candidates in the cytoplasm of B. pertussis. Taken together, 
the above data have provided important and useful information. Firstly, the cytoplasmic 
expression of a foreign antigen especially a big size multimeric protein is likely to be 
toxic to the bacteria. Our previous unsuccessful attempts (see section 5.2.1) to express 
full length H5 in BPZE1 under Pfha further support this hypothesis. Secondly, foreign 
antigens expressed in the cytoplasmic compartment of BPZE1 could not be efficiently 
processed and presented to the host immune system, leading to weak or no immune 
response. It thus appears that the cytoplasmic expression of heterologous vaccine 
candidates in BPZE1 does not represent a promising approach, and that efforts should 
focus on the identification and development of B. pertussis carriers that allow either the 
secretion or surface exposure of the heterologous vaccine candidates.
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6.1 CONCLUSIONS  
The threat of a pandemic spread of highly virulent influenza A viruses currently 
represents a top global public health priority. Mass vaccination remains the most 
effective way to combat influenza. However, current vaccination strategies face 
challenges to address the needs in a pandemic situation. In a mouse model of severe 
influenza-induced pneumonitis, we observed in this study that prior nasal administration 
of an attenuated strain of Bordetella pertussis (BPZE1) provided effective and sustained 
protection against lethal challenge with mouse-adapted H3N2 and H1N1 influenza A 
viruses. In contrast to most cross-protective effects reported so far, the protective window 
offered upon nasal treatment with BPZE1 lasted up to at least 12 weeks, suggesting 
unique mechanism(s) involved in the protection. No significant differences in the viral 
loads were observed between BPZE1-treated and control mice, indicating that the cross-
protective mechanism(s) do not directly target the viral particles and/or infected cells. 
This was further confirmed by the absence of cross-reactive antibodies and T-cells in 
serum transfer and in vitro re-stimulation experiments, respectively. Instead, compared to 
infected control mice, BPZE1-treated animals displayed markedly reduced lung 
inflammation and tissue damage, decreased neutrophilic infiltration, and strong 
suppression of the production of major pro-inflammatory mediators in their broncho-
alveolar fluids.  
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Our findings thus indicate that protection against influenza-induced severe 
pneumonitis can be achieved through attenuation of exaggerated cytokine-mediated 
inflammation. Furthermore, as BPZE1 has recently entered phase I safety trials in 
humans (http://www.child-innovac.org), our observations support the potential 
application of this vaccine strain as a universal prophylactic treatment against highly 
pathogenic influenza A viruses, thus offering a potential alternative to conventional 
approaches in the fight against one of the most frightening current global public health 
threats.  
 
In this study, we also demonstrated that BPZE1 represents a promising vehicle for 
the nasal delivery of subunit vaccine candidates against influenza virus. In particular, the 
expression of the universal influenza vaccine candidate M2e in the recombinant B. 
pertussis BPLR3 strain as FHA-(M2e)3 chimera, triggered the production of anti-M2e 
sIgA antibodies in the respiratory tract  and deserves future improvement as a universal 
vaccine against influenza A viruses. Thus, such approach combines the non-specific anti-
inflammatory properties of the vehicle BPZE1 with the specific adaptive immunity 
induced by the production of the FHA-(M2e)3 chimera.   
 
            The development of attenuated B. pertussis as vehicle for the delivery of 
heterologous vaccine candidates often faces the criticism that most individuals in 
developed and under-developed worlds are pertussis-vaccinated and therefore, would 
clear rapidly any recombinant B. pertussis bacteria introduced in their respiratory tract 
CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS 
190 
 
and given as a prophylactic vaccine against a target disease such as influenza for example. 
However, as BPZE1 has been initially developed as a live pertussis vaccine for infants, 
ideally newborns if the safety profile permits, one can propose to use instead recombinant 
BPZE1strains in order to vaccinate simultaneously against pertussis and other childhood 
diseases.  
In addition, many industrialized countries with long established immunization 
programs are currently facing a resurgence of pertussis cases. The resurgence of pertussis 
is believed to be due to waning of vaccine-induced immunity in adolescents and adults, 
resulting in household transmission to vulnerable infants. In addition, antigenic shift and 
adaptation of the B. pertussis circulating strains to the current acellular vaccines has also 
been suggested to contribute to the resurgence of whooping cough (Mooi et al., 2001). A 
number of countries have thus introduced a pertussis booster shot in the adolescent 
population which currently consists of the administration of one of the available acellular 
pertussis vaccines. It is thus conceivable that live BPZE1 or any recombinant strain of 
BPZE1 producing the desired heterologous vaccine candidates would be given instead as 
a booster shot to the adolescent population. Such approach would be even more 
beneficial as natural infection with B. pertussis has long been known to induce strong and 
long-lasting immunity (Amsbaugh et al., 1993) compared to current pertussis vaccines 
which consist of either whole killed bacteria or purified antigens. Strong anti-B. pertussis 
local and systemic immune responses were also observed in BPLR3-immunized mice, 
demonstrating that the production of an heterologous vaccine candidate does not 
compromise the anti-pertussis immune response. Thus, our study support the 
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development of live attenuated BPZE1-vectored vaccines as an interesting approach to 
provide protection against both pertussis and the target disease.  
 
6.2 FUTURE DIRECTIONS 
First of all, it will be interesting and informative to test the longevity of the 
protection of BPZE1 against influenza A viruses H3N2 challenge. Such experiments are 
currently in progress in the laboratory. Mice have received one or two doses of BPZE1 
and will be challenged 12 months later after the last BPZE1 treatment.  Moreover, it will 
be interesting to investigate whether treatment/infection with the wild type B. pertussis 
also confers similar protection against influenza A viruses. This approach may provide 
further information on possible mechanisms of protection and the candidate bacterial 
factors involved. 
Secondly, the exact mechanism involved in the cross-protection between BPZE1 
and influenza A viruses remains to be addressed. Several mechanisms and cellular 
players may account for this cross-protection and they may not be mutually exclusive. 
They include the action of CD8
+
 T-cells, the regulatory effect of Treg cells, and/or the 
suppressive activity of alveolar macrophages. Foxp3-EGFP mice could be used to 





 T cells as well as macrophage depletion experiments could be done to address the 
involvement of T cells and alveolar macrophages in the protection.  
In addition, different protection efficacy was observed in mice pre-treated with 
BPZE1 and challenged with H3N2 or H1N1 influenza A viruses. We proposed that it is 
CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS 
192 
 
probably due to the difference in the pathogenesis caused by these two viruses. It may 
thus be very useful to further characterize the differential pathological signatures from 
both virus subtypes as they may provide further information on the protective 
mechanism(s) induced upon BPZE1 treatment.  Furthermore, in order to identify the 
cellular players that are primed during BPZE1 treatment, we believe that it is necessary to 
first characterize the host immune response to BPZE1 infection. During infection with 
virulent B. pertussis, most of the virulence-associated effects result in suppression and 
modulation of the host immune response which is skewed towards Th17 profile 
(Carbonetti, 2007). However, BPZE1 strain has been deleted or inactivated for three of its 
major toxins, namely pertussis toxin, dermonecrotic toxin and tracheal cytotoxin, which 
are factors known to be involved in the modulation or suppression of the host immune 
response; it is thus likely that the host immune response to BPZE1 infection will be 
different from the response triggered upon infection with its virulent parental counterpart. 
Such study has not been reported so far and will give valuable information when 
deciphering the mechanisms that are primed during BPZE1 treatment and get re-activated 
later upon influenza challenge. 
 
Interestingly, as the cross-protection observed in this study does not involve the B. 
pertussis specific adaptive immunity but is rather non-specific through attenuation of 
major pro-inflammatory mediators, it is possible that prior treatment with BPZE1 may 
cross-protect against other inflammatory diseases. Virulent B. pertussis has long been 
known to exacerbate asthma (Ennis et al., 2004) whereas a recent study has shown that 
the administration of BPZE1 bacteria attenuates asthma-induced inflammation 
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(Kavanagh et al., 2010). In this study, OVA sensitization and asthma challenge were 
performed while BPZE1 bacteria were still colonizing the respiratory tract. In the cross-
protection against influenza that we described, influenza challenge is performed long 
after the BPZE1 bacteria have been cleared from the lungs. It will thus be interesting to 
test whether prior BPZE1 treatment can also protect against asthma challenge. The level 
of protection may in addition provide some information on the cellular and molecular 
players that are responsible for the anti-inflammatory properties of BPZE1 and that are at 
play in our influenza challenge model.  
 
Last but not least, further exploration of the potential of attenuated B. pertussis 
BPZE1 as a live vaccine delivery vector should also be part of the future work. In 
particular, since CTL responses are another important arm of protection against influenza 
virus infection, and against viral infection in general, it would be very interesting to 
further explore whether BPZE1 can be effective at triggering specific CD8
+
 T-cell 
responses. CD8-immundominant epitopes or peptides should be fused to FHA or other 
carriers and the ability of the recombinant strains to induce a CD8 response should be 
evaluated.  Moreover, although BPLR3 immunization did not provide further protection 
compared with BPZE1, BPLR3 still represents a promising recombinant vaccine that 
deserves future improvement.  In order not to affect the bacteria fitness and colonization 
ability, the cysteine residues in M2e sequence could be replaced by serine to prevent 
disulfide bond formation and thus improve the secretion efficacy and immunogenicity of 
the FHA-(M2e)3 chimera. Other approaches like purifying FHA-(M2e)3 chimera from the 
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APPENDIX I: REAGENTS FOR GEL ELECTROPHORESIS 
1.1     DNA Electrophoresis  
 1.1.1     50 × Tris-Acetate-EDTA (TAE) Buffer  
                                                                                                 Per L  
 Tris base                                                                                   242 g  
 Glacial acetic acid                                                                  57.1 ml  
 0.5 M EDTA (pH 8)                                                                100 ml  
 Final pH adjusted to 7.8  
 1.1.2     Agarose Gel  
                                                                                      1%                      1.5%  
 Agarose                                                                        0.5 g                   0.75 g   
1 × TAE                                                                       50 ml                   50 ml   
1 × TAE was prepared by adding 20 ml of 50 × TAE buffer to 980 ml of ddH2O.  
1.1.3     6 × DNA Loading Dye  
Bromophenol blue                                                                   0.25%   
Xylene cyanol                                                                          0.25%  
Ficoll (type 400) in ddH2O                                                       25% 




1.2.1     SDS-PAGE   
1.2.1.1     5 × SDS/Glycine Electrophoresis Buffer 
                                                                                                 Per L  
 Tris-base                                                                                 15.1 g   
Glycine                                                                                     72 g   
SDS                                                                                           5 g   
 
1.2.1.2     10% or 12% Separating Gel 
                                                                                              Per 30 ml  
30% Acrylamide-bisacrylamide (29:1)                         8.75 ml or 10.5 ml   
1 M Tris-HCl (pH 8.8)                                                            7.5 ml   
10% SDS                                                                                 300 µl   
20% APS                                                                                 400 µl   
TEMED                                                                                   40 µl   
ddH2O                                                                         13.01 ml or 11.26 ml  
 
1.2.1.3     4% Stacking Gel  
                                                                                               Per 10 ml   
30% Acrylamide-bisacrylamide (29:1)                                      2 ml   
1 M Tris-HCl (pH 8.8)                                                            1.25 ml  
10% SDS                                                                                  100 µl   
20% APS                                                                                  400 µl  
TEMED                                                                                    40 µl   
ddH2O                                                                                    11.26 ml 




                                                                                              Per 50 ml  
  
1 M Tris-HCl (pH 6.8)                                                           6.25 ml  
  
100% glycerol                                                                           5 ml  
  
SDS powder                                                                               5 g  
  
Bromophenol blue                                                                  1 drop  
  
β-mercaptoethanol                                                                    5 ml  
  
  
1.2.2     Coomasie Staining of SDS Gel  
  
  
1.2.2.1     Coomasie Blue Staining Solution  
  
Coomasie brilliant blue                                                           0.2%  
  
Ethanol                                                                                    45%  
  
Acetic acid                                                                              10%  
  
ddH2O                                                                                     45%  
  
  
1.2.2.2     Destaining Solution 
  
Ethanol                                                                                    25%  
  
Acetic acid                                                                              10%  
  




APPENDIX II: REAGENTS FOR GROWTH MEDIA  
  
2.1     E. coli Culture Media  
  
2.1.1     Luria-Bertani (LB) Agar 
                                                                                       Per L   
Tryptone                                                                         10 g   
Yeast extract                                                                    5 g  
NaCl                                                                                10 g   
Agar                                                                                15 g   
 
Autoclaved at 121ºC for 15 mins.   
  
2.1.2     LB Broth  
                                                                                       Per L   
Tryptone                                                                         10 g   
Yeast extract                                                                    5 g  
NaCl                                                                               10 g  
  





2.2     B. pertussis Culture Media   
  
2.2.1     Stainer-Scholte (SS) Medium   
Fraction A:  
                                                                                         Per L  
 Na-L-Glutamate                                                             11.84 g   
L-Proline                                                                         0.24 g   
NaCl                                                                                 2.5 g   
KH2PO4                                                                           0.5 g   
KCl                                                                                   0.2 g  
MgCl2.6H2O                                                                    0.1 g   
CaCl2.2H2O                                                                     0.02 g   
Tris                                                                                   1.5 g   
Casamino acids                                                                10 g   
Dimethyl-ß-Cyclodextrine                                                1 g   
  
Final pH adjusted to 7.4. Autoclaved at 121ºC for 15 mins.  
  
Fraction B:  
                                                                                       Per 10 ml   
L-Cysteine                                                                        0.04 g   
FeSO4.7H2O                                                                     0.01 g   
Nicotinic acid                                                                   0.04 g   
Ascorbic acid                                                                    0.4 g   
Glutathione                                                                       0.15 g  
Filter-sterilize with 0.2 µm filter unit.   




2.2.2     Bordet-Gengou (BG) Agar  
                                                                                         Per L   
Potato infusion from 125 g                                              4.5 g   
NaCl                                                                                 5.5 g   
Agar                                                                                  20 g   
Glycerol                                                                            10 g   
  
Autoclaved at 121ºC for 15 mins.  






APPENDIX III: REAGENTS FOR ANIMAL WORK  
  
3.1     Anaesthetic Cocktail for Nasal Administration  
  
Valium                                                                               6%   
Atropine                                                                           10%   
Ketamine                                                                          20%   
1 × PBS                                                                            64%   
  
Cocktail must be prepared under sterile conditions.  
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